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There is compelling evidence from transgenic mouse studies and
analysis of mutations in human carcinomas indicating that the TGF-β
signal transduction pathway is tumor suppressive. We have shown that
overexpression of TGF-β1 in mammary epithelial cells suppresses the
development of carcinomas and that expression of a dominant negative
type II TGF-β receptor (DNIIR) in mammary epithelial cells under
control of the MMTV promoter/enhancer increases the incidence of
mammary carcinomas. Studies of human tumors have demonstrated
inactivating mutations in human tumors of genes encoding proteins
involved in TGF-β signal transduction, including DPC4/Smad4,
Smad2, and the type II TGF-β receptor (TβRII). There is also evidence
that TGF-β can enhance the progression of tumors. This hypothesis is
being tested in genetically modified mice. To attain complete loss of
TβRII, we have generated mice with loxP sites flanking exon 2 of Tgfbr2
and crossed them with mice expressing Cre recombinase under
control of the MMTV promoter/enhancer to obtain Tgfbr2mgKO mice.
These mice show lobuloalveolar hyperplasia. Mice are being followed
for mammary tumor development. Tgfbr2mgKO mice that also express
polyoma virus middle T antigen under control of the MMTV promoter
(MMTV-PyVmT) develop mammary tumors with a significantly shorter
latency than MMTV-PyVmT mice and show a marked increase in
pulmonary metastases. Our data do not support the hypothesis that
TGF-β signaling in mammary carcinoma cells is important for invasion
and metastasis, at least in this model system.
The importance of stromal–epithelial interactions in mammary gland
development and tumorigenesis is well established. These interactions
probably involve autocrine and paracrine action of multiple growth
factors, including members of the TGF-β family, which are expressed in
both stroma and epithelium. Again, to accomplish complete knockout
of the type II TGF-β receptor gene in mammary stromal cells, FSP1-Cre
and Tgfbr2flox/flox mice were crossed to attain Tgfbr2fspKO mice. The
loss of TGF-β responsiveness in fibroblasts resulted in intraepithelial
neoplasia in prostate and invasive squamous cell carcinoma of the
forestomach with high penetrance by 6 weeks of age. Both epithelial
lesions were associated with an increased abundance of stromal cells.
Activation of paracrine hepatocyte growth factor (HGF) signaling was
identified as one possible mechanism for stimulation of epithelial
proliferation. TGF-β signaling in fibroblasts thus modulates the growth
and oncogenic potential of adjacent epithelia in selected tissues.
More recently, we have examined the effects of Tgfbr2fspKO fibroblasts
on normal and transformed mammary epithelium. We analyzed the role
of TGF-β signaling by stromal cells in mammary tumor progression. To
avoid the possibility of endogenous wild-type fibroblasts masking
potential effects of Tgfbr2fspKO cells on tumor progression, we
implanted PyVmT mammary carcinoma cells with Tgfbr2fspKO or wild-
type fibroblasts in the subrenal capsule of nude mice. Mammary tumor
cells implanted with Tgfbr2fspKO cells exhibited an increase in tumor
growth and intravasation associated with an increase in tumor cell
survival, proliferation and an increase in tumor angiogenesis compared
with tumor cells implanted with control fibroblasts. We demonstrated
increased expression of several growth factors by Tgfbr2fspKO fibroblasts
compared with control fibroblasts in primary culture. These included
HGF, MSP and TGF-α. There was an increase in tumor cell activating
phosphorylation of the cognate receptors, c-Met, RON, erbB1, and
erbB2 in carcinomas accompanied by Tgfbr2fspKO fibroblasts.
The Tgfbr2fspKO mouse model illustrates that a signaling pathway
known to suppress cell-cycle progression when activated in epithelial
cells can also have an indirect inhibitory effect on epithelial proliferation
when activated in adjacent stromal fibroblasts in vivo. Loss of this
inhibitory effect can result in increased epithelial proliferation and may
even progress to invasive carcinoma in some tissues.
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Despite over a decade of scrutiny and over 20 published reports from
various countries, the degree to which ATM mutations lead to breast
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cancer in the general population remains unclear. Furthermore, the
methodology of ATM mutation detection is still laborious and costly.
Because the ATM protein kinase phosphorylates such a wide array of
downstream targets, many pathways to oncogenesis are possible and
largely unexplored. What seems clear is that: A-T heterozygotes are at
a fourfold to fivefold increased risk of breast cancer, although
confidence intervals are large; and the spectrum of ATM mutations is
distinct for A-T families versus breast cancer cohorts. Only a handful of
mutations have been identified in both A-T families and breast cancer
cohorts. Missense mutations represent <10% of mutations in A-T
patients and >80% in breast cancer cohorts. ATM missense mutations
are also more common in some leukemias and lymphomas.
Experimental data suggest that some missense mutations represent
dominant interfering mutations [1-5]; however, clinical support for a
dominant interfering model is minimal in family studies, suggesting
either that the model is flawed or that penetrance of these mutations is
very low. Histological classifications of breast cancer are largely
grouped as genetically homogeneous models, although expression
microarray data suggest otherwise. Other studies have associated
ATM-SNPs with increased breast cancer risk; however, just three SNP
haplotypes across the ATM locus include ~95% of a global population,
and this must be factored into such association models. Without the
benefit of mRNA analyses, of minigene experiments, of Maximum
Entropy Scores, of site-directed mutagenesis or of functional assays of
ATM activity, most ‘missense’ mutations cannot be reliably
distinguished from polymorphisms or from other types of mutations,
such as splicing variants that lead to secondary stop codons. Our
recent analyses have focused on two ATM missense mutations,
7271T>G and IVS10-6T>G. For each of these mutations, there are
published functional data suggesting that they act as dominant
interfering mutations, and epidemiological data suggesting a role in
breast cancer. Some family studies of the 7271T>G mutation suggest
that it is a highly penetrant breast cancer susceptibility allele. However,
its infrequency in the population means that its contribution to breast
cancer risk is slight and it is possible that 7271T>G represents only
one of a diverse array of uncommon ATM mutations leading to
increased cancer risk. We found that the frequency of the IVS10-6T>G
mutation was not increased in breast cancer cases as compared with
controls. Furthermore, the evidence that IVS10-6T>G is an A-T
mutation is called into question by our recent evidence that, in the one
known example of a homozygous IVS10-6T>G individual with A-T, a
homozygous mutation at 5644C>T was also present (Purayidom and
colleagues, submitted). Taken together, these studies suggest that
whereas no single ATM mutation impacts significantly upon breast
cancer risk, it may be possible to group mutations that do modulate risk
for breast cancer based on their phenotypic effects. This group of
patients might benefit substantially from a therapeutic approach to
correct missense mutations.
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Cellular responses to DNA damage impact many aspects of cancer
biology. First, damage to cellular DNA causes cancer. We know this
from epidemiologic studies, from animal models, and from the
observation that many human cancer susceptibility syndromes arise
from mutations in genes involved in DNA damage responses. For
example, the genes mutated in Fanconi’s anemia, ataxia-telangiectasia,
xeroderma pigmentosum, Li–Fraumeni syndrome, hereditary breast and
ovarian cancers, and hereditary non-polyposis colon cancer are all
involved in DNA damage responses. Second, DNA damage is used to
cure cancer. The majority of the therapeutic modalities that we
currently use to treat malignancies target the DNA, including radiation
therapy and many chemotherapeutic agents. Third, DNA damage is
responsible for the majority of the side effects of therapy. Bone marrow
suppression, GI toxicities, and hair loss are all attributable to DNA
damage-induced cellular apoptosis of proliferating progenitor cells in
these tissues. Thus, DNA damage causes the disease, is used to treat
the disease, and is responsible for the toxicity of therapies for the
disease. Significant progress has been made in recent years in
elucidating the molecular controls of cellular responses to DNA
damage in mammalian cells. These insights now provide us with
approaches to attempt to manipulate these responses for patient
benefit, such as enhanced tumor cell kill with therapy, protection of
normal tissues from toxic effects of therapy, and even prevention of
cancer development.
Many of the insights that we have gained into the mechanisms involved
in cellular DNA damage response pathways have come from studies of
human cancer susceptibility syndromes that are altered in DNA
damage responses. One of these disorders, ataxia-telangiectasia (A-T),
is characterized by multiple physiologic abnormalities, including
neurodegeneration, immunologic abnormalities, cancer predisposition,
sterility, and metabolic abnormalities. The gene mutated in this
disorder, Atm, is a protein kinase that is activated by the introduction of
DNA double-strand breaks in cells. Atm activity is required for cell cycle
arrests induced by ionizing irradiation (IR) in G1, S, and G2 phases of
the cell cycle. Several targets of the Atm kinase have been identified
that participate in these IR-induced cell cycle arrests. For example,
phosphorylation of p53, mdm2, and Chk2 participate in the G1
checkpoint; Nbs1, Brca1, FancD2, and Smc1 participate in the
transient IR-induced S-phase arrest; and Brca1 and hRad17 have been
implicated in the G2/M checkpoint. Although Atm is critical for cellular
responses to IR, related kinases, such as Atr, appear to be important
for responses to other cellular stresses [1]. Some substrates appear to
be shared by the two kinases, with the major difference being which
stimulus is present and which kinase is used to initiate the signaling
pathway.
Characterization of these Atm substrates permitted us to manipulate
these proteins in cell lines and to selectively abrogate single or multiple
checkpoints. Using this approach, we demonstrated that abrogation of
checkpoints does not by itself result in radiosensitivity. Although this
has been known for several years in regards to the S-phase
checkpoint, it was a surprising finding that abrogation of the G2/M
checkpoint did not cause radiosensitivity. This observation suggested
that some other function of Atm, other than checkpoint control, was
important for cellular survival following ionizing irradiation. In
characterizing targets of the Atm kinase, the only substrate whose
phosphorylation seems to impact on radiosensitivity is Smc1 [2]. We
previously demonstrated that the phosphorylation of Smc1 by ATM
required the presence of both Nbs1 and Brca1 proteins. We recently
found that this dependence results from the role that these two
proteins play in recruiting both Smc1 protein and activated Atm to the
sites of DNA breaks. We generated mice in which the two Atm
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phosphorylation sites in the Smc1 protein are mutated; cells from these
mice demonstrate normal ATM activation, normal phosphorylation of
both Nbs1 and Brca1 after IR, and normal migration of these proteins
to DNA breaks [3]. Despite these normal activities of Atm, Nbs1 and
Brca1, these cells exhibit a defective S-phase checkpoint,
radiosensitivity, and increased chromosomal breakage after IR similar
to that seen in cells lacking Atm. These results suggest that the
phosphorylation of Smc1 is the critical target of this signaling pathway
for these endpoints, and that the reason why cells lacking Nbs1 and
Brca1 are radiosensitive and exhibit chromosomal breakage is due to a
failure to recruit Smc1 to the sites of DNA breaks where it gets
phosphorylated by previously activated Atm.
Recent studies also elucidated the mechanism by which DNA damage
activates the Atm kinase and initiates these critical cellular signaling
pathways [4]. Atm normally exists as an inactive homodimer bound to
nuclear chromatin in unperturbed cells, and introduction of DNA
damage induces intermolecular autophosphorylation on serine 1981 in
both Atm molecules. This phosphorylation causes a dissociation of the
Atm molecules and frees it up to now circulate around the cell and
phosphorylate the substrates that regulate cell cycle progression and
DNA repair processes. This regulation of Atm activity in the cell
represents a novel mechanism of protein kinase regulation and appears
to result from alterations in higher order chromatin structure rather than
direct binding of Atm to DNA strand breaks. Although Nbs1 and Brca1
are not required for the initial activation of Atm after IR, these two
proteins are required for the migration of activated Atm to the sites of
DNA breaks. It is this process of recruitment of activated Atm along with
Smc1 recruitment to the DNA breaks that leads to Smc1 phosphorylation
by Atm and presumably initiation of some repair process(es) that reduce
chromosomal breakage and enhance cell survival.
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Given the increasing clinical importance of microarray expression
classification of breast tumours and the different biology it may reveal
[1], identifying an associated SNP profile may be of considerable value
for pharmacogenetics, early diagnostics and cancer prevention.
Studying the promoter composition of the genes that strongly predict
the patient subgroups, we observed clear separation of the gene
clusters based solely on their promoter composition, making feasible
the hypothesis that SNPs in the regulatory regions of genes that create
or abrogate transcription binding sites have the potential to influence
the expression profiles. Morley and colleagues [2] reported linkage
analysis of expression levels of 3554 genes and 2500 SNPs in 14
CEPH families (retrieved online [3]), and found significant evidence for
the existence of regulation hot spots, suggesting both cis and trans
regulatory effects. We report similar observations from a study with a
different design, performing actual genotyping of 49 unrelated breast
cancer patients, whose tumours have previously been analysed by
genome-wide expression microarrays leading to a robust tumour
classification with strong prognostic impact [4]. These patients were a
part of a pharmacogenetic study of 193 patients who had received
radiation therapy or chemotherapy. A high-throughput solid-phase,
array-based method using primer extension chemistry has been used to
perform the genotyping (GenomeLab™ SNPstream genotyping system;
Beckman Coulter, Fullerton, CA, USA). A total of 583 SNPs in 203
selected genes (1–19 SNPs/gene) were genotyped and tumour
genome-wide expression was studied in 49 patients. Association in
both cis and trans was detected for SNPs in 42 genes. SNP–
expression associations with the top 0.25% best P values (9.81 ×
10–6 < P < 0.001) revealed regulatory SNPs in 115 genes in trans.
The subsets of transcripts that were observed to have significantly
many associations in common with a set of SNPs were further
analysed using the gene ontology (GO) annotations. The GO terms of
the unselected mRNA transcripts found associated to the SNPs in the
selected candidate genes were often similar, suggesting that the
observed associations are within the same functional pathway. Taken
together these data suggest that the observed SNP–expression
associations do exist and are observable even in a small set of
unrelated individuals. A given expression profile of the tumour may be
potentially associated and predicted by the genotype of the patient.
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Long-term exposure to estradiol is associated with an increased risk of
breast cancer in women. The data supporting this conclusion include:
measurements of plasma total and free estradiol, estrone, and estrone
sulfate and the aromatase substrate testosterone in postmenopausal
women; the effect of oophorectomy before age 35; the effect of early
menarche and late menopause; the relationship between bone density
and breast cancer risk; and the role of menopausal hormone therapy on
risk. However, the mechanisms responsible for estradiol-induced
carcinogenesis are not firmly established. The prevailing theory
postulates that estrogens increase the rate of cell proliferation by
stimulating estrogen receptor (ER)-mediated transcription, thereby
increasing the number of errors occurring during DNA replication. An
alternative theory suggests that estradiol is metabolized to quinone
derivatives, which directly remove base pairs from DNA through a
process called depurination. Error-prone DNA repair then results in
point mutations. We postulate that both processes act in an additive or
synergistic fashion. If correct, aromatase inhibitors would block both
processes, whereas anti-estrogens would only inhibit receptor-
mediated effects. Our initial studies demonstrated that depurinating
catechol-estrogen metabolites are formed in MCF-7 human breast
cancer cells in culture. We then utilized an ERKO animal model that
allows dissociation of ER-mediated function from the effects of
estradiol metabolites, and demonstrated formation of genotoxic
estradiol metabolites. We also examined the incidence of tumors
formed in these ERα knockout mice bearing the Wnt-1 transgene. The
absence of estradiol induced by castration markedly reduced the
incidence of tumors and delayed their onset. Re-administration of
estradiol to castrate animals induced tumors in a dose-responsive
fashion. To ensure that all ER functionality was lacking, we
administered fulvestrant and demonstrated that estrogen still induced
breast tumors in these animals. On aggregate, our results support the
concept that metabolites of estradiol may act in concert with ER-
mediated mechanisms to induce breast cancer. These findings support
the possibility that aromatase inhibitors might be more effective than
anti-estrogens in preventing breast cancer. Data from four clinical
Available online http://breast-cancer-research.com/supplements/7/S2
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studies have now suggested that fewer contralateral breast cancers
occur in women treated with aromatase inhibitors in the adjuvant setting
than with tamoxifen. Taken together, our data provide experimental
support for a genotoxic role for estradiol in hormonal carcinogenesis.
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At present, large numbers of at-risk women are treated in order to
prevent relatively small numbers of breast cancers. There is a need to
define risk more precisely in order to target interventions and a need to
improve their efficacy. Risk estimations currently depend upon
integration of familial and endocrine risk factors. We have
demonstrated that the Tyrer–Cuzick model that takes both factors into
account more fully is superior to other risk prediction models in our
clinic [1]. However, prediction remains imprecise for the individual.
Attempts are being made to take additional risk factors into account,
including mammographic density [2], serum estradiol concentration
and bone density. It seems probable that a better understanding of the
interactions between stromal and epithelial cells in the breast including
fibroblasts, adipocytes, macrophages and blood vessels will ultimately
lead to better prediction. We have shown that 5% loss of body weight
during mid life reduces postmenopausal breast cancer risk by 40% [3],
and overviews indicate that use of NSAIDs [4] and exercise [5] may
reduce risk by approximately 30%. The mechanisms of these risk
reductions are not clear but gene array studies indicate that calorie
restriction and exercise predominantly reduce the expression of genes
related to inflammation [6,7]. This raises the question of whether all
these interventions act by similar mechanisms. A better understanding
of the mechanisms of mammographic density and mammary cell
senescence is required. Both are associated with fibroblasts that
increase and stimulate proliferation of local epithelial cells [8,9]. Since
mammographic density is a major risk factor, its reversal is likely to be
beneficial. Another stromal target is aromatase. All adjuvant aromatase
inhibitor (AI) trials have shown an approximately 50% contralateral
breast cancer reduction compared with tamoxifen [10]. Since
tamoxifen reduces contralateral risk by about 50% compared with
placebo, AIs may reduce risk by 70–80%. Trials to test this hypothesis
are underway (IBIS II, MAP3). The aforementioned considerations
indicate that the stroma and stroma–epithelial interactions are already
targets for preventive measures, and this is likely to expand and lead to
new interventions such as NF-κB inhibition [11] and SIRT1 activation
[12].
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The current fashion of using long-term antihormonal therapies for the
treatment and prevention of breast cancer has been remarkably
successful over the past 20 years but this strategy has consequences
for the development of drug resistance in remaining tumor tissue.
Although estrogen is considered to be a survival signal that causes
increased breast cancer cell replication, the study of drug resistance to
antihormonal therapies has revealed an unanticipated new biology of
estrogen action. Long-term antihormonal therapy eventually results in
either tamoxifen or raloxifene (selective estrogen receptor modulators
[SERMs]) stimulated growth and tumors are also stimulated to grow
with estrogen. This is why aromatase inhibitors are effective treatments
after the development of SERM resistance once the SERM is stopped.
Long-term estrogen deprivation initially causes a cessation of breast
tumor cell growth but eventually cells grow out that remain ER-positive
but grow spontaneously. Estrogen deprivation with SERMs or
aromatase inhibitors for more than 5 years causes a remarkable
switching of the estrogen signaling pathway [1]. Instead of being a
survival signal, physiologic concentrations of estrogen now cause
apoptosis and tumor cell death. This knowledge provides an
opportunity to test the hypothesis that low-dose estrogen therapy
following exhaustive antihormonal therapy could be used as a
successful treatment for patients. Studies are in place to evaluate the
mechanism of action of estrogen-induced apoptosis so that a new
target can be discovered to develop a novel apoptotic drug group. The
ER-negative breast cancer cell is the ultimate hormone-resistant cell.
Reintroduction of an active ER gene re-sensitizes the cells to estrogen
that now causes blockade of the cell cycle [2] and apoptosis if cell
survival signaling is also blocked. These data suggest that a universal
target could be identified using the estrogen receptor mediated
mechanism that will permit the broad application of new anti-apoptotic
medicines.
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Both ERα and ERβ are expressed in not only normal breast of the
rodent, cow, monkey and human, but also in breast cancer. Cells that
express ERα are found within the luminal epithelium, but not in the
myoepithelium or stroma in the human breast. ERβ, on the other hand,
is expressed not only in the luminal epithelial cells, but also in
myoepithelial cells, stromal cells and in passenger lymphocytes. This
widespread distribution of ERβ suggests multiple roles for ERβ in the
mammary gland.
We have shown that in the rodent mammary gland ERβ is the dominant
ER, and that, in response to E2, ERα but not ERβ is downregulated in
the early G1 phase of the cell cycle. Cells that contain ERα receive the
signal to proliferate from E2, and within 4 hours of that signal ERα is
lost from the nucleus. The cells then go through a complete cycle and
ERα reappears in daughter cells. ERβ levels do not change in cell
nuclei during the cell cycle. This pattern of ER regulation holds true in
human breast cancer since ERα is never co-localized with proliferation
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markers in breast cancer samples. This means that under the
conditions of a constant high level of E2, ERα does not reappear in the
nucleus. A similar situation exists during pregnancy when there is a
constant high level of E2 and there is no ERα in the mammary
epithelium. This resistance to the proliferative response to E2 in the
presence of a constant high dose of E2 probably explains the very
successful use of high-dose E2 in the treatment of breast cancer. ERβ,
on the other hand, appears to have a differentiative role not a
proliferative role in the mammary gland, and the lactating rodent
mammary gland of ERβ–/– mice does not express gap junction and
adhesion proteins, typical indicators of fully differentiated cells.
In recent years there have been several publications showing that ERβ
is expressed in human breast cancer, and conclusions and
speculations about a causative role for ERβ in breast cancer
development and/or progression have been made. We have studied
500 frozen breast biopsies in collaboration with Prof. RC Coombes,
London, in order to clarify the role of ERβ in normal and malignant
breast. In this study we measured ERα and ERβ proteins by several
techniques (immunohistochemistry, western blotting, ligand binding in
sucrose gradients, and RT-PCR) in various human samples obtained
from both benign breast and malignant breast. We found that ERβ is
the predominant estrogen receptor in the normal mammary gland and
in benign breast disease. There is very little ERα in the normal
mammary gland. This low expression of ERα is one of the striking
differences between rodents and humans. This is in stark contrast to
ERβ, which is expressed in 80% of epithelial cells and is also present
in the stroma.
We found that ERα is abundantly expressed in invasive and in situ
ductal carcinoma but not in medullary cancer. ERβ is also expressed in
breast cancer, both ductal and medullary.
In this study we also found that, in the human breast, the major ER in
breast stroma is ERβ. This surprising finding has necessitated several
new lines of investigation about the function of ERβ in the breast. It has
long been thought that ERα in the stroma was responsible for
secretion of growth factors in response to E2 and that these growth
factors were responsible for epithelial cell proliferation. The discovery
that it is ERβ that is present in the stroma might suggest a role of ERβ
in growth factor secretion.
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The marked protection against breast cancer afforded women by an
early first full-term pregnancy has important clinical implications for
designing chemopreventive approaches to breast cancer and, more
generally, for understanding how cancer susceptibility can be
modulated by normal developmental events. Epidemiologic studies
have repeatedly demonstrated that women who undergo an early first
full-term pregnancy have a significantly reduced lifetime risk of breast
cancer. Similarly, rodents that have previously undergone a full-term
pregnancy are highly resistant to carcinogen-induced breast cancer
compared with age-matched nulliparous controls. Relatively little
progress has been made, however, towards understanding the
molecular basis of this phenomenon. We have used microarray
expression profiling to identify persistent changes in gene expression in
the mouse and rat mammary gland that are induced by an early first full-
term pregnancy. Using this approach, we have isolated a panel of
genes whose expression is persistently altered in multiple strains of
mice and rats by a reproductive event known to reduce breast cancer
risk. Additional studies are underway to compare gene expression
patterns in mammary tissues from parous and nulliparous mice, rats,
and women with parity-induced changes in gene expression that are
evolutionarily conserved. Similarly, gene expression patterns in rats that
have been treated with hormonal regimens that mimic parity-induced
protection are being compared with those induced by non-protective
control regimens in order to identify genes whose expression patterns
are most closely correlated with protection. Finally, gene expression
changes induced by parity in strains of rats that exhibit different levels
of susceptibility to carcinogen-induced tumorigenesis are being
compared. These gene expression changes suggest novel hypotheses
for the mechanisms by which parity may modulate breast cancer risk
and will be useful for probing the mechanisms by which the
developmental state of the mammary gland modulates the response to
an oncogenic stimulus.
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Background Endocrine therapy for breast cancer is a major modality
for the treatment of breast cancer, producing response rates between
30% and 40% of unselected patients with the minimum of toxicity.
However, the majority of patients receive no benefits and, after
successful treatment, tumour regrowth may occur. Optimal manage-
ment therefore requires accurate predictors of response and early
identification of resistance. The present article reviews results from
neoadjuvant studies in which endocrine therapy was given to patients
whose primary breast cancer was still within the breast so that
changes in tumour volume could be used to assess clinical response
and so that sequential biopsies could be taken for molecular analyses
designed to identify predictive markers.
Methods All patients had histologically confirmed breast cancer and
were treated for 3–4 months with either tamoxifen or an aromatase
inhibitor (anastrozole, exemestane or letrozole). Core or excisional
tumour biopsies were taken before and at the end of treatment (and at
10–14 days in certain studies). Oestrogen receptors (ER), progestogen
receptors and c-erbB1 and c-erbB2 were measured by immuno-
histochemistry. Microarray analysis was performed on tumour RNA
extracted and amplified before hybridization on Affymetrix HG_U133A
GeneChips for microarray analysis.
Results Steroid hormone receptor status highly influences the
response to all endocrine therapies, negative tumours failing to
respond and response being more likely with increasing levels of ER
and the concomitant presence of PgR. Conversely, tumour over-
expression of c-erbB2 (and c-erbB1) is associated with resistance to
tamoxifen but not aromatase inhibitors. While these receptors are
helpful in identifying groups of tumours with differing sensitivity to
endocrine therapy, they fail to predict accurately in individual cases. To
address this deficiency, in Edinburgh we have looked for early genetic
changes (at 10–14 days) that occur with treatment and might be
associated with subsequent response to the aromatase inhibitor
letrozole. Clinical response data were available for 43 cases, of which
33 (77%) were classified as responders (>50% reduction in tumour
volume) and 30 (70%) displayed evidence of pathological response.
No gene changed substantially with treatment in all cases; however,
there was consistent upregulation of three genes and downregulation
of 65 genes in 50 of the cases. Based on clustering techniques, it was
possible to identify highly consistent changes in gene expression with
treatment, which allowed tumours to be subdivided into groups
showing distinct patterns of molecular changes. While the change in
expression of any single gene failed to correlate with response,
significant differences in change of expression in 125 genes were
detected between non-responders and responders. A combination of
gene changes produced increased discrimination. The identity of the
genes and their relevance to the prediction of response and
mechanisms of resistance will be discussed.
Available online http://breast-cancer-research.com/supplements/7/S2
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Conclusions Early changes in gene expression profiles may define
tumour groups with differing sensitivity to endocrine therapy and permit
early recognition of response and resistance. However, clinical utility at
the level of individual patients has yet to be validated and explored.
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Studies of human epithelial cells and fibroblasts from healthy
individuals are providing novel insights into how early epigenetic and
genetic events affect genomic integrity and fuel carcinogenesis. Key
epigenetic changes, such as the hypermethylation of the p16 promoter
sequences, create a previously unappreciated pre-clonal phase of
tumorigenesis in which a subpopulation of epithelial cells is positioned
for progression to malignancy [1]. These key changes precede the
clonal outgrowth of premalignant lesions and occur frequently in
healthy, disease-free individuals [2]. Prior work from our laboratory has
shown that surrounding stroma can dramatically influence tumori-
genesis. Proper stromal–epithelial interactions can actually suppress
the expression of preneoplastic phenotypes in epithelial cells and,
conversely, altered stromal–epithelial interactions can promote the
probability that preneoplastic lesions progress to malignancy [3].
Understanding more about these early events should provide novel
molecular candidates for prevention and therapy of cancer.
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Previous studies from our laboratory have shown that non-malignant
and malignant cells can be distinguished easily and rapidly by their
morphology and growth rate when cultured in three-dimensional (3D)
laminin-rich basement membrane but not when cultured on traditional
tissue culture plastic (two-dimensional [2D]) [1,2]. In addition, we have
shown that cellular responses to signaling inhibitors and apoptotic
agents differ in cells cultured in 2D versus 3D [3,4]. This applies also
to our finding with reverted tumor cell lines [3-8]. In this presentation, I
will address two inter-related topics.
First, we asked how the 3D morphology and gene expression profiles
for a panel of 60 breast cancer cell lines for which the Gray laboratory
has obtained 2D expression as well as CGH profiles may differ, and
whether any of the surrogate genes or phenotypes could track with
response to therapy. The cell lines examined so far fell into four distinct
morphologies of ‘round’, ‘mass’, ‘grape-like’ and ‘stellate’. An ANOVA
analysis of Affymetrix gene expression profiles for each of these cell
lines was used to identify genes, the expression profiles of which could
distinguish the other known parameters of the cultured cells. Of the
22,283 genes on the Affymetrix 133A chip, ~5800 genes were
identified where expression patterns differed between different cell
lines both in 2D and 3D, and ~2000 genes were identified where
expression differed between the non-malignant and malignant cell lines.
About 700 genes differed between 2D and 3D, and ~800 correlated
with the morphological differences seen in 3D. These genes fall into a
number of functional classes, which we are currently analyzing to
identify common signaling themes and/or morphological regulators that
will be tested by manipulation of expression and correlated with
therapeutic response of these cell lines in 2D and 3D to Herceptin and
other chemotherapeutic drugs.
Second, we have also shown previously that loss of basement
membrane in both cultured mammary mouse cells [9] and in transgenic
animals led to epithelial to mesenchymal transition (EMT) and mammary
tumors [10]. We have now determined the molecular pathways
induced by MMP-3 to lead to EMT and genomic instability via
production of reactive oxygen species [11]. These mechanisms will be
discussed.
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Advances on several fronts have led to increases in survival duration
and to reduced mortality in patients with breast cancer. These include
improved procedures for earlier detection, optimization of combined
surgical and radiotherapy, and use of optimized selective estrogen
receptor modifiers (SERMS) and new chemotherapeutic strategies
including gene-targeted therapies. In addition, molecular stratification
strategies have been developed that stratify patients according to
outcome. Stratification based on measurement of expression
‘signatures’ have been particularly effective and seem likely to improve
treatment strategies. Patients at increased risk of progressive disease
can be offered standard of care chemotherapy. However, some of
these patients do not respond well to these treatments and current
stratification strategies provide little information to guide treatment of
these patients. This study of tumors from patients treated according to
standard of care identifies genomic and coordinated transcriptional
aberrations — especially amplification at 11q, and 20q in tumors with
the luminal A expression phenotype, and at 17q in tumors associated
with the ERBB2 expression phenotype — that are strongly associated
with poor response to such treatment. Our study identifies genes in
these regions of amplification that can be assessed to identify patients
that will respond poorly to the current standard of care and that are
targets for therapies that will be effective against these poorly
responding tumors. Interesting, this study also shows that patients with
basal-like tumors do not have substantially shorter survival durations
than patients with luminal-like tumors, suggesting that basal-like tumors
respond well to the adjuvant adriamycin and cyclophosphamide
therapies employed during their treatment.
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We performed comprehensive molecular analysis of each cell type
composing normal breast tissue and in situ and invasive breast
carcinomas. Gene expression profiles were analyzed using serial
analysis of gene expression, genetic changes were analyzed by single
nucleotide polymorphism arrays, while epigenetic changes were
analyzed using methylation-specific digital karyotyping. Based on these
data we determined that gene expression and epigenetic changes
occur in all cell types during breast cancer progression, while genetic
alterations were only detected in tumor epithelial cells. Many of the
differentially expressed genes encode for secreted proteins and
receptors suggesting alterations in autocrine and paracrine interactions
in breast tumorigenesis. Two of these genes, the CXCL14 and
CXCL12 chemokines, overexpressed in tumor myoepithelial cells and
in myofibroblasts, respectively, bind to receptors on epithelial cells and
enhance their proliferation, migration, and invasion. Chemokines may
thus play a role in breast tumorigenesis by acting as paracrine factors.
The role of these chemokines, and myoepithelial and stromal cells in
the progression of in situ carcinomas to invasive carcinomas was
investigated using a xenograft model of human ductal carcinoma in
situ. Based on our studies we determined that changes in the tumor
microenvironment and epithelial–myoepithelial and epithelial–stromal
cell interactions play an important role in breast tumor progression.
Reference
1. Allinen M, Beroukhim R, Cai, L, Brennan C, Lahti-Domenici J,
Huang H, Porter D, Hu M, Chin L, Richardson A, et al.: Molecular
characterization of the tumor microenvironment in breast
cancer. Cancer Cell 2004, 6:17-32.
S.18
Biological features and xenograft models of a very
early human premalignant breast lesion
S Lee, Y Wu, SK Mohsin, D Medina, DC Allred
Breast Center, Baylor College of Medicine, Houston, Texas, USA
Breast Cancer Research 2005, 7(Suppl 2):S.18 (DOI 10.1186/bcr1061)
Background Most breast cancers appear to arise from certain
precursors over long periods of time. Enlargement (>50-fold) of normal
terminal duct lobular units (TDLUs) by hyperplastic epithelial cells is one
of the most common and earliest histologically recognizable alterations
with premalignant potential. Understanding how these hyperplastic
enlarged lobular units (HELUs) develop and progress could lead to new
and effective strategies for breast cancer prevention therapy.
Methods The estrogen receptor (ER) and proliferation (Ki67) were
evaluated and compared in TDLUs and HELUs in the same breasts
(n = 250) by immunohistochemistry. Apoptosis was also assessed by
the TUNEL assay. The rate of ER expression in proliferating cells was
assessed by dual-labeled immunofluorescence. Comprehensive gene
expression profiling was performed in a subset of samples (currently six
matched pairs of TDLUs and HELUs) using RNA isolated from
microdissected formalin-fixed paraffin-embedded breast tissue samples
and Affymetrix U133-X3P microarrays analyzed by dCHIP software.
Xenografts of human TDLUs and HELUs were prepared by implanting
isolated epithelial cells into cleared mammary fat pads of estrogen-
stimulated immune-compromised mice ‘humanized’ by prior local
injection of immortalized (h-tert transfected) human mammary
fibroblasts.
Results The average ER expression was significantly elevated in
HELUs compared with adjacent TDLUs (85% vs 30% positive cells,
respectively; P < 0.0001). Proliferation was significantly higher (6% vs
2%; P < 0.0001) and apoptosis was significantly lower (0.6% vs
0.2%; P < 0.001) in HELUs than TDLUs. There was a large increase in
the proportion of ER-positive proliferating cells in HELUs compared
with TDLUs (35% vs 4%; P < 0.0001). In preliminary analysis of the
microarray results, HELUs and TDLUs segregated perfectly in
unsupervised hierarchical comparisons. In supervised comparisons,
many (n = 74) genes showed >3-fold (P < 0.05) differences in
expression, with 45 relatively up (from 3.5-fold to 9.5-fold) and 29
relatively down (from 3.5-fold to 12.5-fold) in HELUs versus TDLUs.
Especially prominent elevations in HELUs included several genes
involved in G-protein signaling, the retinoic acid pathway, and
detoxification. Prominent decreases included genes involved in cell
cycle inhibition, apoptosis, differentiation, and water transport.
Differences were also noted in the expression of genes for ligands of
the epidermal growth factor receptor between HELUs and TDLUs.
Several fresh human samples of TDLUs and HELUs are in various
stages (currently up to generation four) of implantation in mice in
attempts to establish stable xenografts.
Conclusions HELUs are one of the earliest histologically recognizable
lesions in the human breast with premalignant potential. They show
striking elevations of ER, which may partially explain the hyperplasia
leading to their development from TDLUs through increased
proliferation and decreased apoptosis, which are both regulated by
estrogen. DNA microarrays reveal many additional differences in the
expression of genes involved in growth and differentiation. Human
xenograft models are under development to support mechanistic
studies of these genes to understand their roles in the development
and progression of HELUs and how to prevent it.
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Pathogenesis of cancer begins as hyperplastic lesions; some lesions
remain benign, while others progress to malignancy. An increase in cell
proliferation rates and changes in tissue architecture are two properties
commonly observed in hyperplastic lesions. A great deal is known
about the molecular events that regulate cell proliferation and the
knowledge gained is widely used for development of diagnostic and
treatment tools. Our understanding of the mechanisms that deregulate
tissue architecture is poor, and hence it is understandable that the use
of architectural features to determine prognosis of early lesions has
varying success. We used polarized epithelial cells and an inducible
method of ErbB2 activation to investigate whether the cell architecture
influences ErbB2-induced gene expression and to investigate how
activation of ErbB2 disrupts epithelial cell architecture. Activation of
ErbB2 in three-dimensional epithelial acini-like structures leads to
expression of a unique set of genes that was not observed when
ErbB2 was activated in cells grown on plastic dishes, suggesting that
the cell architecture can have significant influence on ErbB2-induced
gene expression. To investigate the effect of ErbB2 activation on
epithelial architecture, we activated ErbB2 in polarized epithelial cells.
ErbB2 induced a loss in apical–basal polarity, re-initiated proliferation
and induced multilayering of epithelial sheets. These changes correlate
with the ability of ErbB2 to regulate the Par complex, a protein complex
known to regulate establishment of epithelial cell polarity. Inactivation
of atypical protein kinase C, a component of the Par complex,
cooperates with ErbB2 to disrupt polarized epithelial cells, suggesting
that the Par complex is a mediator of ErbB2-induced effects on
polarized epithelial cells. In addition, we identify tricellular junctions,
and not bicellular junctions, as a novel site for ErbB2 action in cultured
epithelial cells and in primary breast cancer. We are thus beginning to
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Existing methods to detect breast cancer in asymptomatic patients
have limitations, and there is a need to develop more accurate and
convenient methods. Especially, an accurate method for breast cancer
detection based on peripheral blood as a clinical sample will be highly
desirable because of the easy accessibility and less-invasive nature by
which samples can be obtained.
Results demonstrating that peripheral blood can be used to develop a
gene expression based test for early detection of breast cancer will be
presented. The rationale for using blood cells as monitors for a
malignant disease elsewhere in the body is based on the hypothesis
that a malignant growth will cause characteristic changes in the
biochemical environment of blood. These changes will affect the
expression pattern of certain genes in blood cells.
We initially conducted a pilot study where the expression pattern of
1368 genes in peripheral blood cells of 24 females with breast cancer
and 32 females with no signs of this disease were analyzed using
macroarrays and the expression data analyzed by PAM. The results
were validated using a standard leave-one-out cross-validation
approach. We were able to identify a set of genes that correctly
predicted the diagnostic class in at least 82% of the samples. The
majority of the identified genes had a decreased expression in samples
from breast cancer patients, and predominantly encoded proteins
implicated in ribosome production and translation control. In contrast,
the expression of some defence-related genes was increased in
samples from breast cancer patients.
In order to revalidate these findings and to increase the repertoire of
informative genes, we have now extended the study with a larger
number of breast cancer and non-breast cancer samples and used
Agilent WG oligo arrays for large-scale gene expression analysis. The
preliminary analysis of the data supports our previous finding that a
blood-based gene expression test can potentially be developed to
detect breast cancer in asymptomatic patients.
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The epithelial components of the breast are thought to arise from a
stem cell population that is capable of both self-renewal and lineage-
specific differentiation. We and others have hypothesized that
mammary stem cells or their immediate progeny are targets for trans-
formation during carcinogenesis. Normal stem cells and carcinoma
cells share many characteristics including self-renewal capacity,
telomerase expression, ability to differentiate, resistance to apoptosis,
and ability to home to specific sites. Mammary transformation may
require dysregulation of pathways that control normal stem cell self-
renewal such as Notch, Wnt, Hedgehog, and Bmi-1. In order to study
these pathways in normal mammary development, we have developed
an in vitro culture system in which primary human epithelial cells
isolated from reduction mammoplasties are cultured as ‘mammo-
spheres’ on non-adherent surfaces. Cells within mammospheres are
able to self-renew, as well as to differentiate into all the lineages found
in the mammary gland. Utilizing this system, we demonstrate bi-
directional interaction between Notch and Hedgehog signaling and
Bmi-1 in the regulation of stem cell self-renewal. When mammospheres
are admixed with irradiated human mammary fibroblasts and implanted
into the cleared fatpads of NOD/SCID mice, they are able to
reconstitute the ductal alveolar structures found in the human
mammary gland.
The stem cell model of carcinogenesis may also provide a partial
explanation for the generation of cellular heterogeneity seen within
mammary tumors. Using flow cytometry, we have identified a small
population of cells within primary or metastatic breast cancers that
bear the cell surface phenotype ESA+CD44+CD24–/lowLineage– that
have the properties of human tumor stem cells. As few as 200 of these
cells are able to reproducibly generate tumors in NOD/SCID mice,
while the vast majority of cells in these tumors that lack this phenotype
are incapable of tumor formation even when tens of thousands of cells
are injected. Consistent with a stem cell model, tumorigenic cells
generate tumors that recapitulate the phenotypic heterogeneity found
in the original tumors. We have demonstrated that pathways that
control normal stem cell self-renewal, such as Hedgehog, are activated
in mammary tumor stem cells, compared with their differentiated
progeny. Despite progress in breast cancer therapeutics, metastatic
breast cancer remains an incurable disease. Current therapies that
have been developed by virtue of their ability to induce tumor
regression may selectively target more differentiated cells in tumors,
while leaving the tumor stem cell population intact, accounting for
treatment resistance and relapse. Multiple mechanisms may account
for this resistance to apoptosis, including increased expression of anti-
apoptotic genes, increased DNA repair mechanisms, and transporter
proteins such as BCRP found in the tumor stem cell population. The
targeting of stem cell self-renewal pathways such as Hedgehog or
Notch may thus provide a novel and more effective approach for the
treatment of advanced breast cancer.
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HER2 or c-ERBB2/neu is a member of the epidermal growth factor
receptor (EGFR) family and encodes a tyrosine kinase receptor. Over-
expression of HER2 protein is generally attributable to gene amplification.
HER2 is overexpressed in 20–30% of primary invasive breast
carcinomas and in a greater proportion of in situ breast cancers. Invasive
breast cancers that overexpress HER2 are generally higher stage, show
lymph node positivity, and have higher S-phase. Moreover, they are often
associated with poor prognosis, particularly in node-positive patients.
Microarray studies have subdivided breast cancers into several sub-
types. HER2-overexpressing ER-negative tumors are generally classified
within a single subtype denoted ERBB2-overexpressing. However, ER-
positive HER2-overexpressing tumors are usually intermixed with other
ER-positive tumors that do not show HER2 overexpression.
Our recent population-based study evaluating HER2 overexpression
and hormone receptor status has unexpectedly found that the majority
of HER2-overexpressing tumors are hormone receptor-positive and are
more common than HER2-overexpressing ER-negative breast cancers.
This implies that the ERBB2-overexpressing molecular subtype, which
is associated with ER-negative status, only includes a minority of
HER2-overexpressing tumors. We therefore studied gene expression
patterns of HER2-overexpressing breast cancers and found several
tumor subtypes with distinctive molecular signatures. These ERBB2-
overexpressing subtypes spanned the range of hormone receptor
status and highlighted different biological characteristics. Since the
clinical course varies among patients with HER2-positive tumors, as
does their response to targeted therapy, differences in global gene
expression among HER2-overexpressing tumors could be important in
distinguishing patients for the design and delivery of individualized
targeted therapies.
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Insulin-like growth factors (IGFs) are potent mitogens and survival
factors. In the mammary gland, IGFs stimulate proliferation,
differentiation, and survival during numerous developmental stages;
IGF signaling is required for puberty-dependent ductal outgrowth,
stimulates lobuloalveolar development during pregnancy, and is
reduced or absent during apoptosis-driven involution. Much of our
knowledge of IGF action in the mammary gland in vivo comes from
knockout or transgenic models. However, very few of these studies
have examined the consequence of these gene alterations on IGF
signaling in vivo. We have recently shown that intravenous injection of
IGF-I stimulates IGF-IR and IRS phosphorylation in the mammary gland,
and we are currently assessing the effect of targeted gene deletion of
overexpression of IGF signaling components on downstream signaling
in the mammary gland in vivo.
Many years of research have shown that the proliferative and survival
functions of the IGFs are not only important in mammary gland
development, but are also strongly involved in mammary cancer. Early
work using breast cancer cell lines in vitro showed that IGFs could
increase cell growth and survival; in particular, that IGFs could block
the effects of chemotherapy. We have recently shown that breast
cancer cell lines grown as xenografts in vivo are also sensitive to
intravenous IGF stimulation, and several IGF-IR inhibitors have been
shown in the past year to block MCF-7 xenograft growth.
IGF-IR and its downstream signaling intermediate IRS-1 can transform
fibroblasts in vitro. To date there is no evidence for their transforming
ability in vivo using transgenic mice. We have recently characterized
mice that overexpress IGF-IR, IRS-1, or IRS-2 in the mammary gland,
using mouse mammary tumor virus directed overexpression. We have
found that overexpression of a constitutively active IGF-IR in the
mammary gland disrupts normal development, such that female mice
are unable to lactate, and that mice rapidly develop mammary tumors.
Interestingly, overexpression of IRS-1 or IRS-2 also causes mammary
tumorigenesis, albeit with a longer time to tumor formation than
dominant active IGF-IR. These are the first mouse models showing that
IGF-IR or IRS overexpression leads to tumorigenesis in vivo. We are
currently examining the pathways required for IGF-IR and IRS-mediated
tumorigenesis in the mammary gland.
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Cyclin E is a G1-cyclin that plays a key role in the G1 to S transition of
the cell cycle. Cyclin E is processed in tumor cells by an elastase-like
protease into low-molecular-weight (LMW) isoforms that are bio-
chemically hyperactive. The LMW isoforms of cyclin E are unique to
cancer cells. In breast cancer, such alteration of cyclin E is a very
strong predictor of poor patient outcome.
Alterations in the binding properties of these LMW isoforms to CDK2
and the CDK inhibitors (CKIs), p21 and p27, result in their functional
hyperactivity. The LMW forms of cyclin E are several-fold more effective
at binding to CDK2. Additionally, compared with the full-length cyclin
E–CDK2 complexes, the LMW cyclin E–CDK2 complexes are
significantly more resistant to inhibition by p21 and p27, despite equal
binding of the CKIs to the LMW complexes. When both the full-length
and the LMW cyclin E are co-expressed, p27 preferentially binds to the
LMW forms yet is unable to inhibit the CDK2 activity. When
overexpressed in breast cancer cells, the LMW forms of cyclin E, but
not the full-length form, result in their hyperactivity due to increased
affinity for cdk2 and resistance to inhibition by the CDK inhibitors p21
and p27, result in resistance to the growth inhibiting effects of anti-
estrogens, and result in chromosomal instability. Finally, tumors from
breast cancer patients overexpressing the LMW forms of cyclin E are
polyploid in nature and are resistant to endocrine therapy.
To assess the oncogenic role of cyclin E-LMW as compared with full-
length cyclin E, we examined the consequences of overexpressing
these isoforms in the mammary glands of transgenic mice using the
MMTV promoter. Four constructs were generated: MMTV-M46A
coding for the full-length cyclin E (EL1), MMTV-EL1/EL4 coding for
EL1 and the isoform translated at methionine 46 (EL4), and MMTV-T1
and MMTV-T2 coding for the isoforms generated by elastase cleavage
at the first site (EL2 + EL3) and at the second site (EL5 and EL6),
respectively. For each construct at least two transgenic lines were
established. Transgene expression was demonstrated by RT-PCR,
northern blotting and western blotting. Overexpression of cyclin E was
seen in more than 90% of ductal and lobular cells of the mammary
glands for each independent line. Mammary-specific LMW cyclin E
overexpression induced extensive abnormalities at 2 months, including
perturbed architecture, polyploidy, anysocytosis and apoptosis. Whole-
mount preparations of mammary glands at different development
stages showed that overexpression of EL1/EL4 and cyclin E-T1
induced growth delay, while at 6 months of age an increased
proportion of cells in the S phase was found (25.6 ± 5.6% for
EL1/EL4, 9.0 ± 2.7% for T1 compared with 3.9 ± 1.9% for non-
transgenic animals). We observed a 34% (13/38) incidence of
mammary adenocarcinomas in the EL1/EL4 transgenic lines with a
mean latency of 18.3 months, and observed a 20% (5/25) incidence in
the T1 transgenic lines with a mean latency of 17.1 months. The tumor
incidence rate of the other transgenic lines, M46A and T2, are still
unknown due to the young age of the mice (all under 7 months of age)
and the long latency of cyclin E-mediated tumor generation. Thirty
percent (4/13) of the EL1/EL4 and 40% (2/5) of the T1 tumor-bearing
animals developed lung metastasis. The tumors induced by the
EL1/EL4 and T1 transgenes were mainly solid adenocarcinomas with
very little differential to glandular for EL1/EL4 and mostly glandular for
T1. Since p53 alterations are common in human breast carcinomas, we
bred a T1 line with p53+/– mice. The T1 × p53+/– cross generated
tumors that are much more malignant than the T1 tumors; the
incidence increased to 100%, with a much shorter latency of
11 months. Biochemical analysis of the tumors revealed that 64%
(9/14) retained cyclin E expression and that, on average, the cyclin
E-overexpressing tumors had threefold higher cyclin E kinase activity
than the non-cyclin E-expressing tumors. Taken together, these data
indicate that tumor progression in cyclin E transgenic mice follow
sequential steps of dysplasia, mammary intraepithelial neoplasia and
invasive/metastatic tumors.
Collectively, the biochemical and biological differences between the
full-length and the LMW isoforms of cyclin E provide a molecular
mechanism for the poor clinical outcome observed in breast cancer
patients harboring tumors expressing high levels of the LMW forms of
cyclin E. The transgenic mouse model system can serve as a useful
system in which to study the mechanisms responsible for LMW cyclin
E-induced genetic instability and may help identify those factors that
promote tumor progression and metastasis. The properties of the LMW
forms of cyclin E suggest that they are not just surrogate markers of
poor outcome, but that they are bona fide mediators of aggressive
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Mutations derange growth regulations of cancer cells. They can also
make the cells more subject to apoptosis. We have investigated two
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drugs that produce specific apoptotic chemotherapeutic mechanisms
that cause tumor shrinkage in mice without deleterious side effects.
The small natural product b-lapachone is specifically apoptotic to a
variety of cancer cells. It synergizes strongly with taxol. It seems to have
several mechanisms of lethality depending on the tumor type and the
drug concentration. One mechanism is to elevate the major S-phase
transcription factor E2F-1, to an apoptotic concentration [1]. It is now
in clinical trial.
Tumor cells often mutate to apoptosis resistance; for example, by
inactivating the p53 protein. We have reported that Go6976, a kinase
inhibitory small molecule, can decrease activation of the anti-apoptotic
transcription factor NF-κB [2].
These two novel therapies thus specifically cause cancer cell
apoptosis; one by increasing an apoptotic factor, and the other
restoring apoptosis by decreasing an anti-apoptotic factor.
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Background Combining representational oligonucleotide microarray
analysis (ROMA) of tumor DNA with quantitative multigene fluores-
cence in situ hybridization (QM-FISH) of individual tumor cells provides
the opportunity to detect and validate a wide range of gene amplifica-
tions, deletions, duplications and rearrangements directly in frozen
tumor samples.
Methods We have used these combined techniques to examine 101
aneuploid and diploid breast tumors (highly aneuploid A-tumors and
pseudo-diploid D-tumors), for which long-term follow-up and detailed
clinical information were available.
Results We have determined that ROMA provides accurate and
sensitive detection of duplications, amplifications and deletions, and it
yields defined boundaries for these events with a resolution of less than
50 kbp in most cases.
Conclusion Diploid tumors are particularly useful subjects for this
approach, revealing complex rearrangements and repeated sequential
amplification events on certain chromosomes that provide unique
insights into the genomic progression of the disease. First, the fine
structure of these amplification clusters, as detected by ROMA and
quantitatively validated by FISH, provides extremely high-resolution
‘pointers’ to potential novel oncogenes, since many of the detected
amplicons contain only one or two known or prospective genes.
Second, FISH patterns provide a means for interpretation of the
mechanism of these events. Third, the reproducibility and frequency of
these events, especially in very early stage tumors, provides insight into
the earliest chromosomal events in breast cancer. Finally, we have
identified correlations between certain sets of rearrangement events
and clinically relevant parameters such as long-term survival. These
correlations may enable novel and powerful prognostic indicators for
breast cancer and other cancers when more samples can be examined.
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Breast cancer is a spectrum of diseases comprised of different tumor
subtypes, each with a distinct biology and clinical behavior. To capture
this diversify, we characterized the variation in gene expression across
human breast tumors using DNA microarrays and identified at least five
distinct tumor subtypes that are statistically significant predictors of
patient overall survival [1]. Recently, we further validated these findings
using a training set of 102 tumors, which was used to derive a new
‘intrinsic gene set’. This gene set was then validated using a true test
set of 311 tumors compiled from three different microarray studies.
Our analyses demonstrate that common patterns of gene expression
can be identified across different microarray platforms, that the breast
tumor ‘intrinsic’ subtypes are reproducible across different datasets,
and that this classification was a significant predictor of outcomes after
correcting for standard clinical parameters such as estrogen receptor
(ER), grade and node status [2].
The biology of the ‘intrinsic’ subtypes is rich and extensive, and many of
these expression features suggest distinct therapies. The ‘intrinsic’
subtypes include at least two types of ER-negative tumors (Basal-like
and HER2+/ER–) and at least two types of ER-positive tumors (Luminal
A and Luminal B). Basal-like tumors typically show low expression of
HER2 and ER, and these tumors exhibit high expression of genes
characteristic of the basal epithelial cell layer, including expression of
keratin 5, keratin 6, keratin 17 and four Kallikrein genes (KLK5–KLK8).
The Basal-like tumors pose a challenge from the treatment perspective
because they lack ER and HER2. However, we have recently shown
that most are HER1-positive and/or c-KIT-positive [3], and we have
initiated a clinical trial to evaluate the efficacy of HER1-inhibitors in pre-
selected Basal-like tumor patients.
HER2-positive (i.e. gene amplified) tumors fall into at least two distinct
expression groups: those that are ER-negative and typically cluster
near the Basal-like tumors (HER2+/ER–), and those that are ER-positive
and cluster with tumors of luminal cell origin. These findings suggest
that both types of HER2+ patients should receive transtuzumab, but
that the ER+/HER2+ may gain a benefit from hormone therapy.
Finally, the Luminal subtype A and Luminal subtype B tumors express
ER, GATA3, and genes regulated by both ER and GATA3. Compared
with Luminal B tumors, Luminal A tumors express higher levels of ER,
BCL2 and GATA3, and they show more favorable patient outcomes.
Luminal B tumors more often express HER1, HER2 and/or cyclin E1,
and they show worse outcomes. Our data, when coupled with data from
others [4], suggests that Luminal A patients are likely to benefit from
hormone therapy and are not likely to benefit from chemotherapy, while
the opposite may be true of Luminal B patients. Experiments to answer
these questions in Luminal patients are underway and will be discussed.
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Microarray gene expression profiling combined with advanced bio-
informatics is beginning to show its power in delineating disease
entities that are otherwise indistinguishable. This refinement in tumor
classification allows a more accurate prediction of outcome of disease
for patients that present with the same stage of disease based on
conventional clinical and histopathological criteria. Gene activities
determining the biological behaviour of the tumor may indeed be more
likely to reflect the aggressiveness of the tumor than general
parameters such as tumor size, age of the patient, or even tumor grade.
The immediate clinical consequences are therefore that treatment
schemes can be tailored based on the gene activity patterns of the
primary tumor.
Using gene expression profiling with cDNA microarrays, Perou and
colleagues showed that there are several subgroups of breast cancer
patients based on unsupervised cluster analysis: those of ‘basal type’
and those of ‘luminal type’. These subgroups differ with respect to
outcome of disease in patients with locally advanced breast cancer. In
addition, microarray analysis has been used to identify diagnostic
categories (e.g. BRCA1 and BRCA2, estrogen receptor status).
We used gene expression profiling with DNA microarrays harboring
25,000 genes on 78 primary breast cancers of young lymph-node-
negative patients to establish a signature, predictive for a short interval
to distant metastases. This ‘poor prognosis’ signature consists of
genes involved in the cell cycle, invasion and angiogenesis. The
prognosis signature is superior to currently available clinical and
histopathological prognostic factors in predicting a short interval to
distant metastases (odds ratio = 18 [95% confidence interval =
3.3–94], P < 0.001, multivariate analysis). We have validated our
findings of this poor prognosis profile on a large unselected
consecutive series of LN0 as well as lymph-node-positive (LN+) young
breast cancer patients (n = 295). The analyses confirm that the profile
is a strong independent factor in predicting outcome of disease for
LN0 patients in general (10-year overall survival for the good prognosis
profile 96% vs 50% for the poor prognosis profile). Furthermore, the
profile is also powerful for LN+ patients. At present, the prognostic
significance of the 70 genes is tested in older breast cancer patients.
Nowadays, consensus guidelines in the management of breast cancer
select up to 95% of lymph-node-negative young breast cancer patients
for adjuvant systemic therapy (e.g. NIH and St Gallen consensus
criteria). As 70–80% of these patients would have remained disease-
free without this adjuvant treatment, these patients are ‘overtreated’.
The ‘poor prognosis’ signature provides a novel strategy to accurately
select patients who would benefit from adjuvant systemic therapy and
can greatly reduce the number of patients that receive unnecessary
treatment.
Our data revealed that already small tumors display the metastatic
signature, and recent results show that the molecular program
established in a primary breast carcinoma is highly preserved in its
distant metastasis. These findings suggest that metastatic capability in
breast cancer is an inherent feature, and is not based on clonal
selections. The results further imply that neo-adjuvant treatment given
to patients based on (yet to be established) response expression
profiles of their primary breast tumor might indeed prevent the
outgrowth of micrometastases.
Currently, the EORTC breast group is preparing a 5000-patient
randomized trial to compare the efficacy of guidance of breast cancer
patients for adjuvant chemotherapy based on either ‘conventional’ St
Gallen consensus criteria or the microarray prognosis test (MINDACT
trial within the EU-TRANSBIG program). The aim of the study is to
confirm that the microarray test will save up to 30% of the patients
from unnecessary chemotherapy and to identify 5% of them who are
nowadays ‘undertreated’.
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Cancer and other genetic diseases are characterized by genome
alterations, including DNA copy number changes. Comparative
genomic hybridization (CGH) represents a powerful technique to
detect and map these aberrations, and recent improvements in
resolution and sensitivity have been possible through implementation of
microarray-based platforms. Germline mutations in the two major
breast cancer susceptibility genes, BRCA1 and BRCA2, account for a
significant proportion of all hereditary breast cancers. Earlier studies
have shown that inherited and sporadic tumors progress along
different somatic genetic pathways and that global gene expression
profiles distinguish between these groups. Using 1 Mbp resolution
BAC-array CGH analysis, we now show that genomic copy number
profiles similarly discriminate between BRCA1/BRCA2-related tumors
and sporadic tumors. Overall, BRCA1 tumors had a higher frequency
of copy number alterations than sporadic breast cancers. In particular,
frequent losses on 4p, 4q and 5q in BRCA1 tumors and frequent gains
on 7p and 17q24 in BRCA2 tumors distinguish these from sporadic
breast cancer. Distinct amplicons at 3q27.1-q27.3 were identified in
BRCA1 tumors, and amplicons at 17q23.3-q24.2 in BRCA2 tumors.
Moreover, evidence of a homozygous deletion in a BRCA1 tumor on
5q12.1 was obtained. Using a set of 169 BAC clones that detect
significantly different frequencies of copy number changes in inherited
and sporadic tumors, these subsets could be discriminated into
separate groups using hierarchical clustering. Further validation may
prove this tumor classifier to be useful for selecting familial breast
cancer cases, likely to carry BRCA1 or BRCA2 germline mutations, for
further mutation screening, particularly as these data can be obtained
using DNA prepared from archival tumor tissue.
Further improved genomic profiling was obtained by construction of
microarrays comprising 32,433 BAC clones, offering complete
genome coverage at single gene resolution, on average <50 kbp.
These new tiling 32k-arrays were evaluated on breast cancer cell lines
(BT-474, MCF7, HCC1937, SK-BR-3, L56Br, ZR-75-1), validated by
FISH and gene expression analysis. Known amplicons were resolved
and found to include complex patterns of narrow peaks, occasionally
including a few or even single genes. Several amplified regions and
genes on 17q and 20q were depicted and confirmed by demonstrating
strong correlations between gene copy numbers and expression.
Previously described as well as novel homozygous deletions, ranging
from a few BAC clones (<300 kb) to several Mbp, were observed,
including PTEN and other regions on 10q, CDH1/CDH3 on 16q22,
and new regions on 4q34 and 19p12, emphasizing the power of array
CGH in pinpointing genes of importance in tumor development. Array
CGH is a promising diagnostic tool in profiling of somatic and
constitutional genomic alterations.
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the age of onset of cancers in humans: the SNP 309
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The HDM-2 gene in humans has two promoters for transcription. 5′ to
the first exon is a maintenance promoter providing low levels of HDM-2
in the cell. In the first intron are the P53 DNA binding sites and the p53
inducible promoter that yields threefold to 10-fold more HDM-2 mRNA
after a p53 activation and response. When this intronic promoter is
employed, transcriptional initiation starts at the second exon and this
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mRNA is translated more efficiently than mRNA that starts at the first
exon. The coding region of the HDM-2 protein starts in the third exon.
At residue 309 in this first intron is a single nucleotide polymorphism,
with 12% of people being a G/G homozygote, 40% being a G/T
heterozygote and 48% of people being T/T wild-type homozygotes (the
G/G genotype is lower in black Americans and the sample size is now
over 300 people). We have found that the G/G genotype creates a
better SP-1 transcription factor binding site, raises the level of m-RNA
in unstressed cells and produces threefold to sixfold more HDM-2
protein in cells (cancer cells in culture) with the G/G genotype. This
mRNA starts at the second exon, and is probably translated better in
unstressed cells. After DNA damage or other stresses, P53 activity in
cells with the G/G genotype is lower and the percentage of cells
undergoing apoptosis is lower when compared with cells in culture
with T/T genotypes. We have reproduced these observations with
lymphocytes taken from human volunteers and placed in culture, with
EBV-immortalized B cells in culture, with primary fibroblasts in cell
culture and with cancer cell lines in culture. In 92 individuals that have
donated lymphocytes we see individuals forming a distribution of
apoptotic responses between 20% and 60% after gamma radiation,
with individuals being quite reproducible in repeated experiments. The
lower half of the distribution is heavily weighted with the G/G
genotype, while the upper half of the distribution has mainly the T/T
genotype. The higher HDM-2 levels in cells thus result in a lower
apoptotic index in cells from these volunteers. It has become clear in
recent studies that SNP 309 has a clinical impact. We have genotyped
two cancer cohorts, one at MD Anderson and one in Germany,
containing patients with sarcomas and breast cancers. The results
have been statistically significant (P = 0.01–0.02) and clear in both
cohorts, and the average age of onset of these cancers is 10–15 years
earlier in people with the G/G genotype than in people with the same
cancer with the T/T genotype. The interpretation is then that the
probability of eliminating pre-cancerous clones of cells via a p53
mechanism is lower in people with a G/G genotype (high HDM-2
levels) and the probability of developing a cancer at an earlier time in
life is higher. In addition, in patients that have a germline mutation in the
p53 gene (this yields one-half of the p53 protein level in a cell) those
individuals that have a G/G genotype or a G/T genotype develop
multiple cancers (three, four or five cancers) over their lifetimes, while
no T/T homozygotes develop that many independent cancers.
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Apoptosis is a regulated form of cell death that is important for normal
development and tissue homeostasis. Senescence produces ‘genetic
death’, in that the senescent cell is incapable of further propagation.
Both processes are frequently disrupted in cancer cells, and each act
as potent barriers to tumorigenesis. Since radiation and many
chemotherapeutic agents induce apoptosis or senescence, the
integrity of these programs can influence the outcome of cancer
therapy. Our laboratory strives to understand how cancer genes
control apoptosis and senescence in normal cells, and how mutations
that disrupt these processes impact tumor development and therapy.
The goal of these efforts is develop therapeutic strategies based on an
understanding of drug action and cancer genotype. We currently are
using genetically engineered mouse models to understand how
apoptosis and senescence are controlled in tumor cells, as well as the
response of tumors to conventional and targeted therapeutics. Recent
work exploring the action of tumor-derived myc mutants in oncogenesis
and the role of the p53 tumor suppressor network in the action of
targeted therapeutics will be discussed.
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Resistance to chemotherapy is the main obstacle to cancer cure.
Despite encouraging results from preclinical studies, we have limited
knowledge regarding mechanisms causing therapy resistance in vivo.
We previously identified mutations affecting the L2 and/or L3 domains
of the TP53 gene to predict resistance to anthracycline as well as
mitomycin therapy [1,2]. However, while TP53 mutations were
significantly associated with therapy failure, we observed tumours
resistant to therapy despite harbouring wild-type p53. We also saw
responding tumours among those harbouring TP53 mutations affecting
the L2 or L3 domains.
Based on these assumptions, we postulated that chemoresistance
could be due to failure of the ‘p53 pathway’ acting in concert with one,
or more, redundant pathways [3]. In a recent paper we thus reported a
mutation of the CHEK2 gene among one of the tumours resistant to
therapy despite harbouring wild-type TP53 [4]. In addition, we are
searching for redundant pathways that may compensate for the p53
mechanism. Strikingly, looking at genetic alterations associated with
resistance to other drugs with respect to other malignancies, this
seems to concentrate on drugs known to be involved in so-called
‘family cancer syndromes’, meaning genes involved either in growth
arrest, apoptosis or DNA damage repair [3]. This may seem logical, as
much of the damage created by chemotherapeutic drugs resemble
genetic events involved in carcinogenesis. Thus, at this stage, our
interest is focused on genetic pathways involving genes involved in
‘family cancer syndromes’. An update of our current results will be
presented.
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Cancer cell interactions with the extracellular matrix and the migration
therein require adhesion and traction provided by integrins, together
with pericellular proteolysis executed by extracellular matrix degrading
proteases. We have used experimental interference strategies and
identified plasticity of migration modes resulting in new ways of
dissemination. As imaged by three-dimensional matrix-based models
and intravital microscopy, quantitative reconstruction from movies has
shown how tumor cells depend on adhesion mechanisms but continue
to migrate after adhesion receptors are blocked, has shown how
proteases generate proteolytic tracks but are dispensable if ‘physical’
strategies allow cells to bypass tissue barriers, and has shown why
individual and collective invasion patters predispose to a different
outcome after pharmacotherapeutic intervention.
These findings have implications with reference to invasion as a
therapeutic target in progressive cancer disease.
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HER2-positive breast carcinomas have been shown to display an early
peak of relapses in the first 4 years after surgery, especially in the
node-positive subgroup. To explain this observation, growth factors
released at the time of surgery were investigated. The level of growth
factors of the EGF family, detected in postsurgical sera from breast
carcinoma patients, was found to correlate with surgical invasiveness.
Indeed, following radical mastectomy, higher levels of serum EGF-like
factors were found than after conservative surgery. This implicates that
the growth of tumors overexpressing HER2, activated by these growth
factors, should be stimulated after invasive surgery. Two retrospective
analyses of the HER2 status of primary tumors included in a
randomized clinical trial addressing the issue of conservative versus
invasive surgery and of radiotherapy were performed by immuno-
histochemistry using the standardized herceptest. Survival analysis
according to surgery indicated no differences in HER2-negative cases
but indicated a poorer survival for HER2-positive node-positive patients
who had mastectomy in comparison with those who had conservative
surgery. Furthermore, local relapses in patients who had conservative
surgery without radiotherapy were found to be anticipated in the
HER2-positive subset. This is a ‘proof of principle’ that surgery by
inducing growth factor release may be detrimental for patients with
HER2-positive tumors. To verify these findings, a prospective analysis
of the follow-up of more than 2000 patients who have had mastectomy
or conservative surgery is ongoing. Preliminary data indicate a
significantly worst prognosis of HER2-positive tumors after invasive
surgery, above all for tumors scoring 2+ by immunohistochemistry.
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Background Molecular profiling of breast cancer by DNA microarrays
has been used to classify tumors into five distinct subclasses that show
significant differences in clinical outcomes. Of these subclasses, the
luminal subtype A is associated with a relatively good prognosis [1-3].
Detection of disseminated tumor cells (DTC) in bone marrow (BM) can
independently predict future metastasis, which was confirmed in our
study of 817 early BrCa patients [4].
Materials and methods Fresh tumor samples were prospectively
collected during primary surgery from 123 of these patients, for
evaluation of the clinical significance of gene expression profiling and
for comparison of tumor subtypes with DTC detection in BM. The BM
samples were collected from iliac crests at primary surgery, followed by
immunocytochemical staining (anti-cytokeratin mAbs) and morphology-
guided screening for DTC. Gene expression patterns of the primary
tumors were examined using 42,000 spot cDNA microarrays (Stanford
Functional Genomics Facility). Data were analyzed by hierarchical
clustering and were compared with our previously published breast
tumor subclassifications. Data were further analyzed by supervised
analysis methods (SAM, PAM).
Results The tumors were classified by gene expression analysis into
luminal A (41%), luminal B (13%), ERBB2+ (17%), basal-like (14%)
and normal-like (12%). The luminal A subtype showed high ER/PgR-
positivity (98%), low ERBB2-positivity (4%) (assessed by IHC) and low
frequency of TP53 mutations (6%). Luminal B, ERBB2+ and basal-like
subtypes showed high frequencies of TP53 mutations (43%, 65%, and
82%, respectively), whereas the ER/PgR-positivity was 94%, 24% and
6%, respectively. Expression of the ERBB2 protein differed between
these groups. At median 60 months follow-up, luminal A patients
showed improved survival compared with patients within the other
subtypes (P = 0.02, log rank), with BrCa death in 14% versus 29%,
respectively. DTC in BM were detected in 23.7%. No particular
subtype was associated with DTC, and no particular gene profile was
associated with DTC status, as determined by SAM analysis. However,
when we stratified the patients based on the molecular subtype, and
first considered only the luminal A tumors, we identified 193 genes
(FDR 23%) associated with high expression in tumors from patients
with DTC. Moreover, a considerable number of patients with a luminal
A type of tumor experienced systemic relapse of the disease (28%)
and SAM analysis identified 147 genes associated with different
expression patterns in tumors from relapsed patients versus disease-
free patients
Conclusion This early BrCa study confirms the consistency of the
gene expression profiles and their clinical implications. DTC detection
can further distinguish the clinical outcome in patients with the luminal
A subtype. The gene expression patterns in DTC-positive patients, and
in all patients with systemic relapse, will be further explored.
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Hormonal therapies involving estrogen deprivation or SERMs such as
tamoxifen reduce the risk of relapse and improve the survival of the
>75% of breast cancer patients with ER-positive tumours.
Nonetheless, many of these patients relapse with disease that was
either intrinsically resistant to treatment or that has acquired resistance
to the endocrine treatment. Laboratory studies have revealed that
growth factor receptor pathways form an important route of growth
signalling in both these circumstances, and there is now a series of
agents available that target these pathways at different points. This
provides the opportunity to utilise these agents in combination with
endocrine treatment and the possibility that this may extend the
effectiveness of the hormonal agents. The effective delivery of such
combinations depends on a detailed knowledge of the degree to which
the highly encouraging laboratory findings are translated into the
clinical scenario. We have demonstrated that almost all breast ER-
positive cancer shows some proliferative dependence on oestrogen,
but that this is very variable. We have begun to identify in clinical
samples the key genes whose expression both determines this
variability and are themselves dependent on it. The development of
novel models of drug development that allow the assessment of the
expression of these genes, particularly within the presurgical setting,
offers major opportunities to assess the potential of the various new
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The cyclin-dependent kinases form a large family of enzymes in human
cells that are involved in the control of cell proliferation and
transcription. A large number of small molecule inhibitors of this class
of enzyme have been developed in both the pharmaceutical and
academic communities, and at least two have entered clinical trial,
having shown efficacy in preclinical models. Alterations in the activity of
this class of enzymes is a frequent feature of human cancers, brought
about by altered expression of either the enzymes themselves or their
regulators such as p21, p27 and p16. The exact role of each of the
different kinases has proved hard to determine as knockout mouse
studies have implied a degree of redundancy and the exact substrates
of each enzyme in vivo are still unclear. In addition, most of the current
inhibitors are not specific to a single form of the enzyme and new
regulatory pathways are still being discovered. Intense studies of one
such inhibitor, R-Roscovitine (CYC202), including trials involving more
than 100 patients, have established the potential of the class as non-
genotoxic anti-cancer drugs. In some model systems the activity of this
class of compound is best explained by their activity as inhibitors of
transcriptional elongation, and a link between this mechanism and the
induction of apoptosis has been established. The concept of cyclin-
specific inhibitors as more sophisticated genetic models of target
validation in this field will be discussed.
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Background Fifteen per cent to 20% of the familial clustering of breast
cancer is explained by the effects of highly penetrant mutations in
BRCA1 and BRCA2. Modelling based on the patterns of familial
aggregation of breast cancer in the relatives of cases ascertained on a
population basis suggests that much of the remaining familial effect is
due to the combined effects of genetic variants individually of small
effect. The numbers of such variants, their allele frequencies and the
strength of their effects is not known.
Methods We have carried out association studies to search for
common variants (minor allele frequency >5–10%) that contribute to
predisposition,. To date we have studied 400 SNPs in 110 genes
using a two-stage study design, in which a first set of 2300 cases and
controls is analysed and all SNPs with a significance value of P < 0.1
or better are then tested in a second, similar, case/control set.
Results No individual SNP has, to date, given a P value for association
(based on genotype distribution) lower than 10–4. A number of SNPs
give P values between 10–2 and 10–4, depending on the genetic model
that is chosen for the analysis. Most of these are probably false
positives, the consequence of multiple testing. However, comparison of
the distribution of P values across the entire study set with that
expected if there were no genetic effect suggests that some of these
are probably true positive associations, representing low-level
predisposing effects.
Conclusions A candidate gene approach is slow and relatively
expensive, and has not so far yielded unequivocal positive results for any
individual gene. The ‘genetic architecture’ of breast cancer — that is, the
number and characteristics of predisposing genetic variants — is still not
known. In an attempt to elucidate this and to hasten the process of gene
discovery, we have initiated (with collaborators in the UK and at
Perlegen Science Inc.) a genome-wide scan. Again we use a two-stage
approach. In the first stage we will evaluate 266,000 SNPs in 400
breast cancer cases and 400 controls. The cases will be ‘enriched’ for
genetic effects by choosing those with a family history, tested negative
for BRCA1/2 mutation. In the second stage, ~5% of SNPs will be
further evaluated in 4600 cases and controls. A final stage of evaluation
for positives from the second stage, and from our earlier studies, will
require analysis of a further, very large (~10,000), case/control set,
which we hope to assemble through international collaboration.
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Background One of the major remaining deficits in our understanding
of the human genome is that information regarding gene function is
available for only one-quarter of the approximately 30,000 genes. Many
of these hitherto anonymous genes are potential targets for the
development of new anti-cancer drugs. It is therefore important to
functionally annotate the tens of thousands of genes for which this
information is currently lacking. My laboratory has developed functional
genetic approaches to obtain information regarding gene function
using high-throughput screens in mammalian cells. We have developed
both gain-of-function genetic screens (using retroviral cDNA
expression libraries) and loss-of-function genetic screens (using vector-
based RNA interference libraries) to carry out large-scale genetic
screens in mammalian cells. We focus on the central growth-regulatory
pathways that are most frequently deregulated in cancer.
Methods We have designed a mammalian expression vector (pSUPER),
which directs the synthesis of short hairpin transcripts (shRNAs) that are
processed intracellularly into siRNA-like molecules. This vector mediates
persistent inhibition of gene expression in a highly specific fashion. We
have used this vector to stably suppress expression of individual
members of several cancer-relevant gene families.
Results We used a retroviral derivative of the pSUPER siRNA vector
to generate a large collection of siRNA vectors that each target a
single gene for suppression. In total, we constructed a set of 23,742
siRNA vectors that together target 7914 human genes for suppression
by RNA interference. Furthermore, we developed a very efficient way to
identify biologically active shRNA vectors in a large population of
vectors, a technology that we named ‘siRNA bar code screening’. We
will present two applications of this technology to study major
questions in breast cancer. First, we have used the RNAi library to
identify genes whose suppression causes resistance to anti-hormonal
therapy (tamoxifen resistance). In addition, we have used RNAi
technology to ask how clinical resistance to the Her2/neu/ErbB2-
targeted therapeutic Herceptin can arise.
Conclusion RNA interference is a powerful technology to identify
genes that are causally involved in disease processes. Application of
this technology to breast cancer may greatly expedite the development
of novel diagnostics and therapeutics for the treatment of this disease.
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The completion of the human genome as well as the explosion of novel
technologies within genomics, proteomics and functional genomics
promise to have a major impact on clinical practice, as these
technologies are expected to accelerate the translation of basic
discoveries to the clinical practice. In particular, proteomic
technologies are expected to play a key role in the study and treatment
of cancer as they provide invaluable resources to define and
characterize regulatory and functional networks, to investigate the
precise molecular defect in diseased tissues and biological fluids, and
to develop specific reagents to precisely pinpoint a particular disease
or stage of a disease. For drug discovery, proteomics assist with
powerful tools for identifying new clinically relevant drug targets, and
provide functional insight for drug development.
Today, the application of novel technologies from proteomics and
functional genomics to the study of cancer is rapidly shifting to the
analysis of clinically relevant samples such as fresh biopsy specimens
and fluids, as their use will accelerate the translation of basic
discoveries. Being a patient-oriented organisation, The Danish Cancer
Society catalysed in 2002 the creation of a multidisciplinary research
environment, the DCTB, to fight breast cancer. The DCTB hosts
scientists working in various areas of preclinical cancer research (cell
cycle control, invasion and microenvironmental alterations, apoptosis,
cell signalling, and immunology) with clinicians (surgeons, oncologists)
and pathologists in an integrated, mission-oriented, discovery-driven
translational research environment. The unifying concept behind our
experimental strategy is the use of multiple experimental paradigms for
the prospective analysis of clinically relevant samples obtained from the
same patient, along with the systematic integration of the biological
and clinical data.
Here I will describe our efforts to apply proteomics approaches to
search for markers for early detection of breast cancer using the newly
characterized interstitial fluids recovered from fresh tissue biopsies of
both normal (NIF) and tumour (TIF) origin. The protein composition of
the fluids is strikingly different to that of serum and cyst fluids, although
they share some of their major components. The TIF is highly enriched
in proteins that are either secreted via the classic endoplasmic
reticulum/Golgi pathway, shed by membrane vesicles (membrane
blebbing), or externalized by plasma membrane transporter. Hundreds
of primary translation products, as well as post-translational
modifications, have so far been identified using a combination of
procedures that include mass spectrometry, two-dimensional gel
immunoblotting, and cytokine and signalling pathway-specific antibody
arrays. The workflow to biomarker discovery as well as recent
developments will be discussed.
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Objective Our aim is to identify new molecular targets and
mechanisms for therapeutic intervention in cancer. To achieve this aim,
we develop and apply multiple high-throughput technologies including
‘in silico’ screening as well as technologies for molecular, cellular and
clinical discovery research. Finally, data integration from these
technology platforms is applied to facilitate interpretation and
prioritization of the findings.
In silico screening In order to make use of the exponential increase of
published data on gene expression arrays, we have launched a project
to acquire and make use of these data as a discovery resource. We
currently have data on 5700 samples analyzed on the Affymetrix gene
expression platform stored in our relational database. These samples
include, for example, 64 normal tissues/cell types, 43 tumor types,
many other diseases as well as functional experiments; altogether
84 million data points. We have developed methods to mine these data
to identify tissue-specific and disease-specific expression patterns of
transcripts, to identify gene coexpression profiles, to explore networks
of gene regulation as well as methods to interpret new microarray
experiments. In silico transcriptomic screening makes it possible to
generate dozens of testable hypotheses for laboratory analysis based
on datasets that are much larger and more extensive than any single
academic laboratory can afford to generate. Analysis of gene
expression profiles across hundreds of tissue and tumor types,
diseases and experimental manipulations generates novel, often
unexpected, insights of gene function as well as of the underlying
biology and medicine. 
Molecular screening Large cohorts of clinical samples are now being
investigated not only at the RNA level by gene expression profiling, but
also at the DNA-level using comparative genomic hybridization (CGH)
arrays for analysis of somatic genetic alterations or SNP arrays for
studies of allelic gains and losses. There is also an emerging interest
for large-scale proteomic and metabolic profiling. It will be increasingly
important to integrate multiple levels of molecular profiling data to gain
new insights and comprehensive views on mechanisms of cancer
development. We are applying single-gene resolution oligo-CGH
arrays and integrating these data with gene expression information on
the same samples. The increased CGH resolution has highlighted
several microdeletions as well as small amplifications, whose impact on
gene expression can be substantial and highly specific. This has led to
an opportunity for rapid identification of genes that may be targets of
genetic alterations in cancer. As demonstrated by several recently
approved drugs for cancer, such mutated genes represent attractive
targets for the development of effective cancer-specific therapeutics.
Functional screening using RNA interference The molecular profiling
of DNA expression patterns, RNA expression patterns or protein
expression patterns in patient samples is not sufficient for implicating
these molecules or molecular mechanisms as therapeutic targets. It is
also necessary to generate functional information on such genes and
pathways. Towards this aim, we have developed a high-throughput
screening system that is composed of a robotic, automated platform for
the analysis of up to 20,000 functional experiments with living cells at a
time using the 384-well microplate format. Cells are dispensed into
culture wells, exposed to siRNAs or small molecule compounds,
incubated for 1–3 days, washed, and stained with phenotype-specific
markers for cell growth, cell cycle distribution or induction of apoptosis.
The results are read by plate readers or cell cytometers. Functional
studies with RNAi libraries (e.g. 1000–10,000 siRNAs) have
implicated genes whose targeting by RNAi is lethal to specific cancer
types, such as breast cancer. Integration of such functional RNAi data
with gene expression and aCGH data has enabled us to identify genes
that are targets of genetic alterations and whose expression is required
for the maintenance of the malignant phenotype. Such genes represent
attractive candidate drug targets.
Clinical screening Data on molecular targets arising from functional in
vitro studies need to be corroborated in studies of large-scale clinical
sample cohorts in order to verify that such molecular targets are
relevant in clinical patient samples. A number of technologies are being
developed towards this aim. First, the in silico screening
transcriptomics database with 5700 samples has made it possible to
develop an approach for ‘in silico clinical validation’. It is possible to
determine the expression levels of any gene across a very large number
of tumor types and normal sample types. Second, more established
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technologies, such as tissue microarrays, facilitate the analysis of
individual DNA, RNA and protein targets in thousands of arrayed
patient samples, typically from formalin-fixed tumors. Tissue microarray
analysis with antibody binders produces definitive clinical data on the
expression of therapeutic protein targets, and enables quantitation of
drug target distributions at the population level (target epidemiology).
In order to further increase the throughput of molecular analyses, we
are developing methods to print tissue lysates from frozen samples in
an array format. Tissue protein lysate arrays will help to automate and
expand antibody-based validation of molecular targets in large cohorts
of tissue specimens.
Conclusion In summary, high-throughput technologies can be applied
in the ‘in silico’, molecular, cellular and clinical screening studies,
thereby substantially increasing the information and insights that can be
obtained on a single platform. Integration of data from the various high-
throughput platforms will facilitate a deeper, mechanistic interpretation
and understanding of cancer biology, which is an essential requirement
for the development of next-generation targeted therapies.
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We aim to understand how genome maintenance and stress
responses are coordinated by dynamically changing, multiprotein
complexes. Reversible complexes involve composite interfaces from
modular preformed and unstructured regions that provide strong,
specific contacts from the combination of relatively weak, modular
interactions. These individual modular interaction sites, which allow
protein exchanges and pathway progression, also provide possible
targets for new therapeutic strategies. DNA genetic integrity and
cancer avoidance depends upon the structure-specific repair and
replication nuclease flap endonuclease (FEN-1) and upon the trimeric
processivity factor PCNA. FEN-1 and PCNA complex structures and
mutational results provide a coherent model for DNA substrate
recognition and PCNA activation of FEN-1. Together, these structural
and mutational results support an interface exchange hypothesis for
coordinated transfer of DNA intermediates during PCNA-mediated
processes. We have furthermore defined analogous interface
exchange as an important coordinating factor for homologous
recombination repair (HRR) of DNA double-strand breaks. The
Mre11/Rad50 (MR) complex that first recognizes DNA double-strand
breaks and Rad51 complexes that promote recombination are
essential for DNA break repair and recombination processes. To help
understand the molecular mechanism of the MR complex in DSB
repair, we determined crystal structures of Mre11 and Rad50 catalytic
domains (Mre11cd and pfRad50cd), their interface, DNA interactions,
and a unique Zn-hook linking the 600 Å coiled-coil domain of Rad50.
The MR complex must handoff the DNA ends to Rad51, which
catalyzes homologous pairing and exchange between dsDNA and
ssDNA via orchestrated interactions with BRCA2, Rad52, and other
HRR proteins. We determined an atomic structure of a polymeric full-
length RAD51 homolog to reveal atomic details of quaternary
assembly, we experimentally test a proposed BRC repeat-induced
RAD51 disassembly mechanism and we address the molecular
mechanism for the orchestrated interactions of RAD51 in HRR. The
Rad51 structure reveals a polymerization motif involving an interdomain
linker key for quaternary assembly. Structural and mutational results
suggest how differences in RAD51 ring and helical nucleoprotein
filament assemblies may regulate ATPase activity. A RAD51 filament
assembly based on 3D EM reconstructions and crystallographic
interfaces suggests a novel role for RAD51 N-terminal domains in
binding dsDNA within a large outer groove. By taking advantage of the
simpler organization of archaeal recombination systems, our structural
and mutational results in conjunction with HsRAD51-AD:BRC4 results
establish at the molecular level how BRC repeats disrupt RAD51
assembly and direct RAD51 to form foci in cells in response to DNA
damage. Our results help support a molecular mechanism for the
ordered interactions of HRR partners BRCA2, RAD52, RAD54 and
RAD55 by protein-mediated and DNA-mediated exchanges of RAD51
polymer interface elements. To achieve accurate structural information
on these difficult but biologically relevant molecular complexes, we
have designed and developed the Structurally Integrated Biology for
Life Sciences beamline at the Advanced Light Source. This provides a
unique resource for X-ray diffraction characterizations of both static
and time-resolved solution states of macromolecular machines.
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Background The relationship between smoking and the risk of breast
cancer has been unclear for several decades, and whether or not
young women should be warned about smoking as a possible cause of
breast cancer remains controversial [1-3]. A recent pooled analysis of
53 epidemiologic studies found that the positive relationship with
smoking and breast cancer was present only among those consuming
alcohol, an established cause of breast cancer [4]. The purpose of this
report was to examine the effect of smoking on breast cancer risk
among non-drinking women in a large population-based cohort of
women, many of whom started smoking as teenagers.
Methods We followed 102,098 women, aged 30–50 years,
completing a mailed questionnaire at recruitment to the Norwegian–
Swedish Cohort Study in 1991/1992, through December 2000.
Altogether, 1240 women were diagnosed with incident, invasive breast
cancer. We used Cox proportional hazard regression models to
estimate the relative risk of breast cancer associated with different
measures of smoking initiation, duration, and intensity adjusting for
confounding variables. We conducted analyses on the non-drinking
study population, and especially among non-drinking women who had
smoked for at least 20 years.
Results We identified 214 breast cancer cases among the 19,288
non-drinking women. Compared with never smokers, women who
smoked for at least 20 years, and initiated smoking prior to their first
birth (relative risk = 1.75; 95% confidence interval = 1.02–2.99),
before menarche (relative risk = 1.66; 95% confidence interval =
0.79–3.49) or before age 15 (relative risk = 2.20; 95% confidence
interval = 0.92–5.30), had an increased risk. In contrast, women who
had smoked for at least 20 years, but started after their first birth, did
not experience an increased breast cancer risk (relative risk = 0.97;
95% confidence interval = 0.44–2.12).
Conclusion Our results support the notion that non-drinking women
who start smoking as teenagers and who continue to smoke for at least
20 years may increase their risk of breast cancer.
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Background Germline mutations in BRCA1 and BRCA2 genes
account for most of the hereditary breast and ovarian cancers (HBOC).
Recently, other low-penetrance candidate genes involved in breast
cancer susceptibility, CHEK2 and ATM, have emerged. We have
initiated mutation screening of suspected HBOC families to improve
health care for affected individuals and their asymptomatic relatives in
the Slovak Republic.
Methods We performed a mutational analysis of the entire coding
region of the BRCA1 gene in 110 suspected HBOC families from all
parts of Slovakia. DNA from peripheral blood lymphocytes was
analyzed by the combination of a single-strand conformation poly-
morphism (SSCP), heteroduplex analysis (HDA), protein truncation test
and direct DNA sequencing. Initial screening of the first 16 BRCA2
exons in 40 HBOC families was performed using SSCP and HDA. To
investigate the presence of the CHEK2*1100delC variant, DNA from
65 selected patients was screened by denaturing high-performance
liquid chromatography.
Results To date, we have detected eight previously described mutations
(185delAG, C39R, C61G, 962del4, L1013X, 2072del4, 3819del5,
5382insC) and one novel BRCA1 deletion (2057delCAGTGAAGAG)
in DNA samples of 16 HBOC families. Initial screening for germline
mutations in BRCA2 revealed one recurrent mutation, 6696delTC, in
the very large HBOC kindred. Out of 67 asymptomatic relatives from
families with the identified BRCA1 or BRCA2 mutations, 31 were
found to be mutation carriers. These individuals are included in the
Special Program of Preventive Health Care. Mutation analysis has also
identified 17 different polymorphisms or unclassified sequence variants
scattered through the BRCA1 and BRCA2 genes in 48 patients from
the analyzed collection of HBOC families. From these, the most
frequent alterations were L771L, E1038G and K1183R, presented in
11, 10 and nine patients, respectively. We have not detected any
1100delC variant of the CHEK2 gene in 65 tested HBOC patients.
Conclusion In order to identify patients and families predisposed to
hereditary breast and ovarian cancer, we searched for germline
mutations in two major breast and ovarian cancer susceptibility genes,
BRCA1 and BRCA2. Screening of the whole coding sequence of the
BRCA1 gene and the first 16 exons of BRCA2 in selected families has
identified the spectrum of mutations previously reported in HBOC
families of different ethnic or geographic origin. In addition, we found
the novel BRCA1 mutation 2057del10, detected in a very high-risk
family characterized by different types of cancer (breast and ovarian
cancer, male breast cancer, lung cancer, colorectal cancer and
testicular cancer). The first results from a small collection of 65 patients
did not confirm the correlation between the CHEK2*1100delC variant
and breast cancer in these cases, according to the fact that none of
the tested DNA was found to be positive. Although the screening of
BRCA2 gene needs to be completed, the achieved results represent
the first molecular characterization of Slovak HBOC families.
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Background The human BRCA1 gene is under transcriptional control of
two alternative promoters, α and β, that drive the transcription of exon 1a
or exon 1b, respectively. Additionally, the 5′-UTR region, encompassing
both exons 1, contains multiple putative and functional regulatory
sequences. At the RNA level each exon 1 is linked, by splicing, with exon
2 that contains the translation start site. The aim of this study was to
search for sequence alterations within the BRCA1 promoter and 5′-UTR
in patients with breast and/or ovarian cancer, and to assess whether these
sequence variants influence activity of the BRCA1 promoter region.
Methods The 5′ region of the BRCA1 gene, containing promoters α
and β as well as exons 1a and 1b and the fragment of intron 1, was
sequenced in 87 breast/ovarian cancer cases. All patients had a strong
family history of breast and ovarian cancer, but were found mutation-
negative in our previous search for founder mutations in BRCA1
(185delAG, 300T/G, 4153delA, 5382insC) and BRCA2 (6174delT,
9631delC). The frequency of the 2223delAAAAA deletion was
assessed using allele-specific PCR amplification (ASA) in a larger
group of breast/ovarian cancer patients fulfilling the aforementioned
criteria. The functional significance of sequence variants within the 5′-
UTR of BRCA1 was analyzed by luciferase assay. A 1.5 kb DNA region
encompassing minimal BRCA1 promoter and 5′-UTR, both wild type
and variant sequence, was cloned into the pGL3 vector containing the
luciferase reporter gene. The luciferase activity reflected the influence
of the sequence alterations on the transcriptional activity of the BRCA1
promoter and other gene regulatory regions.
Results We found several sequence variants within the examined non-
coding region of BRCA1. The frequency of the largest sequence
alteration found, deletion 2223delAAAAA (according to the Acc.
U37574) within exon 1b, was determined in a group of 150 patients.
Three families have been identified bearing the said deletion. We also
found two linked nucleotide substitutions (2642A>T, 2743T>C) in
BRCA1 intron 1. The functional impact of the most frequent sequence
alterations was examined in lung cancer cell line NCI-H1299 and
breast cancer cell line MCF7. In the MCF7 cell line all tested variants of
BRCA1 promoter/5′-UTR showed lower activity than the control wild-
type sequence, while in NCI-H1299 cells the variant promoter/5′-UTR
activity was higher than the control. However, observed differences of
luciferase activity were not statistically significant.
Conclusion Our luciferase assay showed that sequence variants
detected in our study within the BRCA1 promoter/5′-UTR do not
change the functional activity of the BRCA1 promoter in the
experimental system that we have used, and may not be associated
with an increased risk of breast and ovarian cancer. The detailed
results of the analyses will be presented.
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Background The implementation of informative BRCA1 testing
programs is aided by acquisition of population-specific genetic data.
Available online http://breast-cancer-research.com/supplements/7/S2
S18
From this it emerges that a number of mutations have been found
repeatedly, and specific mutations are common in defined populations.
This can be referred to a founder effect that in human genetics refers to
the presence of genetic disorders that are either endemic to an
isolated population or are very rare elsewhere. In a previous population-
based study we described the first example of a founder BRCA1
mutation in Italy, with a strong recurrence of the 5083del19 in high-risk
patients all of Calabrian origin selected for family history of the disease
[1]. The same mutation accounts in Canada for a significant percen-
tage of women of Italian ancestry with breast–ovarian cancer [2].
The aim of this study was to investigate the extent to which the
5083del19 mutation contributed to breast–ovarian cancer incidence in
Calabria, and to perform some genotype–phenotype correlations.
Methods We tested 70 paraffin-embedded tissue specimens from a
consecutive series of breast or ovarian cancer cases. It is estimated
that our tissue archive collects more than 90% of incident cancers in
the Catanzaro area. Archival tissue samples were genotyped only for
the 5083del19 founder mutation. Immunohistochemical staining of
several markers (i.e. ER, PR, Ki67, p53, HER2, CK5/6) as well as some
pathological features (i.e. histology, grade) were evaluated.
Results Seven out of the 70 samples screened for this BRCA mutation
had mutations. Haplotype analysis revealed a common ancestor. All
cases aged in premenopausal years. The phenotype of the 5083del19
BRCA1-associated breast tumours appears characterized by a lack of
expression of hormone receptors and is generally associated with high
proliferation markers and poorly differentiated aspects. All cases were
ductal invasive carcinomas and showed a ‘basal-like’ portrait according
to expression profiling studies [3]. The median age at diagnosis of the
ovarian cancer carriers was 49 years and the histological type was
serous adenocarcinoma.
Conclusion A predominant BRCA1 gene founder mutation associated
with a high risk of early onset breast cancer and ovarian cancer and
unfavourable immunophenotype features has been identified and found
to occur in a restricted geographical area, thereby allowing timely and
cost-effective mutation screening using blood samples or archival
histological material.
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Standard PCR-based mutation detection strategies performed on the
BRCA1 and BRCA2 genes of breast and ovarian cancer families are
mostly aimed at identifying changes in the coding sequences and in the
donor–acceptor splice sites. Hence, mutations in the promoter and the
untranslated regions, and large rearrangements, are not detected by
these methods. To assess the importance of BRCA1 and BRCA2
alterations that are neglected by standard screening methods, we
monitored germline rearrangements in these genes using ‘multiplex
ligation-dependent probe amplification’ technology [1]. One hundred
and seventy-nine Norwegian breast and ovarian cancer families were
screened for rearrangements in BRCA1 while 97 families were tested
for aberrations in BRCA2. Whereas no rearrangements were detected
in BRCA2, four distinct deletions were found in BRCA1. Those
deletions originating by Alu-mediated homologous recombination
include: exons 1–13, exons 3–16, exons 8–13 and exon 23,
respectively. The large 23.8kb deletion excluding exons 8–13 in
BRCA1 has been found both in the French and British breast cancer
population [2-4]. The deletions of exons 1–13, exons 3–16 and exon
23 have not been previously reported.
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Background Germline mutations in the highly penetrant cancer
susceptibility genes BRCA1 and BRCA2 cause genetic predisposition
to breast and ovarian cancers. Molecular genetic testing of pathogenic
mutations in these two genes is an effective method for breast cancer
risk prediction. Genetic counselling and testing has been provided to
high-risk women in our institute since 1997. Until now 589 probands
(580 women and nine men) with breast/ovarian cancer have been
tested for BRCA1/2 germline mutations.
Methods Genetic counselling was performed by a medical geneticist
in our institute or in other genetic centres of the Czech Republic.
Informed consent was signed in all tested individuals. For genetic
testing the non-radioactive protein truncation test of exon 11 of
BRCA1 and exons 10 and 11 of BRCA2 were used, followed by
heteroduplex analysis of the remaining exons with their splice sites and
by sequencing. The frequency of unknown variants was tested in a
control group of healthy women older than 60 years without a positive
family history of breast/ovarian cancer.
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Results The pathogenic mutation was found in 179 of 589 tested
probands (30%), 106 in the BRCA1 gene and 73 in the BRCA2 gene.
The frequency of detected mutations was calculated in different
categories of family history and in sporadic cases. Mutation was found
in 86 of 213 (overall 40.4%, hereditary ovarian cancer [HOC] +
hereditary breast and ovarian cancers [HBOC] 63.6%, hereditary
breast cancer [HBC] 30.8%) families with three or more cases of
breast or ovarian cancer (bilateral cancer was counted as two cases),
in 66 of 258 (overall 25.6%, HOC + HBOC 46.8%, HBC 22.1%)
families with two breast or ovarian cases, in four of 14 (28.6%)
probands with sporadic bilateral breast cancer first diagnosed before
age 50, in three of seven (42.9%) women with sporadic bilateral
ovarian cancer under age 50, in 11 of 12 (91.7%) women with
sporadic breast and ovarian cancer diagnosed at any age, in six of 66
(9.1%) women with sporadic unilateral breast cancer before age 40, in
zero of 10 women with sporadic unilateral ovarian cancer before age
40, in three of six (50%) males with familial form of breast cancer, and
in one of three (33.3%) males with sporadic breast cancer.
There are five most frequent mutations in the Czech population,
which represent 56.8% of all mutations found (c.5385dupC,
c.3819_3823delGTAAA and c.300T>G in BRCA1;
c.8138_8142delCCTTT and c.8765_8766delAG in BRCA2). Overall
14 novel pathogenic mutations were detected, eight of them have been
published by our group [1,2] and the other six mutations have not yet
been published. A spectrum of 28 variants (13 in BRCA1 and 15 in
BRCA2) with unknown clinical significance was found. The most
frequent variant was c.5075G>A, p.M1652I, in the BRCA1 gene (in
22 cases), but the frequency of this variant in a control population was
6.3%. The missense mutation in the BRCA1 gene c.172T>A, p.M18K,
was detected three times in HBOC and HBC families, and is very
probably pathogenic (localised in a highly conserved structure of the
Ring finger domain); it was not detected in a control group. Another
two variants were detected in a control population with frequency
1.6%: IVS24/c.9485-16T>C and c.10323delCins11 in the BRCA2
gene.
By predictive testing, positive carrier status was disclosed in 163
individuals of 395 tested. The clinical follow-up was offered to all
individuals at high risk. The high-risk clinic at MMCI is following 62
healthy carriers, 139 healthy people at risk, 47 patients–carriers and
29 high-risk patients with negative testing result. From these, 14
patients and three healthy carriers underwent prophylactic mastectomy,
26 patients and four healthy carriers underwent prophylactic
adnexectomy. According to the questionnaire for diagnoses of
depression CES-D instituted before testing, 51% of women did not
report any signs of depression, 27% reported very mild, 14% middle
and 8% severe signs of depression. A psychologist in our institute
follows 27 women. No severe psychological complications of testing
have so far been reported.
Conclusion Overall, pathogenic mutation was disclosed in 30% of all
our tested individuals with familial or sporadic breast (or ovarian)
cancer. At least one ovarian cancer in a high-risk family increases twice
the likelihood of mutation detection. Fourteen novel mutations and a
spectrum of unknown variants were detected. Prophylactic
mastectomy is not so frequently accepted by mutation carriers as in
Western Europe, but there is an increasing tendency especially in
young women. The quality of preventive care in other institutions and
the psychosocial influence of genetic testing are now being
investigated.
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Germline mutations in BRCA1 and BRCA2 account for approximately
2–3% of breast cancers while CHEK2*1100delC may account for an
additional 0.7% [1]. To date, several small studies have suggested a
worse outcome of survival in BRCA1 and BRCA2 carriers. However,
the evidence is inconsistent and most studies were subject to different
types of bias. An increased risk for contralateral breast cancer,
especially in interaction with radiotherapy, for CHEK2*1100delC
carriers has been shown [2]. Only one study has so far evaluated the
impact of CHEK2*1100delC on survival, showing a worse disease-free
survival compared with control breast cancer patients [3].
Our aim is to evaluate breast cancer survival and to determine risk
estimations for the development of contralateral breast or ovarian
cancer (as a second primary), as well as to evaluate tumour
characteristics, in BRCA1/2 and CHEK2*1100delC carriers in an
unselected, non-family based, retrospective cohort of breast cancer
patients diagnosed under age 50. The cohort to be evaluated will
include approximately 5000 patients, treated in several Dutch hospitals
between 1973 and 1995. Tissue blocks from these patients are being
obtained and, after coding, about 70 BRCA1/2 founder and recurrent
mutations, representing approximately 72% of the Dutch BRCA1/2
mutations, and the CHEK*1100delC mutation are being determined.
Data for 1700 patients from the Netherlands Cancer Institute and the
Leiden University Medical Center are being completed. We have so far
found, in 1255 samples, 4.1% BRCA1/2 carriers (41 BRCA1 and 11
BRCA2 mutations) and 3.8% CHEK2*1100delC, with no overlap
among these groups. An interim analysis showed that BRCA1 tumours
seem to have less favourable prognostic characteristics while BRCA
carriers have an OR of 3 for contralateral breast cancer compared with
the non-BRCA carriers. Genetic determinants of tumour
characteristics, risk for contralateral breast cancer and survival of
CHEK2*1100delC carriers will be presented.
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Background Women who carry germline mutations in the BRCA1 and
BRCA2 genes are at a greatly increased risk of breast cancer (BC).
Numerous studies have shown that exposure to ionizing radiation is a
risk factor for BC. Because of the role of the BRCA proteins in DNA
repair it is plausible that women who carry mutations in these genes
might be more sensitive to ionizing radiation than women in the general
population. We therefore determined the role of low-dose ionizing
radiation in carriers of a BRCA1 or BRCA2 mutation.
Methods A retrospective cohort study of 1601 female BRCA1/2
carriers, of whom 879 were affected with BC at the time of interview,
was performed. Exposure data were analyzed using a weighted Cox
proportional hazards model. We assessed the relative risk of BC as a
function of exposure to chest X-rays as assessed by questionnaire.
Results In the entire cohort, any reported exposure to chest X-rays was
associated with a significantly increased risk of BC (hazard ratio [HR] =
1.54, 95% confidence interval [CI] = 1.1–2.1, P = 0.007) compared
with those reporting never having had an X-ray. This risk was increased
in carrier women aged 40 and younger (HR = 1.97, 95% CI = 1.3–2.9,
P < 0.001), and in women born after 1949 (HR = 3.6, 95% CI =
2.1–6.2, P < 0.001). Estimated risks were highest in women exposed
to X-rays before age 20 only, particularly those born in later birth
cohorts (HR = 4.85, 95% CI = 2.2–10.9, P < 0.001).
Conclusions The observed patterns of risk are consistent with those
found in previous studies of radiation and BC, but the extent of the risk
increase in BRCA carriers appears to exceed several-fold that
observed for other radiation-exposed cohorts. The results of this study
have important implications for the use of X-ray imaging in BRCA1/2
carriers, particularly before age 20.
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Studies have shown that (bilateral) prophylactic mastectomy in
genetically predisposed populations reduces the risk of breast cancer.
Since BRCA1 and BRCA2 germline mutation testing became widely
available (1995), breast cancer patients with a family history of breast
cancer have also been tested. After having been identified as a
BRCA1 or BRCA2 carrier, some women decide to undergo a
contralateral prophylactic mastectomy (CPM) while others choose for
intensive surveillance. The impact of this choice on contralateral breast
cancer incidence and survival is still unknown.
We identified a cohort of 148 female BRCA1 or BRCA2 mutation
carriers (115 and 33, respectively) who previously were treated for
unilateral invasive breast cancer stage I–IIIa. Seventy-nine women
underwent a CPM, while the other women remained under intensive
surveillance. The mean follow-up was 3.5 years and started at the time
of CPM or at the date of mutation testing, whichever came last (i.e. on
average, 5 years after diagnosis of the first breast cancer).
One woman developed an invasive contralateral primary breast cancer
after CPM, whereas six were observed in the surveillance group
(P < 0.001). CPM reduced the risk of contralateral breast cancer by
91%, independent of the effect of bilateral prophylactic oophorectomy
(BPO). At 5-year follow-up, overall survival was 94% for the CPM
group versus 77% for the surveillance group (P = 0.03). Unexpectedly,
this difference in survival was mostly due to higher mortality related
with the first breast cancer and ovarian cancer in the surveillance
group. After adjustment for BPO in a multivariate Cox analysis, the
CPM effect on overall survival was no longer significant.
Our data show that CPM markedly reduces the risk of contralateral
breast cancer among BRCA1 or BRCA2 mutation carriers with a
history of breast cancer. Longer follow-up is needed to study the
impact of CPM on contralateral breast cancer specific survival. The
choice for CPM is highly correlated with that for BPO while only BPO
so far leads to a significant improvement in overall survival.
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Background The marked reduction of the risk of breast cancer
following a prophylactic oophorectomy illustrates that endogenous
hormones play an important role in the etiology of breast cancer among
BRCA1/2 mutation carriers, as they do in the general population. In the
general population the use of oral contraceptives has been associated
with a slightly increased risk. Little is so far known about the safety of
oral contraceptives among BRCA1/2 carriers, who have much higher
premenopausal background rates of breast cancer.
Methods A retrospective cohort study was performed using an
international cohort of 1601 BRCA1/2 mutation carriers. A time-
dependent proportional hazard Cox regression was used, stratified for
birth cohort, gene, country of residence and relatedness. All analyses
were adjusted for prophylactic oophorectomy and number of full-term
pregnancies. To reduce possible testing bias, the analyses were
weighted to achieve the rate of breast cancer within the cohort as a
priori estimated for BRCA1/2 mutation carriers.
Results We found a slightly increased risk of breast cancer for
BRCA/12 mutation carriers who ever used oral contraceptives, with an
adjusted hazard ratio of 1.47 (95% confidence interval = 1.16–1.87).
The risk increase did not vary according to various aspects of oral
contraceptive use, such as time since stopping, duration of use, age at
start, and calendar year at start. In addition, the risk increase was
similar for BRCA1 and BRCA2 mutation carriers.
Conclusion Use of oral contraceptives seems to be associated with a
slightly increased relative risk of breast cancer among BRCA1/2
mutation carriers, comparable with the general population. However,
due to the high background rates of breast cancer among BRCA1/2
carriers, oral contraceptive use may result in a considerable absolute
excess risk of breast cancer, if the association is causal.
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Background A conventional model of inherited breast cancer
susceptibility is that disease risks are affected by mutations in a small
number of genes causing a high risk of the disease and by a larger
number of lower risk gene variants probably interacting together [1].
Model-based linkage analysis in multiple-case families, followed by
positional cloning, led to the identification of BRCA1 and BRCA2. The
cancer risks conferred by mutations in these genes are now well
established, but together they explain only approximately 25% of the
overall excess familial risk. Families with at least four cases of breast
cancer and at least one case of ovarian cancer can be attributed
largely to BRCA1. Multiple-case families with at least one case of male
breast cancer are mainly due to BRCA2. But the majority of families
with four or five cases of female breast cancer diagnosed before the
age of 60 are not due to BRCA1 or BRCA2. This has been taken as
evidence that one or more moderate-risk to high-risk breast cancer
susceptibility genes still remain to be identified [2].
Methods There have been several linkage claims since BRCA1 and
BRCA2 were identified, but none of these have been replicated in
other, often larger, studies. Most studies, however, are heavily
underpowered to detect a new breast cancer locus by linkage in the
presence of substantial genetic heterogeneity. The Breast Cancer
Linkage Consortium is currently compiling genome-wide linkage data
on approximately 200 families in which the role of BRCA1 or BRCA2
has been excluded with >90% certainty. This comprises the largest
post-BRCA1/2 linkage search effort in breast cancer families in the
world to date. These families are characterised by the presence of at
least three cases of breast cancer diagnosed before the age of 60, and
no cases of ovarian or male breast cancer.
Results Here we present the Dutch contribution to this effort, including
GENEHUNTER analysis of 56 families in which 208 patients were
genotyped at 410 microsatellite markers. Allowing for heterogeneity, there
were two regions, on 1q and 15q, that gave lod scores of 1.40 (α = 0.12)
and 1.19 (α = 0.29), respectively. Lod scores for all other markers were
<1.0. In non-parametric analysis, lod scores >1.0 were found for one or
more markers at 4p, 6q, 7q, 9p, 15q, and 21q. All of these regions are
currently being followed up by additional flanking marker typings.
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We have looked for genetic differences influencing cancer risk in the
general human population. One human chromosomal region that recent
data indicate as important for cancer risk is 19q13.2-3, more
specifically a 69 kb region including the genes XPD, RAI, ASE1 and
ERCC1. We and others have produced evidence of association
between this region and occurrence of a variety of cancers, including
basal cell carcinoma, melanoma, lung cancer, glioma, breast cancer,
bladder cancer, and possibly head and neck cancer (see for instance
[1]). A recent search along the region for markers with maximal
association to basal cell carcinoma has led to a focus on the gene RAI
[2]. Moreover, the effect appears to be strongest among fairly young
persons (<56 years of age).
These studies mainly involved analysis of single nucleotide
polymorphisms in unrelated cases and controls. However, other
studies have mapped a glioma tumor suppressor function to an almost
overlapping region using deletions in tumor DNA [3]. Finally, a recent
genome-wide scan for chromosomal regions associated with
aggressive prostate cancer located the strongest effector in a 6 Mb
region, which includes the four genes mentioned [4].
It appears that this region of chromosome 19, most probably the gene
RAI, often contains a genetic variant, which increases the risk of
several cancers among fairly young humans. RAI produces an inhibitor
of NF-κB, and may thus be involved in apoptosis, which makes it very
easy to rationalize its importance for cancer. In addition, studies of lung
cancer have produced evidence for an independent effector within the
69 kb region of interest, possibly related to DNA repair.
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Background Breast cancer is one of the major cancers around the
world but its etiology is still not well understood. Only about 50% of
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the disease is associated with known risk factors including high-
penetrance genes and lifestyle factors. Candidate low-penetrance
genes are involved in a variety of pathways; for example, DNA damage
by free radicals. The enzymes involved in this mechanism are
N-acetyltransferase2 (NAT2) and manganese superoxide dismutase
(MnSOD). NAT2 catalyzes acetylation of aromatic amines and
hydrasines and forms of free radicals, and MnSOD catalyzes their
dismutation. Genes TGFBR1 and RGS19IP1 encode proteins that
take part in transforming growth factor beta signaling, mainly resulting
in inhibition of cell proliferation. The first exon of TGFBR1 contains a
polymorphic GCG repeat; (GCG)6 was previously reported as the
tumor susceptibility allele associated with some types of cancer. The
5′-untranslated region of RGS19IP1contains a CGG repeat, the
polymorphism of which had not been studied before.
Methods SNPs of NAT2 and MnSOD were detected by the PCR-
RFLP method, alleles of TGFBR1 were detected by electrophoresis
and RGS19IP1 alleles were detected by fragment analysis on 123
breast cancer cases and 121 controls.
Results We have assessed the frequency of frequent allelic variants of
NAT2 (NAT2*4 [wild type], NAT2*5 [T341C], NAT2*6 [G590A],
NAT2*7 [G857A]). The NAT2*11 allele in the Russian sample was
found as well. Our breast cancer cases had statistically significant
positive association with NAT2*6/*6 or NAT2*11 (33.4% vs 11.0%;
P = 0,0005; OR = 3.06 [95% CI = 1.62–5.77], cases vs controls).
The frequency of the NAT2*5 and NAT2*7 alleles was not significantly
elevated in our breast cancer sample compared with controls. The
MnSOD gene was studied for polymorphism of valine (V) versus
alanine (A) in the leader peptide at position 16. The V/V genotype
(MroNI–/–) was associated with decreased risk of breast cancer
(24.4% vs 38.0%; P = 0.0268; OR = 0.53 [95% CI = 0.03–0.91]).
The risk of breast cancer decreased in a combination of NAT2*4,
NAT2*5 or NAT2*7 alleles and V/V genotype MnSOD (20.3% vs
36.1%; P = 0.0068; OR = 0.45 [95% CI 0.25–0.79]).
Our breast cancer cases had statistically significant positive
association with the (GCG)6 allele of TGFBR1 (13.8% vs 6.1%,
P = 0.016, OR = 2.47 [95% CI = 1.21–5.07]). Statistically significant
positive association with the genotype 6A/9A (20.2% vs 11.6%,
α = 0.05, OR = 1.92 [95% CI = 1.05–3.49]) was also revealed.
Genotype 6A/9A can be used as a predisposition marker, the relative
risk for this genotype carrier being increased 1.7-fold. We have
identified a polymorphism of the CGG repeat in RGS19IP1 with at
least eight alleles: four major (CGG10–CGG13), with frequencies
20.4%, 41.6%, 27.6% and 10.4%, respectively; the rest of the alleles
are rare with overall frequency of 1% in control; heterozygosity, 0.729.
Our breast cancer cases had statistically significant positive
association with the rare alleles (4.7% vs 1%, P = 0.01, OR = 4.92
[95%, CI = 1.42–17.1]).
Conclusion All polymorphisms tested could be used as a panel of
markers for detecting families and individuals of high breast cancer risk
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BRCA1 and BRCA2 are high-penetrance genes that account for
around 25% of families with hereditary breast cancer [1]. Given that no
additional high-penetrance susceptibility genes have been found to be
involved in breast cancer, it has been proposed that different genetic
backgrounds due to the combination of low-penetrance genes
(polygenic mechanism) could explain the remaining familial breast
cancer risk [2]. Hence there is much interest in the search for low-
penetrance gene/variants for breast cancer, which exist with high
prevalence in the general population.
Single nucleotide polymorphisms (SNPs) have emerged as genetic
markers of choice because of their high density and relatively even
distribution in the human genomes [3,4], and are being using for fine
mapping of disease loci and for candidate gene association studies.
Approximately 10 million SNPs have been identified across the human
genome and new technologies are available today for high-throughput
genotyping.
In this study we used the SNPlex™ (Applied Biosystems, Foster City,
CA, USA) high-throughput genotyping platform, which allows the study
of up to 48 SNPs simultaneously, to study 984 SNPs of 92 cancer-
related genes, in a total of 480 female cases of breast cancer and 480
female controls.
Gene selection was made on the basis of their involvement in different
cancer pathways and genes: DNA reparation, cell cycle control,
BRCA1-associated binding proteins, and so on. SNP selection was
performed using an indirect approach (1 SNP/10 kb) and based on the
individual allele frequency (FAM ≤10%) in the European population,
using public and private SNP databases and bioinformatics tools
(dbSNP, HapMap, Sequenom Real SNP, PUPASNPI Ensembl, and
Celera, among others).
To date, 415 SNPs from 44 genes have been genotyped in nine
SNPlex pools. A case–control analysis was conducted for the 318
remaining SNPs. Preliminary results showed association in 24 SNPs
from 12 candidate genes (P < 0.05). We will present the analysis of
the remaining 48 genes at the time of the congress.
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Background Pharmacogenetic studies provide data of increasingly
many SNPs in relation to response to various treatments of
psychological disorders, cardiovascular disease and cancer.
Simultaneously, the HapMap and projects like it reveal the linkage
disequilibrium (LD) map of unselected genes in different human
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populations. To what extent does this knowledge of the LD domains
affect previous findings from pharmacogenetic studies of single
candidate SNPs? Here we select candidate genes as part of a given
functional pathway, and report their chromosomal localization and
extent of LD.
Methods A total of 193 breast cancer patients have been genotyped
for 725 SNPs in 206 genes selected through the candidate gene
approach. Two hundred and fifty-three of the SNPs have also been
genotyped in a cohort of 109 healthy Norwegian women. SNPs that
had a discovery rate lower than 75% were excluded. Hardy–Weinberg
equilibrium was calculated prior to further statistical analysis of LD. 
LD estimations were made using PHASE, a program that implements
methods for calculating haplotypes from population genotype data [1].
Results The 725 SNPs were divided between 206 different genes
with 1–20 SNPs per gene distributed on all chromosomes. Initially,
SNPs were grouped in clusters containing a minimum of three SNPs
with no more than 100 kb between neighbouring SNPs. Based on the
PHASE output, D′ and the P value of the Fisher’s exact test were
calculated. We observed strong LD in 74 genes, and 10 genes were
split into more than one LD domain. Furthermore, neighbouring clusters
of genes were studied for common LD. Genotype frequencies and the
extent of LD were compared in a case–control study when possible.
Conclusion Our findings are restricted by our choice of genes and the
number of SNPs per gene. Nevertheless, they reveal LD between
SNPs in multiple genes, which have been previously studied in
separate and independent studies. This notion of the existing LD may
be of potential value in designing new pharmacogenetic studies.
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The inter-individual variation of response to cancer chemotherapy and
radiation therapy has a substantial genetic component and is a subject
of pharmacogenetic studies. Our goal is to develop assays to analyze
selected single nucleotide polymorphisms (SNPs) in genes with proven
relevance for pharmacogenetics. Today’s research in the field needs
technological platforms for which the demands both in terms of quality
and throughput are high. Pharmacogenomics utilizes various
genotyping techniques as well as gene-expression studies in studying
the effect of different pharmaceuticals as well as the pathways that
influence them. Here we provide an overview of the platforms currently
in use, and discuss their efficiency, precision and technological
stability. The amount of hands-on time needed and the cost-
effectiveness are discussed. We also compared the success rate of
several methods. SNaPshot is a homogeneous-phase-based primer
extension method and SNPstream UHT is a solid-phase-based primer
extension method. The Nanogen chip employs binding of a biotinylated
probe to a chip coated with hydrogel enriched with streptavidin. This
universal design presents the possibility to perform both genotyping as
well as gene-expression experiments, even on the same chip. Results
were compared with the classical enzymatic restriction enzyme
fragment polymorphism (RFLP) assay. The initial set included eight
SNPs in the X-ray cross-complementing group 1 protein, XRCC1;
APEX nuclease (multifunctional DNA repair enzyme) 1, APEX1;
multidrug resistance gene, MDR1; gluthation-S-transferase P1,
GSTP1; and tumor protein p53, TP53. Functional SNPs in these
genes have been shown to influence the therapeutic effect of a series
of anti-cancer drugs such as 5-fluorouracyl, doxorubicin, etoposide,
thioguanine and irinotekan. Three series of 36 breast cancer patients
treated with 5-fluorouracyl and mitomycin, of 92 breast cancer patients
treated with doxorubicin and of 109 control individuals have been
genotyped. This resulted in 1527 genotypes. Of these, 391 had been
analysed by SNaPshot, 900 by SNPstream UHT, 454 by Nanogen and
966 by RFLP. The success rate was 91% for SNaPshot, 97% for
SNPstream UHT, 96% for Nanogen, and 99% for RFLP. When
comparing the methods pairwise, the lowest variation was observed
between SNPstream UHT and Nanogen (0.4%). SNPstream UHT and
Nanogen had similar rates of discrepancy when compared with RFLP:
3.2% and 2.6%, respectively. Close re-analysis of those samples
revealed false calls due to incomplete cutting during the RFLP. The
highest observed dis-concordance observed was between SNaPshot
and SNPstream UHT (8.9%). Careful evaluation of genotyping quality
is needed both for large epidemiological studies and smaller clinical
trials, and especially in prospective pharmacogenetic studies of
separate individuals in clinical settings.
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Glutathione-S-transferase P1 (GSTP1) is involved in thiol-mediated
detoxification and breakdown of reactive oxygen species created by
anticancer drug exposure. GSTP1 is also an inhibitor of c-Jun N-
terminal kinase 1, a kinase involved in stress response, apoptosis and
cellular proliferation. Hypermethylation of the GSTP1 promoter has
been associated with gene silencing in prostate cancer, kidney cancer,
and breast cancer, among others. Although frequently described, the
mechanism underlying promoter hypermethylation of the GSTP1 gene
is poorly understood. It has been reported that an ATAAA repeat of the
GSTP1 promoter separates methylated from unmethylated CpGs in
normal prostate tissue [1]. These separate methylation domains are
lost in prostate cancer, and methylation extends throughout the whole
promoter region. It has been proposed that hypermethylation of GSTP1
requires a combination of gene silencing and random seeds of
methylation in prostate cancer cells, and that these combinatorial
effects lead to histone deacetylation and subsequent chromatin
remodeling [2]. To further elucidate the mechanisms underlying the
hypermethylation of the GSTP1 promoter, we genotyped the (ATAAA)
repeat and the linked SNPs in positions –354, –288, –287 and –282
in the GSTP1 promoter and we performed methylation analysis using
mass spectrometry in tumor DNA from 82 breast cancer patients. The
role of the different allelic variants on methylation status of the GSTP1
promoter and expression levels was assessed. We quantitatively
determined the methylation status of six CpGs spanning the
transcription start site of the GSTP1 promoter: –22, +8, +14, +38,
+47 and +55. The average percentage methylation for each individual
CpG for the 82 tumor samples analyzed was 16.9%, 30.3%, 18.2%,
21.2%, 18.6% and 8.1%, respectively. The average percentage
methylation for all CpGs in all tumor samples was 19%. There was a
correlation between the degree of methylation of the individual CpGs
and their neighboring CpGs (P < 0.001). When correlating the extent
of methylation to the mRNA levels previously assessed by whole
genome gene-expression profiling of the same tumors, a significant
inverse correlation was observed (P < 0.01). The methylation status of
the three CpGs closest to the transcriptional start site was more highly
associated with the level of GSTP1 mRNA expression than the CpGs
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further downstream of the +1 site. Furthermore, we observed
differences in the degree of GSTP1 promoter methylation between the
different tumor subclasses defined by whole-genome microarray
analysis [3]. The methylation of the GSTP1 promoter was significantly
lower in the basal subtype compared with the luminal subtype, which
corresponded to elevated GSTP1 mRNA levels in the basal subtypes
[4]. We further analyzed the impact of the most frequent haplotype
structure of the GSTP1 promoter in relation to the extent of
methylation, and a correlation was observed (P = 0.003) suggesting
that haplotype structures can affect de novo methylation of adjacent
sequences.
References
1. Millar DS, et al.: J Biol Chem 2000, 275:24893-24899.
2. Stirzaker C, et al.: Cancer Res 2004, 64:3871-3877.
3. Perou CM, et al.: Nature 2000, 406:747-752.
4. Troester MA, et al.: Cancer Res 2004, 64:4218-4226.
P1.18
The rare ERBB2 variant Ile654Val is associated with
an increased familial breast cancer risk
B Frank1, K Hemminki1,2, M Wirtenberger1, JL Bermejo1, 
P Bugert3, R Klaes4, RK Schmutzler5, B Wappenschmidt5, 
CR Bartram4, B Burwinkel1
1Division of Molecular Genetic Epidemiology, German Cancer
Research Center, Heidelberg, Germany; 2Department of Biosciences
at Novum, Karolinska Institute, Huddinge, Sweden; 3Institute of
Transfusion Medicine and Immunology, Red Cross Blood Service of
Baden-Württemberg-Hessia, University of Heidelberg, Faculty of
Clinical Medicine, Mannheim, Germany; 4Institute of Human Genetics,
University of Heidelberg, Germany; 5Division of Molecular Gynaeco-
Oncology, Department of Gynaecology and Obstetrics, Clinical Center
University of Cologne, Germany
Breast Cancer Research 2005, 7(Suppl 2):P1.18 (DOI 10.1186/bcr1105)
Background Overexpression of the proto-oncogene ERBB2
(HER2/NEU) has been observed in 20–30% of breast cancers
involving ligand-independent activation and more aggressive growth
behaviour, reduced response to chemotherapy and hormonal therapy,
as well as poor prognosis. Genetic alterations within ERBB2 have
been shown to induce carcinogenesis and metastasis.
Methods The ERBB2 variants Ile654Val, Ile655Val and Ala1170Pro
were investigated for their influence on familial breast cancer risk by
sequencing and TaqMan allelic discrimination.
Results The case–control study analysing 348 German familial breast
cancer cases and 960 controls showed no significant association of
Ile655Val and Ala1170Pro with familial breast cancer risk. Differences
in haplotype frequencies between cases and controls could not be
detected either. The ERBB2 variant Ile654Val, however, revealed an
increased risk for carriers of the heterozygous Val654 allele (odds ratio =
2.56, 95% confidence interval = 1.08–6.08, P = 0.028).
Conclusion The rare Val654 is linked to the more frequent Val655,
resulting in two consecutive valine residues instead of two isoleucine
residues within the transmembrane domain. Computational analyses
suggest that the Val654–Val655 allele provokes receptor dimerisation
and activation, thus stimulating kinase activity and cell transformation.
We hypothesise that ERBB2 Val654 represents an oncogenic variant
that might, in addition, influence clinical outcome and predict worse
prognosis. The occurrence of the Val654–Val655 haplotype in human
breast cancer cells (MCF-7) supports the significance of our results.
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Alpha-1 antitrypsin (1-AT) is a secretory glycoprotein mainly produced
in the liver and monocytes. It is the most abundant serine protease
inhibitor in human plasma. Proteolytic enzymes play a significant role in
the expression of the malignant phenotype, including the loss of growth
regulation, invasiveness and formation of metastases. Deficiency of
1-AT is an inherited disorder characterized by reduced serum level of
1-AT. Protease inhibitors Z (PiZ) and protease inhibitors S (PiS) are the
most common deficient genotypes of 1-AT. The association of deficient
1-AT subtypes with several tumors such as primary liver carcinoma,
lung cancer, bladder cancer and malignant hepatoma was reported.
This study aimed to determine the incidence of 1-AT genotypes (PiZ
and PiS) in breast cancer female patients. Blood samples were
collected from 111 patients. DNA was isolated and the PCR technique
was performed to amplify the regions contain the Z and S mutations in
exon V and exon III, respectively. Genotyping of the Z and S alleles was
performed by restriction fragment length polymorphism analysis using
the Taq1 restriction enzyme. Our results demonstrated that 100% of
the breast cancer patients were homozygous for the normal allele
(PiMM) and no PiZ and PiS genotypes were found.
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The nuclear receptor coactivator 3 (NCOA3, also known as AIB1) is a
coactivator of nuclear receptors like the estrogen receptor. NCOA3 is
overexpressed in ~60% of primary human breast tumours, and high
levels of NCOA3 expression are associated with tamoxifen resistance
and worse survival rate. In contrast, NCOA3 deficiency suppresses
v-Ha-ras-induced breast cancer initiation and progression in mice. Here
we analysed the influence of NCOA3 coding single nucleotide
polymorphisms on breast cancer risk by performing a case–control
study using a German and a Polish study population, and identified an
association between NCOA3 polymorphisms and breast cancer. A
joint analysis of the German and Polish study population revealed a
significant protective effect for the 1758G>C (Q586H) and 2880A>G
(T960T) variants. In addition, haplotype analysis showed a protective
effect of the 1758C-2880A and 1758G-2880G haplotypes (odds ratio =
0.79, 95% confidence interval = 0.67–0.93, P = 0.004). Due to the
impact of NCOA3 in anti-estrogen therapy resistance, these
polymorphisms might also influence therapy outcome in breast cancer.
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Background Recent findings suggest an important influence of the
GH1/IGF1 axis in the development of breast cancer. By binding to its
receptor, IGF-1 stimulates numerous downstream signaling proteins
resulting in the regulation of cell proliferation, differentiation and
apoptosis [1]. One member of this pathway is CRK (v-crk sarcoma
virus CT10 oncogene homolog), which is tyrosine phosphorylated
upon IGF-1 stimulation. CRK has been found to be overexpressed in
various human tumor tissues and cell lines [2]. However, little is known
about alterations in the genomic sequence of this gene.
Methods We sequenced the promoter and the coding region of the
CRK gene in a small sample set of 23 breast cancer samples. We
confirmed a C to A polymorphism at nucleotide position 49 with a
synonymous amino acid change at Arg17, which was in nearly 100%
linkage to the promoter polymorphism C-289A, and we identified a
novel polymorphic duplication of 22 bp in the promoter region. In the
further analyses we used a TaqMan allelic discrimination assay for the
Arg17 polymorphism and a fluorescent fragment analysis to detect the
duplication in a sample set of 352 Polish familial breast cancer cases
and 485 matched controls. We determined the genotype and
haplotype frequencies and calculated the odds ratios with 95%
confidence intervals.
Results We did not observe any differences in the allele or genotype
frequencies between the cases and controls for the duplication
polymorphism. For the Arg17 polymorphism, the allele frequency of the
A allele was slightly decreased among the cases compared with the
controls (52.3% vs 56.0%, respectively), but the difference was not
statistically significant. In the haplotype analysis, we observed a
protective effect for the carriers of the Arg17 A and the duplication
alleles (odds ratio = 0.17, 95% confidence interval = 0.03–0.76,
P = 0.007).
Conclusions CRK is a member of the GH1/IGF-1 pathway, whose
members are often found to be overexpressed in human tumors. The, to
our knowledge, novel 22 bp duplication in the promoter region results
in multiplication of various putative transcription factor binding sites.
This may lead to an altered expression of the CRK gene. In
combination with the Arg17 A allele it showed a protective effect. The
Arg17 polymorphism was in nearly 100% linkage with a polymorphism
in the promoter, which also might have an effect on transcription.
However, a functional analysis is needed to investigate the effect of
these polymorphisms on the expression.
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It has been proposed that the excess of the familiar risk associated with
breast cancer could be explaining by multiple weakly predisposing
alleles. Hence there is much interest in the search for low-penetrance
genes/variants for breast cancer, which exist with high prevalence in
the general population. Maeda and colleagues [1] recently identified
the transcriptional repressor FBI1, which they called Pokemon (POK
erythroid myeloid ontogenic factor), as a critical factor in oncogenesis.
This protein is codified by the ZBTB7 gene (‘zing finger and BTB
domain containing 7’; GeneID, 51341). Mouse embyronic fibroblasts
lacking Zbtb7 were completely refractory to oncogene-mediated
cellular transformation. Conversely, FBI1 overexpression led to overt
oncogenic transformation both in vitro and in vivo in transgenic mice.
FBI1 can specifically repress the transcription of the tumor suppressor
gene ARF (600160). Maeda and colleagues [1] found that FBI1 is
aberrantly overexpressed in human cancers, and its expression levels
predict biologic behavior and clinical outcome. On the other hand,
tissue microarray analysis (TMA) in breast carcinomas has revealed
high levels of Pokemon expression in a subset of these tumors. In
addition, the genomic region where the ZBTB7 gene resides
(19p13.3) is a hotspot for chromosomal translocations [2]. ZBTB7 is
therefore a good candidate for a breast cancer low-penetrance gene.
We aim to determine whether common polymorphisms (frequency
≥10%) in the ZBTB7 gene are associated with breast cancer risk in
Spanish patients. A set of 22 validated binary SNP polymorphisms
were selected from public databases (e.g. HapMap) and private
databases (e.g. Celera and RealSNP) according to criteria of coverage
(average 1 SNP/1.7 kb). These SNPs cover the flanking regions
(10,000 bp), including the promoter region, introns, and coding non-
synonymous SNPs. About 550 cases and 550 controls have been
genotyped. Genotyping was performed using the MassARRAY SNP
genotyping system (Sequenom Inc., San Diego, CA, USA).
To our knowledge, this is the first time that the ZBTB7 gene has been
analyzed in breast cancer patients. The results will be presented at the
time of the congress and will be interpreted in the light of the
worldwide population study shown in another presentation from the
same authors.
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The ZBTB7 gene is aberrantly overexpressed in human tumours [1] and
is an obvious candidate for a breast cancer low-penetrance gene. Here
we aimed to analyze the SNP and haplotypic variability of the ZBTB7
gene in human populations. The information available in SNPs databases
is still limited; for example, HapMap contains information of only four
ethnic groups, two of them from East Asia [2,3]. The inference of the
portability of tagSNPs using this limited amount of information is
therefore still under debate. We have thus selected 22 validated
polymorphisms covering the ZBTB7 gene and flanking regions using
public and private SNP databases. There are more than 1200 worldwide
DNA samples (40 human populations), which include those contained in
the CEPH Genome Diversity Cell Line Panel. Genotyping was performed
using the MassARRAY SNP genotyping system (Sequenom Inc., San
Diego, CA, USA). Briefly, it involves multiplex PCR and minisequencing
assays, designed with Spectro DESIGNER software (Sequenom Inc.),
followed by mass spectrometry analysis with the Bruker Bi-flex MALDI-
TOF mass spectrometer (Bruker Daltonics, Billerica, MA, USA). Spectral
output was analyzed using SpectroTYPER–RT 3.1 software (Sequenom
Inc.) and by manual review.
The present high-density SNP mapping study will facilitate a map of
specific population variation and patterns of linkage disequilibrium at
the ZBTB7 region in different human populations, and will facilitate the
adequate selection of a highly efficient set of tag SNPs that will capture
the bulk of the (potentially pathogenic) variation. We have found that
patterns of LD and haplotype diversity at the ZBTB7 gene vary
considerably among different populations. Thus, sub-Saharan African
populations showed higher levels of haplotype diversity and shorter
blocks, while non-Africans showed a higher level of LD and lower
haplotype diversity, as expected according to population history.
According to these patterns, we will discuss the efficiency of these LD
patterns and tagSNPs to capture candidate SNPs at the ZBTB7 gene
in tumor association studies.
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Carcinogenesis is a chronic disease process underlying the clonal
evolution of cells progressing to the point of uncontrolled growth,
metastatic potential, and molecular heterogeneity. By convention,
chemoprevention drugs are developed from a molecular perspective
with the goal of interrupting carcinogenesis before the occurrence of
invasive lesions or extreme heterogeneity. The most successful
demonstration of cancer chemoprevention to date has been an overall
49% reduction of invasive breast cancer, with a similar reduction in
premalignant lesions by tamoxifen in the Breast Cancer Prevention Trial
(BCPT) [1]. It is noteworthy that the main effect of tamoxifen is likely to
be mediated through the estrogen receptor (ER), as reflected by a
70% reduction of lesions that are ER-positive in contrast to little or no
effect on the incidence of ER-negative lesions. For interventions that
are related to ER as a target, a number of drug development issues
remain to be addressed including dose, schedule, and the comparative
net clinical benefit of various selective ER modulators versus pure anti-
estrogens, aromatase inhibitors, and combinations. In the BCPT there
were 13,388 participants, and there were more than 22,000 in the
STAR trial. The large sample size that may be needed for a randomized
clinical trial to observe a prevention effect severely limits the
opportunity to explore a multiplicity of important questions in clinical
chemoprevention.
Molecular studies have been helpful in classifying breast cancers
according to categories of response to intervention. For instance,
cytogenetic studies combined with molecular profiling suggest that ER-
focused interventions are likely to address a particular subset of tumors
arising from the luminal cell population [2]. As tumor subsets become
better characterized, the need for additional prevention studies can be
anticipated to address larger subsets (e.g. a combination of drugs for
overlap) versus smaller subsets of individuals at risk. In order to reduce
the sample size of future prevention trials, new molecular approaches
are needed. One strategy would be to use non-invasive molecular tests
to identify individuals at increased breast cancer risk so that
populations for prevention trials could be further enriched according to
that risk. Of the approaches currently under investigation, proteomic
studies theoretically offer an opportunity to improve risk identification.
Investigators who are performing proteomic studies for early detection
are encouraged to expand their investigations to see whether it is
possible to delineate according to ER status and between non-invasive
conditions such as hyperplasia and DCIS versus invasive cancer.
Another strategy for increasing the efficiency of breast cancer prevention
trials is the validation of intermediate endpoint biomarkers [3] to secure
validated intermediate endpoint biomarkers (VIEBs). If molecular entities
in serum could be identified on the basis that they are predictably
correlated with the future development of breast cancer, then a reduction
in the VIEB level could serve as evidence of a preventive effect. Early
work in this area suggests that nucleic acids in serum might be used to
identify individuals with premalignant lesions [4].
Clinical correlation is needed for VIEBs and other molecular indicators of
risk so that targets in addition to the ER can also be more efficiently
studied. Targets of interest for breast cancer prevention include the EGFR
family, RAR/RXR and mediators of inflammation or oxidative damage.
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Background Accumulating evidence on postmenopausal hormone
therapy confirms the deleterious effects on risk of breast cancer or stroke
and questions the positive effects on quality of life and coronary disease
risk. A large-scale gene expression study may present promising new
insights into the effect of hormone replacement therapy (HRT). Our study
explores the gene expression profile from whole-blood total RNA, which
is an important and relatively unexplored issue in human biology.
Methods In early autumn 2003, 500 women participating in the
Norwegian Women and Cancer (NOWAC) cohort were randomized
and invited to give blood samples (393 returned the questionnaire).
Blood samples were collected in a PAXgene tube in late autumn 2003
and a short questionnaire additional to those previously given in the
NOWAC study was completed. In our study, 100 women (50 HRT
users and 50 non-HRT users) born between 1943 and 1949 with
normal body mass index (18.5 < BMI < 29.9 kg/m2) and no other
medication use were selected. After extraction amplification and
labelling of the samples, we hybridized them overnight to Agilent
Human 1A oligoarrays (G4110b; Agilent Technologies, Palo Alto, CA,
USA) containing 22,153 features representing 20,173 unique genes.
Results Genes identified by t test with P < 0.03 (n = 253) were used to
build a classifier using the nearest shrunken centroids method. Results
did not reveal any distinct gene list that predicts accurately HRT
exposure (error rate = 0.42). We performed a new analysis including,
among HRT users, only women who were using continuous combined
treatment (ethinylestradiol and norethisterone acetate). The performance
of the classifier (i.e. 98 genes) improved (error rate = 0.25). The
specificity (78.7%) was slightly better than the sensitivity (68.0%).
We then tested the significant changes in a single gene by different
methods like the t test, significance analysis of microarrays controlling
for the false discovery rate and Bayesian ANOVA analysis, which
balance the false discovery rate and the true positive rate. Only few
expression alterations of minor magnitude caused by HRT could be
detected in whole-blood total RNA. The weak signals of exposure-
induced changes in whole blood made it very difficult, or even
impossible, to identify single genes statistically significant with the
background of thousands of individuals genes tested simultaneously.
Instead, we focused on identifying significant pattern changes of
biologic process in genes identified from the t test, using the
annotations defined by the Gene Ontology Consortium.
Conclusions Mixed cell types in whole blood made it more difficult to
observe differences in gene expression profiles. According to the little
amplitude of expression alterations observed in whole blood, large
sample sizes are needed to conduct global expression profiling.
Although one gene change may be small and difficult to detect
accurately in a significant test, significant enrichments in the biologic
process of genes with small changes after HRT use have been
assessable.
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AH Sims, KR Ong, CL Wilson, A Howell, RB Clarke
Breast Biology Group, Division of Cancer Studies, University of
Manchester, Christie Hospital, Manchester, UK
Breast Cancer Research 2005, 7(Suppl 2):P2.02 (DOI 10.1186/bcr1113)
Background Oestrogen (E2) is central to the development of breast
cancer, and anti-oestrogens have been shown to reduce the risk of the
disease. However, little is known about the effect of E2 on the normal
human breast, particularly when the epithelium and stroma are intact.
Previous expression profiles of the response to E2 were performed on
tumour cell lines, in the absence of stroma [1-3].
Methods We investigated gene expression in normal human breast tissue
(removed from benign lesions in premenopausal women) transplanted into
9-week-old to 10-week-old athymic nude (Balb/c/nu/nu) mice.
Transplantation was performed in order to obviate the potential effects
of the phase of the menstrual cycle. After 2 weeks, when proliferation
and progesterone receptor (PR) expression are minimal, the mice were
treated with E2 using a 2 mg slow-release pellet for 1 week, which we
have previously shown to be optimal for inducing proliferation and PR
[4]. At completion of treatment, three tissue samples were generated
from each of the six original normal breast tissue samples — two of
which were untreated and one of which had been treated with
oestrogen. RNA was isolated from each of these samples, then
labelled and hybridised to Affymetrix HG-U133A (human) chips on
which 22,283 genes are represented. RMA and MAS5 normalisation
methods were utilised with bioconductor analysis software.
Results Oestrogen treatment was found to be the major source of
variation in gene expression. Our study shows that known E2-
responsive genes such as trefoil factor 1 (pS2) and amphiregulin are
also differentially expressed due to oestrogen treatment of normal
breast tissue. In addition, many of the genes that showed the greatest
responses to E2 have previously been suggested as independent
breast cancer prognostic or diagnostic markers (including
mammaglobin, prolactin-inducing peptide and keratin 19).
Conclusion We report the first global gene expression study to look at
the effects of oestrogen on the epithelium and stroma of normal human
breast tissue, which may give clues to the paracrine action of
oestrogen in proliferation. These data form the basis for efforts towards
the detection of early gene expression changes leading to breast
cancer development.
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A full-term pregnancy or a 3-week treatment with estrogen and
progestins induces a protective state against chemical carcinogen-
induced mammary tumorigenesis in rats and mice. These experimental
models are a paradigm for the well-established fact that an early full-
term pregnancy in humans induces a life-long decreased risk for breast
cancer. Up to now, this hypothesis has not been successfully tested in
non-carcinogen-treated rodents. We tested the hypothesis in p53 null
mouse mammary epithelium. A 2-week exposure to estrogen and
progesterone reduced significantly (P < 0.05) the incidence of
spontaneous breast cancer in p53 null epithelial cells. The hormone-
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treated cells had a unique gene expression profile at 40 weeks post
hormone removal compared with untreated p53 null epithelial cells.
Current experiments are examining the developmental stage specificity
of the response to estrogen and progesterone. Additionally, genes
specific to the hormone-treated p53 null cells are being further
evaluated. These results indicate that short periods of hormone
treatment can markedly delay mammary tumorigenesis in models where
the initiating oncogene is relevant to human breast cancer.
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Background Mutations in the tumor suppressor gene BRCA1 are
associated with an elevated risk of breast and ovarian cancer. The tissue-
specific nature of BRCA1 mutation-associated tumors stands in stark
contrast to the diverse array of nuclear functions mediated by the wild-
type BRCA1. These functions include regulation of transcription and the
DNA damage response. While the DNA repair function of BRCA1 clearly
contributes to overall genetic stability, loss of BRCA1 function in DNA
repair, a process that is universally important to all cell types in both
genders, cannot easily explain why BRCA1 mutations predominantly
affect breast and ovary, two major estrogen-responsive tissues in women.
We hypothesize that BRCA1 confers tissue-specific tumor suppression
by directly modulating expression of a set of breast-cancer-related genes.
Methods and results Aromatase, which catalyzes conversion from
androgen to estrogen, is a rate-limiting enzyme in estrogen
biosynthesis and is a key player in breast cancer development.
Aromatase is specifically expressed in ovarian granulosa cells and
several peripheral tissues via the actions of multiple tissue-specific
promoters. In premenopausal women, expression of aromatase in
ovarian granulosa cells dictates levels of circulating estrogen. In many
postmenopausal breast cancer and endometrial malignancy tissues,
the in situ aromatase production is significantly elevated. Here, we
show that the cyclic AMP-dependent expression of aromatase is
inversely correlated with the protein level of BRCA1 in human ovarian
granulosa cells. Importantly, transient knockdown of BRCA1 enhances
the expression of aromatase in both ovarian granulosa cells and cells
from breast tissue. Chromatin immunoprecipitation indicates that
endogenous BRCA1 is preferentially associated with a tissue-specific
transcriptional promoter of the aromatase gene. Thus, BRCA1
negatively controls estrogen biosynthesis by repressing aromatase
expression, providing a novel and logical molecular explanation for the
tissue-specificity conundrum in BRCA1 biology.
Conclusion and significance The notion that BRCA1 confers tissue-
specific tumor suppression in an endocrine fashion is also consistent
with results from recent clinical and animal studies. In particular,
prophylactic oophorectomy reduces the risk of both breast cancer and
ovarian cancer in carriers of BRCA1 mutations [1,2], suggesting that
circulating estrogen in premenopausal women may contribute to the
development of BRCA1-associated tumors. Moreover, tissue-specific
knockout of Brca1 in mouse ovarian granulosa cells induces tumors in
the ovaries and uterine horns. Importantly, these tumors still carry wild-
type alleles of Brca1 [3]. Given that aromatase inhibitors are one of the
most efficacious endocrine agents in breast cancer treatment, the link
between BRCA1 and aromatase expression may lead to novel
therapies for both prevention and treatment of breast cancer.
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Background Although HER2 expression is more common in ER-
negative and PR-negative breast cancers, HER2 overexpression is
observed in ER-positive cancers and these cancers seem to have
intrinsic resistance to endocrine treatment. There are controversial
reports about the effect of HER2 on estrogen dependence. ERβ2 has
been reported to act as a dominant-negative regulator of ERα in the
breast, and ERβ1 and/or ERβ2 might be co-expressed with ERα in
breast cancer. It is therefore necessary to investigate the effect of
HER2 and ERβ2 expression on the ERE-mediated transcription activity
in the cells co-expressing ERα.
Methods NIH3T3 cells, T6-17 cells (NIH3T3 cells stably transfected
with HER2), and MCF-7 cells were maintained in dextran-coated
charcoal-stripped 10% Dulbecco’s modified Eagle medium. Transient
transfection of constructs (pcDNA3-ERα, pcDNA3-ERβ2, pERE-luc,
pcDNA-HER2) into each cell was performed using the Lipofectamine
PLUS™ system. The reporter gene assay using estrogen-responsive
element (ERE)-luciferase was used to measure the ERα transcriptional
activity after treatment of 17-β-estradiol and tamoxifen.
Results The reporter gene assay using ERE-luciferase showed much
less responsiveness to estrogen in HER2-overexpressing T6-17 cells
than in NIH3T3 cells, but there was no remarkable difference after
treatment of tamoxifen. The responsiveness to estrogen in HER2-
transfected MCF-7 cells was a little less, but not remarkable, than that
in control MCF-7 cells. However, the responsiveness to estrogen in
MCF-7 cells was decreased in a dose-dependent manner of HER2
expression. ERE-mediated transcriptional activity was decreased with
the increase of ERβ2 expression; it is much more remarkable in HER2-
overexpressing T6-17 cells.
Conclusion Expression of HER2 and/or ERβ2 reduces estrogen
responsiveness in ERα-positive tumor cells. HER2 might be associated
with growth dependence of the tumor cells, but ERβ2 seems to be
associated with binding affinity to estrogen and DNA.
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Long-term culture of MCF-7 wild-type cells in steroid-depleted medium
(long-term estrogen deprivation [LTED]) results in hypersensitivity to
estradiol (E2) coinciding with elevated levels of ERα, and enhanced
type I receptor tyrosine kinase growth factor signalling. In this study we
aimed to compare the effects of the pure anti-estrogen ICI 182,780
(ICI) with the competitive anti-estrogen tamoxifen (TAM) on estrogen
and IGF signalling in these cells. Wild-type MCF-7 and LTED cells
were treated with a seven-log concentration range of E2, TAM or ICI.
Effects on cell growth, ERα transactivation, expression of ERα, ERβ,
and components of the IGF pathway were measured in the presence of
or the absence of insulin. In the presence of insulin, growth of LTED
cells was refractory to TAM but was inhibited by ICI and E2. In the
absence of insulin, LTED cells showed persistent hypersensitivity to
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E2, and remained inhibited by ICI but largely unaffected by TAM. Most
noteworthy in the absence of insulin, we revealed that E2 doses in
excess of 10–10 M were inhibitory for the LTED cells leading to
enhanced apoptosis. ICI but not TAM inhibited ER-mediated gene
transcription and resulted in a concomitant dose-dependent reduction
in ERα levels, while having no effect on ERβ. As previous studies have
suggested that endocrine resistance may result from the non-classical
interaction of ERα with AP-1, we transfected the wild-type and LTED
cells with an AP-1 reporter construct and monitored activity in
response to E2, TAM and ICI. No alteration was detected, suggesting
that in this setting transcriptional activity via the ER remained wholly or
partially classical via a direct ER/ERE interaction. Analysis of the
expression level of proteins within the IGF pathway plus or minus
insulin revealed elevated levels of IGF-1 receptor and insulin receptor
substrate 2 in LTED versus the wild-type MCF-7 cells, and ICI but not
TAM reduced their expression in a dose-dependent fashion. IGF
signalling, as well as ERα expression and function, are thus enhanced
during LTED. While the resultant cells were resistant to TAM, ICI
downregulates ERα, reducing IGF signalling and cell growth. These
results support the use of ICI in women with ER-positive breast cancer
who have relapsed on an aromatase inhibitor.
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Background Estrogen receptor (ER) alpha-positive breast cancer
patients are commonly treated with tamoxifen, a potent and widely
used anti-estrogen. However, only one-half of the recurrences of ER-
positive breast tumors respond to tamoxifen while the other half is
resistant [1]. The ability to accurately predict tamoxifen treatment
outcome would therefore significantly advance the management of
breast cancer. The aim of the current project is to identify a gene
expression profile associated with tamoxifen resistance using
microarray analysis.
Patients and methods To identify gene expression patterns that might
predict response to tamoxifen, 90 breast cancer patients were
selected for whom fresh frozen tissue was available. All these patients
had received surgery with or without radiotherapy for primary breast
cancer, while none had received adjuvant systemic treatment. All
patients developed metastatic disease and were subsequently treated
with tamoxifen. Response was mainly determined radiographically [2].
Approximately 40% of these patients had CR/PR or clinical benefit
during less than 6 months and are defined as tamoxifen resistant,
whereas the remaining 60% are defined as tamoxifen sensitive (CR/PR
or clinical benefit for more than 6 months). Of the latter group, 17 out
of 54 even showed no progression for at least 2 years.
Gene expression profiling was performed using 44K oligo microarrays.
Data analysis is ongoing and results will be presented at the MBBC
symposium.
Future directions A validation set will be analyzed to confirm our initial
findings. Furthermore, we will test whether this profile can also be used
in the adjuvant setting. In addition, we will evaluate the combination of
microarray analysis and targets identified by RNAi screens in vitro in
determining diagnostic tools for prediction of therapy outcome.
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Despite advances in endocrine therapies, the majority of patients
receiving tamoxifen will eventually relapse while retaining functional
estrogen receptors. We have previously shown, using an MCF-7 cell
line (TamR) resistant to the anti-proliferative effects of tamoxifen, that
elevated levels of phosphorylated AKT and p90RSK lead to an apparent
ligand-independent phosphorylation of ERα ser167. Analysis of the
growth factor receptors in these cells indicated elevated levels of both
phosphorylated ERBB2 and total ERBB3, which we postulated formed
heterodimers and activated the PI3 kinase pathway leading to elevated
AKT. However, our recent data suggest that elevated AKT results from
an interaction between ERα and ERBB2. This association is knocked
out by treatment with the pure anti-estrogen ICI 182,780 and is absent
in the WT parental cell line. Similarly, we have demonstrated an
association between the p85 subunit of PI3K and ERα in TamR but not
in WT cells. Treatment of the cell lines with the specific AKT inhibitor
SH6 and the MEK1/2 inhibitor U0126 caused greater decrease in cell
proliferation and concomitant ERα-directed transactivation in the TamR
cells versus the WT, confirming that these pathways are integral to the
TamR phenotype. To establish whether p90RSK or AKT was responsible
for the phosphorylation of the estrogen receptor at ser167, TamR and
WT cells were treated with SH6, U0126 or a combination of the two.
Blocking either pathway individually had little effect on ERα ser167
phosphorylation. However, a combination of the two inhibitors resulted
in almost complete loss of phosphorylation. These data were confirmed
using siRNA technology to suppress MAPK and AKT expression.
Taken together these data suggest that, in this setting, the ER
functions via a non-genomic mechanism, associating with ERBB2 and
PI3K at the cell membrane leading to activation of both p90RSK and
AKT. This in turn leads to phosphorylation of ERα ser167, ultimately
regulating cell growth via genomic mechanisms. Although several of
these complexes have previously been postulated, to our knowledge
this is the first demonstration of this phenomenon in a tamoxifen-
resistant cell line.
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Background Breast cancer studies in cell culture and in animals have
been performed using a limited number of well-characterized, but old,
cell lines and xenograft lines. With the aim of developing new breast
cancer model systems, particularly for in vivo biology studies related to
hormone-dependent and hormone-independent tumor growth,
progression and invasion, and for use in experimental therapy studies,
we have collected and implanted biopsy tissues from patients operated
for mammary carcinomas in immunodeficient animals.
Methods Primary tumor tissue from 30 patients with breast cancer
(staged as T2 tumors) was harvested and implanted in SCID mice, in a
subcutaneous pocket containing Matrigel. All mice were implanted with
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continuous-release estrogen pellets. The tumors were transferred when
reaching a size of approximately 15 mm, to new animals using the
same technique. Tumor tissue was harvested for further morphological
and molecular characterization from passage six.
Results Of 32 tumors implanted into mice, two gave rise to viable
tumors beyond passage four. One of these proved to be estrogen
receptor alpha (ERα)-positive and the other ERα-negative. Both
showed characteristic epithelial cell morphology. Separate experiments
showed that even the ERα-negative tumor was growth accelerated in
the estrogen-supplemented animal. RNA expression analysis confirmed
the ERα status in the tumors. Furthermore, the expression of the
estrogen-regulated genes TFF1 and CCND1 were high in the ERα-
positive tumor but absent in the ERα-negative tumor. Although
described as being ERα regulated, the VEGF transcript was expressed
in the ERα-negative tumor, but not in the ERα-positive tumor. A
difference between the tumors was also seen in the expression of other
genes relevant to the tumor growth, progression and invasion, as
CDKN1A, COM1, TIMP-1 and MMP-14 demonstrated a high
expression in the ERα-negative tumor and a low or missing expression
in the ERα-positive tumor. The expression of CDK4, TIMP-2 and
MMP-2 was similar in the two different tumors.
Conclusion As in other studies, the establishment of breast cancer
xeonografts is difficult, with a success rate below 10%. However, the
two established breast cancer xenograft lines have different
characteristics and show marked differences in gene expression
patterns that can be related to their ERα status. Further studies and
characterization have been initiated using RNA expression microarray
analysis.
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Background Both estrogen (E2) and growth factors stimulate
proliferation of E2-dependent breast tumor cells. Functional cross-talk
exists between E2-directed and growth factor-directed pathways.
Convergence between these pathways may lead to a synergistic feed-
forward circuit, resulting in a stronger or more sustained proliferative
response in breast cancer cells [1]. Another signaling pathway involved
in the modulation of breast cancer cell proliferation is mediated by the
receptor for sex hormone-binding globulin (SHBG-R). SHBG has been
found to function as part of a novel steroid signaling system that is
independent of the ‘classical pathway’ for intracellular steroid
receptors. This ‘alternative pathway’ (Fig. 1) involves the activation of
membrane SHBG-Rs by SHBG and E2. It has been demonstrated that
SHBG, through cAMP and protein kinase A (PKA), can inhibit the
proliferative effect of E2 on breast cancer cells [2-4]. Its role in E2-
dependent cancer cell proliferation may in the longer term be exploited
for therapeutic strategies. The pathways involved have not yet been
elucidated. Indeed, the receptor has not yet been identified, although it
is known to exist from binding kinetics studies.
Methods We are applying proteomics techniques to identify the
plasma membrane SHBG-R, and to elucidate the key signaling
proteins involved in pathway(s) mediated by SHBG/SHBG-R binding.
The following cell lines are the source material for membrane and
cytosolic preparations: MCF-7, estrogen-dependent (estrogen receptor
positive [ER+]) breast cancer cultured cells; MDA-MB 231, estrogen-
insensitive (ER–) breast cancer cultured cells; MCF-10A, non-
neoplastic mammary cells [control]. The steps for identification of
SHBG-R are as follows. MCF-7 cells are known to have SHBG-R (a
transmembrane protein) on their surfaces. Cell membranes are
prepared from MCF-7 cells and then, following extraction, the
membrane proteins are separated via two-dimensional electrophoresis
(2D-E). Identification of SHBG-R on immunoblots involves a ligand
binding assay using SHBG as the primary binder followed by anti-
SHBG (to detect bound SHBG) then a tertiary antibody conjugated to
an enzyme system. Identification and partial characterization of SHBG-
R involves peptide mass fingerprinting and sequencing of amino acids,
and international database searching. The design of experiments for
identification of signaling components of SHBG-mediated pathway(s)
is as shown in Fig. 2.
Results Progress will be reported on the identification and
characterization of the SHBG receptor.
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Figure 1
Model for SHBG-mediated signaling. The plasma membrane binding
site for SHBG is preferentially expressed in ER+ cells with a reduced
proliferative index [2-4]. SHBG-R only binds steroid-free or unliganded
SHBG. Following binding of unliganded SHBG to SHBG-R on the cell
membrane, E2 binds to the SHBG–SHBG-R complex, thereby
activating it. Activation induces the synthesis of cAMP, which, in turn,
triggers downstream signaling via PKA [2-4]. The biological outcome
of this signaling pathway in cells of the human breast carcinoma cell
line MCF-7 is decreased E2-mediated cell growth.
Figure 2
Identification of key signaling components of SHBG-mediated
pathway(s). A flow-chart of the experimental design and method
(involving comparative proteomic analyses) for identification of key
regulated signaling components in SHBG-mediated pathways in
breast cancer cells. Each cell type will be exposed to SHBG (vs not
exposed to SHBG), and to human estradiol (E2) (vs not exposed to
E2). Differential analysis of proteomes for the different cell
lines/treatments will then be carried out. Differences in
expression/post-translational modifications of specific proteins will
determine what proteins are of interest. End effects will be examined
as well as the results of time-dependent experiments.
S31
Acknowledgement The authors wish to acknowledge a Macquarie
University research grant.
References
1. Shupnik MA: Crosstalk between steroid receptors and the c-
Src-receptor tyrosine kinase pathways: implications for cell
proliferation. Oncogene 2004, 23:7979-7989.
2. Rosner W: The functions of corticosteroid-binding globulin and
sex hormone-binding globulin. Endocr Rev 1990, 11:80-91.
3. Fortunati N, Fissore F, Fazzari A, Becchis M, Comba A, Catalano
M, Berta L, Frairia R: Sex steroid binding protein exerts a nega-
tive control on estradiol action in MCF-7 cells (human breast
cancer) through cyclic adenosine 3′,5′-monophosphate and
protein kinase A. Endocrinology 1996, 137:686-692.
4. Fortunati N, Becchis M, Catalano MG, Comba A, Ferrera P,
Raineri M, Berta L, Frairia R: Sex hormone binding globulin, its
membrane receptor, and breast cancer: a new approach to
the modulation of estradiol action in neoplastic cells. J Steroid
Biochem Mol Biol 1999, 69:473-479.
P2.11
Identification of molecular apocrine breast tumours
by microarray analysis
P Farmer1,2, H Bonnefoi3,4,5, V Becette6, M Tubiana-Hulin6, 
P Fumoleau7, D Larsimont8, G MacGrogan9, J Bergh10, 
D Cameron11, D Goldstein1,2, S Duss2, A-L Nicoulaz2, M Fiche12,
C Brisken2, M Delorenzi1,2, R Iggo2
1Swiss Institute of Bioinformatics, Lausanne, Switzerland; 2National
Centre of Competence in Research Molecular Oncology, Swiss
Institute for Experimental Cancer Research, Epalinges, Switzerland;
3Hôpitaux Universitaires de Genève, Geneva, Switzerland; 4Swiss
Group for Clinical Cancer Research, St Gallen, Switzerland;
5European Organization on Research and Treatment of Cancer,
Brussels, Belgium; 6Centre René Huguenin, St-Cloud, France;
7Centre René Gauducheau, Nantes, France; 8Institut Jules Bordet,
Brussels, Belgium; 9Institut Bergonié, Bordeaux, France; 10Swedish
Breast Cancer Group, Stockholm, Sweden; 11Anglo-Celtic
Cooperative Oncology Group, Edinburgh, UK; 12Centre Hospitalier
Universitaire Vaudois, Lausanne, Switzerland
Breast Cancer Research 2005, 7(Suppl 2):P2.11 (DOI 10.1186/bcr1122)
Previous microarray studies on breast cancer identified multiple tumour
classes, of which the most prominent, named luminal and basal, differ
in expression of the estrogen receptor alpha gene (ER). We report here
the identification of a group of breast tumours with increased androgen
signalling and a ‘molecular apocrine’ gene expression profile. Tumour
samples from 49 patients with large operable or locally advanced
breast cancers were tested on Affymetrix U133A gene expression
microarrays. Principal components analysis and hierarchical clustering
split the tumours into three groups: basal, luminal, and a group we call
molecular apocrine. All of the molecular apocrine tumours have strong
apocrine features on histological examination (P = 0.0002). The
molecular apocrine group is androgen receptor-positive (AR+) and
contains all of the ER-negative tumours outside the basal group.
Kolmogorov–Smirnov testing indicates that oestrogen signalling is
most active in the luminal group, and androgen signalling is most active
in the molecular apocrine group. ERBB2 amplification is more common
in the molecular apocrine group than the other groups. Genes that best
split the three groups were identified by the Wilcoxon test. Correlation
of the average expression profile of these genes in our data with the
expression profile of individual tumours in four published breast cancer
studies suggest that molecular apocrine tumours represent 8–14% of
tumours in these studies. Our data show that it is possible with
microarray data to divide mammary tumour cells into three groups
based on steroid receptor activity: luminal (ER+ AR+), basal (ER–
AR–) and molecular apocrine (ER– AR+).
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Background The protective effect of an early first full-term pregnancy
in relation to breast cancer risk is well established, but the molecular
and cell-specific changes in the human mammary gland remain unclear.
The search for these early predictive markers for breast cancer risk is of
high priority because these markers could identify women at increased
risk and could monitor preventive strategies.
Methods To identify the molecular changes associated with
pregnancy-induced differentiation, we analysed the global gene
expression profiles of normal mammary tissues from both a parous and
a nulliparous woman, using serial analysis of gene expression (SAGE)
[1]. This approach allowed us to identify sets of genes, known and
unknown, that are differentially expressed in parous versus age-
matched nulliparous mammary gland tissues. Pair-wise comparisons of
each tag were carried out in both SAGE libraries.
Results The normal mammary gland of a multiparous woman is
characterised by several known differentiation markers such as casein
κ, casein β, keratin 14, CCAAT/enhancer binding protein β and δ, and
adipsin. Candidate genes involved in cyto-architectural remodeling and
growth inhibition with a potential role in pregnancy-induced protection
against breast cancer were also observed.
Several of the genes that are highly expressed in the nulliparous
mammary gland and that are lost after pregnancy encode for growth-
promoting, cytoskeletal and extracellular matrix proteins. One of these
genes, the small breast epithelial mucin, is almost completely
downregulated upon first full-term pregnancy but is known to be
expressed in more than 90% of invasive ductal carcinomas [2].
A subset of these differentially expressed genes was selected for real-
time PCR validation experiments. Small-scale real-time PCR
experiments revealed certain trends showing the upregulation of the
genes BPAG1, VIM, DCN, RARRES2, EGR1 and ADH1B and the
downregulation of SPARC and SBEM in the mammary gland after
pregnancy, but nevertheless individual differences in expression levels
were observed. These differences could be due to fluctuations in
hormone levels at the time of surgical resection. However, these
individual differences also may reflect the differential risk for breast
cancer for each of the patients (nulliparous and parous) involved.
Conclusions This study demonstrates that the SAGE technique is
useful to detect alterations in gene expression, induced by an early first
full-term pregnancy, in the human mammary gland. Our results show
that pregnancy induces permanent gene expression modifications in
the breast, which can be potentially valuable in the search for
predictive markers for breast cancer. Ongoing additional research on
these genes in a larger patient population will possibly lead to the
development of early markers for breast cancer.
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Cell proliferation in the mammary epithelium is stimulated in part by EGF
receptor activation, while differentiation requires ErbB4/HER4, prolactin
and STAT5A [1]. Unlike other EGFR family members, HER4 undergoes
ligand-dependent transmembrane domain cleavage, releasing a soluble 80
kDa tyrosine kinase (s80HER4) that localizes to the nucleus; the
physiologic relevance of s80HER4 is unknown [2]. Using HC11 mouse
mammary cells, we showed that EGF, HB-EGF and prolactin increased
STAT5A phosphotyrosine and promoter transactivation, but only HB-
EGF and prolactin induced differentiation markers and organization into
polarized three-dimensional, lumen-containing structures in Matrigel.
Heregulin did not stimulate lumen formation; rather, it increased and
disorganized HC11 cell growth. Selective inhibition of ErbB1/ErbB2
activation unmasked heregulin-dependent differentiation and lumen
formation. Kinase-dead HER4, or a HER4V675A mutant abolishing
transmembrane cleavage, were expressed in HC11 cells. HC11 HER4kd
or HER4V675A cells exhibited impaired HB-EGF and prolactin-dependent
STAT5A translocation, promoter activation and lactogenic marker
induction, indicating that both differentiation pathways need ErbB4
kinase activity and s80HER4 formation. HC11 cells constitutively
expressing s80HER4 exhibited basal expression of differentiation markers,
increased basal STAT5A activity and three-dimensional lumen formation.
These results demonstrate that mammary cell differentiation can be
stimulated by HER4 through a process requiring s80HER4 production.
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Jak2 is a hormone-receptor-coupled kinase that mediates the tyrosine
phosphorylation and activation of signal transducers and activators of
transcription (Stat). The biological relevance of Jak/Stat signaling in
hormone-responsive adult tissues is difficult to investigate since Jak2
deficiency leads to embryonic lethality [1-3]. We therefore generated
various Jak2 conditional knockout models to study essential functions
of Jak2 during particular stages of mammary gland development and
during neoplastic transformation in a Her2/neu-overexpressing breast
cancer model. Our experiments show that Jak2 is essential for
mammogenesis in virgin, pregnant, and postpartum females [4]. In
addition to its pivotal role for mammary epithelial cell proliferation,
specification, and differentiation, we demonstrate that this kinase is
indispensable for the prolactin-mediated activation of Stat5 and the
maintenance of functionally differentiated alveolar cells during lactation.
A primary focus of our current research is to examine how Jak/Stat
signaling cascades are altered in breast cancer models that initiate
tumorigenesis through overexpression of growth factor receptors, in
particular ErbB2 (Her2/neu). The uniqueness of our model design
enables us to genetically modify Jak/Stat signaling both prior to growth
factor-mediated neoplastic transformation (cancer prevention) and
during particular stages of the progressing disease (cancer therapy).
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Our laboratory has previously identified a rare subpopulation of variant
human mammary epithelial cells (vHMEC) that have the capacity to
propagate beyond an in vitro proliferation barrier and accumulate
multiple chromosomal changes [1]. These cells contain hyper-
methylated and silenced p16(INK4a) (p16) promoters and overexpress
COX-2. We found evidence that cells with these characteristics exist in
disease-free women in morphologically normal tissue [2]. Furthermore,
these distinguishing characteristics have also been found in DCIS
lesions, indicating that these cells are very relevant to the carcinogenic
process. In order to investigate the molecular mechanisms required for
these cells to progress to a malignant phenotype, we examined the
effect of oncogenic stress on the transformation of vHMEC by
introducing constitutively active Ha-Ras V12 into these cells.
Consistent with the idea that vHMEC are already engaged in the
transformation process, upon exposure to oncogenic stress vHMEC
failed to undergo a proliferative arrest as seen in normal fibroblasts or
normal epithelium. We have used this model system to examine the
early events that control expression of tumorigenic phenotypes in these
cells. We find that critical interactions between stromal cells and
initiated epithelial cells are necessary for the manifestation of specific
tumorigenic phenotypes such as epithelial-to-mesenchymal transition.
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It is generally believed that tumours originate from adult tissues, in which
most cells are quiescent, and that the proliferative advantage of tumour
cells arises from their ability to bypass senescence. Once this is
obtained, cells can accumulate further genetic alterations that drive
progressive transformation into highly malignant derivatives. How normal
cells evade the senescence program remains an unresolved issue.
Recent findings suggest the alternative possibility that stem/progenitor
cells are the targets of transformation. Many tumours contain only a
small subset of cells endowed with the property of uncontrolled growth
(cancer stem cells). Although the program of senescence in stem cells
is suppressed, their lifespan is restrained by signalling pathways (p19-
p53; p16-Rb) that are activated by DNA damage (telomere
dysfunction, environmental stresses). It is proposed that inactivation of
these pathways in stem cells might contribute to tumour formation.
We set out to cultivate in vitro breast stem cells from the mouse
mammary gland (BSC) based on their ability to survive in suspension as
‘mammospheres’ and to differentiate into myoepithelial and epithelial
cells. Murine mammospheres do not result from passive cell aggregation
and have clonal origin, as assessed by labelling cell membranes with
different epifluorescent dyes. To prove the ‘staminality’ of these cellular
populations we performed in vivo reconstitution experiments, by
inoculating single cell suspensions of mammospheres in the mouse
cleared fat pad.
Using the same experimental approach, we were also able to generate
mammospheres from MMTV-ErbB2(cNeu) transgenic mice. These
mice develop polyclonal mammary adenocarcinomas arising
synchronously. The mammospheres arising from MMTV-ErbB2 mice
show a dramatically prolonged lifespan upon serial passages and are
bigger than their normal counterparts (more than 1000 cells/sphere vs
200–400 cells in the w.t. mice). To prove that cancer mammospheres
are enriched in cancer BSC, we are performing transplantation
experiments in which single cell suspensions of these mammospheres
are inoculated in the normal gland of singenic mice.
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Background Human breast luminal epithelium and the stromal
compartment are separated by a layer of myoepithelial (ME) cells and
basement membrane, whose disruption is required for tumor invasion.
Basement membrane degradation has been ascribed largely to an
overproduction of proteases by the tumor and stromal cells. However,
the causes and phenotypes of ME cell layer disruption and its
contribution to the initiation of tumor invasion remain to be further
explored.
Methods Human ductal carcinoma in situ samples with ME disruption
and microinvasion were sectioned and immunohistochemically stained
with Ki-67, estrogen receptor (ER), leukocyte common antigen, and
other biochemical markers.
Results A subset of pre-invasive and micro-invasive tumors contained
focal disruptions in their ME cell layer. ER-negative cell clusters
overlying a focally disrupted ME cell layer and the basement membrane
showed a significantly higher proliferation rate than adjacent cells
within the same duct. These disruptions were associated with
histochemical and genetic alterations in the overlying tumor cells,
including the loss of ER expression, a higher frequency of loss of
heterozygosity, and a higher expression of cell cycle, angiogenesis, and
invasion-related genes. Focal ME layer disruptions were, in general,
associated with a higher rate of epithelial proliferation and leukocyte
infiltration; however, a small fraction of these ER-negative cells lacked
proliferation and differentiation markers resembling dormant cancer
stem cells.
Conclusions We propose a novel hypothesis that a localized death of
ME cells and immunoreactions that accompany an external environmental
insult or internal genetic alterations are triggering factors for ME layer
disruptions, basement membrane degradation, and subsequent tumor
progression and invasion. Inflammation may contribute to the death of
focal ME cells. Putative dormant cancer stem cells may be partially
responsible for tumor drug resistance and recurrence.
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Objective The aim in breast cancer treatment is to provide the correct
diagnosis with minimal delay that makes it possible to immediately plan
further treatment with the patient. In addition, the imprint method can
be used to make a diagnosis on material that will be snap-frozen for
future research purposes.
Method Imprints are made by gently pushing the core biopsy to a
coated glass slide, and then air-drying and staining with Diff-Quick. The
diagnosis is usually made within 5 min.
Results Of 51 imprints, 15 were diagnosed as carcinoma. Histology
confirmed carcinoma in 13. The two apparent false positives turned out
to be cancer on further investigation. Two of the imprints were given a
benign diagnosis; both turned out to be invasive lobular carcinoma. The
rest of the imprints that were given a benign diagnosis were all
confirmed as benign on histology.
Conclusions There was no true false positive diagnosis, but there were
two false negatives, both invasive lobular carcinoma. Imprint of core
biopsies is a reliable cytological method for diagnosing invasive ductal
carcinoma in breast. The diagnosis is reached within minutes and
treatment can be planned without delay, which ensures optimal patient
care. In addition, this method can be used to establish a diagnosis on
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Background Cell immortalization has been considered a hallmark of
malignancy, yet the molecular signature identifying a tumor’s ability to
immortalize is not known. To better understand the immortalization
process, we used in vitro model systems developed from clinical
primary breast cancer specimens. While spontaneous immortalization
of tumor cells in vitro is a rare event, immortalization can be achieved
through the introduction of the hTERT component of telomerase.
Because spontaneously arising cancer cell lines are already immortal
and display high levels of telomerase expression, they are not amenable
for study of the immortalization process in malignancy. However, finite
life primary tumor cultures show low hTERT expression, providing a
tool to study the effect of exogenously introduced hTERT.
Methods and results We introduced the hTERT gene into 17 primary
breast cancer cultures and analyzed global gene expression changes
before and after hTERT transduction in nine cases. All transduced
cultures achieved immortalization without other genetic manipulation.
Using 42,000 feature cDNA microarrays, we identified 594 genes (the
immortalization-associated signature [IAS]) that distinguished hTERT-
transduced and non-transduced cultures. We suggest that hTERT
immortalization reflects a physiologic process since expression
patterns of hTERT-transduced and spontaneously immortalized primary
cultures along IAS genes were correlated. To identify whether these
genes relate to in vivo breast cancer, we used the IAS to supervise the
analysis of 295 breast cancer patients. The signature strongly
predicted distant metastasis-free (P = 0) and overall survival
(P < 0.001) in ER-positive tumors but not in ER-negative tumors.
Notably, hTERT gene expression level itself did not predict clinical
outcome in primary tumors.
Conclusion To our knowledge, this is the first demonstration of an
immortalization signature in human breast cancer. This signature is
strongly associated with specific cellular pathways in human tumors
that may underlie the immortalization process and influence tumor
behavior. The association between the IAP signature and outcome for
ER-positive tumors but not ER-negative tumors suggests that different
pathways are involved in the outcome of ER-negative tumors.
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The selective expression of keratin genes is highly tissue-specific, and
antibodies to keratins have long been used as markers of differentiation
in cell and developmental biology and in pathology applications.
Antibodies to keratins can mark the progress of normal versus
abnormal differentiation, can detect early apoptotic changes and may
even identify stem cell-enriched tissue populations. A better
understanding of the function of keratins has come from identifying
links between keratin mutations and a wide range of tissue fragility
disorders, which have shown that keratin intermediate filament proteins
contribute physical resilience to epithelial tissues. The tissue specificity
of keratins may thus reflect different requirements for stiffer or more
plastic cells in particular organ sites. We re-examined the early
development of the mammary gland to ask whether differences in the
plasticity of cell compartments, proposed to result from expression of
different keratins, may contribute to morphogenesis in development. If so,
such physical differences might also be important in cancer metastasis.
During early development, mouse mammary glands, like other
epidermal appendages, first appear as thickenings of the ectoderm,
which then expand to form solid buds of epithelial cells protruding into
the mesenchyme. These buds then undergo substantial growth and
remodeling. Many well-established signaling molecules are now known
to play a role in epidermal appendage development, yet the physical
changes that take place within the cells at these early stages, and
which ultimately enable them to develop their functional tissue
morphology, are still poorly understood. Using immunohistochemistry
on mouse mammary gland precursors between days 12 and 19 of
gestation, we mapped the sequential changes in expression of keratins
and some other key structural proteins. Compartmentalization of keratin
expression was observed to divide the mammary gland rudiment into a
number of different zones. The subsequent fate of these zones
suggests that the specific expression of keratins and other structural
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Background Hypoxia induces the transcription of various genes
involved in angiogenesis and anaerobic metabolism necessary for the
growth of tumor cells. Hypoxia-inducible factor 1 alpha (HIF-1α)
regulates genes involved in the response to hypoxia and promotes neo-
angiogenesis in cancer. Thus, to develop an anticancer agent with anti-
angiogenic activity in hypoxic cancer cells, 6-(1-oxobutyl)-5,8-dimetoxy-
1,4-naphthoquinone (OXO) was synthesized.
Methods The XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetra-
zolium-5-carboxanilide) assay for cytotoxicity, the ELISA, RT-PCR and
western blotting analysis were employed in MCF-7 human breast
cancer cells under hypoxic conditions.
Results OXO showed cytotoxicity against MCF-7 cells, human breast
cancer cells with an IC50 value of 10 µM. OXO also reduced the levels
of vascular endothelial cell growth factor (VEGF) and HIF-1α in MCF
cells exposed to hypoxia. Similarly, OXO downregulated the expression
of HIF-1 and VEGF by western blotting and RT-PCR. In addition, OXO




inhibited the basic fibroblast growth factor (bFGF)-induced
proliferation, inhibited tube formation of human umbilical vein
endothelial cells (HUVECs) and also disrupted the neovascularization
in bFGF-treated Matrigel in vivo.
Conclusion Taken together, these results show that OXO may exert
anti-tumor and anti-angiogenic activity against MCF-7 cells via
regulation of HIF-1α and VEGF.
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Overexpression of the HER2 oncogene is observed in approximately
30% of human breast carcinoma specimens. HER2-overexpressing
breast cancer cells, such as SK-BR-3 and BT-474 cells, express fatty
acid synthase (FAS) at a higher level than MCF-7 cells or MDA-MB-231
cells, where HER2 is expressed at a moderate or low level. Adenovirus-
mediated HER2 expression in MDA-MB-231 cells increased acetyl-CoA
carboxylase alpha (ACCα) and FAS protein levels without significant
increases of their mRNA. HER2-mediated increases of ACCα and FAS
proteins were inhibited by the PI3K inhibitor, LY294002, and the mTOR
inhibitor, rapamycin. But sterol regulatory element-binding protein 1
(SREBP1) and ATP citrate lyase (ACL) mRNA and protein levels were
not changed by HER2 overexpression, LY294002 or rapamycin. In
conclusion, our results suggest that HER2-overexpressing cells lead to
increased ACCα and FAS proteins at a translational level via the
activation of the mTOR signaling pathway and not through SREBP-1c-
mediated transcriptional activation.
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Breast cancer patients with advanced disease often benefit from
endocrine therapy. However, many patients develop acquired
resistance to treatment after a period of response. In the Department of
Available online http://breast-cancer-research.com/supplements/7/S2
Figure 4
Effect of OXO on VEGF and HIF-1α in MCF-7 cells exposed to hypoxia.
Figure 5
Effect of OXO on the content of hemoglobin in bFGF-treated Matrigel.
Figure 2
Effect of OXO on the proliferation of bFGF-treated HUVECs.
Figure 3
Effect of OXO on the tube formation of bFGF-treated HUVECs.
S36
Tumor Endocrinology we have established several human breast
cancer cell lines with acquired anti-estrogen resistance through long-
term treatment with different anti-estrogens. These cell lines have been
used for our studies of the signaling pathways, which may be activated
in cells with acquired anti-estrogen resistance.
Analysis of the expression of genes known to be important for human
breast cancer has revealed that the majority of the anti-estrogen-
resistant breast cancer cell lines have decreased estrogen receptor
expression and signaling. However, increased expression of
phosphorylated PKB/Akt (p-Akt) and Akt kinase activity was observed
in several anti-estrogen-resistant cell lines. The PI3 kinase is an
upstream signaling molecule for Akt, and inhibition of PI3-kinase activity
with wortmannin or LY294002 deceases the level of p-Akt. Both PI3-
kinase inhibitors inhibited growth of the resistant cells. However,
wortmannin displayed a more profound growth inhibitory effect on anti-
estrogen-resistant cell lines than on parental MCF-7 cells. Treatment
with the novel Akt inhibitor SH-6 resulted in a very strong growth
inhibition of three resistant cell lines overexpressing p-Akt, whereas the
parental MCF-7 cells were significantly less growth inhibited.
It was investigated whether the increased level of p-Akt in the resistant
cells was due to signaling from IGF-IR and IRS-1, or whether it resulted
from decreased PTEN activity. Both involvement of IGF-IR and PTEN
could be excluded.
At present, our working hypothesis is that anti-estrogen-resistant
human breast cancer cell lines with an increased p-Akt level require
signaling via activated Akt to survive and maintain growth in the
presence of the anti-estrogen. Studies on clinical material will be
important to evaluate whether anti-estrogen-resistant tumors
overexpress p-Akt and whether Akt may be a target for treatment of
anti-estrogen-resistant breast cancer.
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Background High in normal 1 (HIN-1) is a small, secreted protein that
was initially identified as a protein the expression of which is lost in the
vast majority of breast cancers. The silencing of HIN-1 expression is
due to methylation of its promoter, which in addition to breast cancer
also occurs in a significant fraction of many other types of solid tumors
including prostate cancer, lung cancer, pancreas cancer, and
retinoblastoma, suggesting a potential tumor suppressor function.
Consistent with this hypothesis, in non-small-cell lung cancer,
downregulation of HIN-1 expression was found to be the most
significant independent predictor of poor clinical outcome in stage I
disease, suggesting loss of HIN-1 expression is a functionally important
event. The receptor of HIN-1 is unknown, but ligand-binding studies
indicate the presence of high-affinity cell surface HIN-1 binding sites
on the same epithelial cells that express HIN-1, suggesting that HIN-1
functions as an autocrine factor.
Methods To further explore the function and mechanism of action of
HIN-1, we examined the effect of HIN-1 on immortalized mammary
epithelial cells and a panel of breast cancer cell lines in vitro. HIN-1
was delivered via multiple expression systems, including a tetracycline-
regulated expression system, recombinant adenovirus, and
recombinant HIN-1 fusion protein.
Results We find that HIN-1 is a potent inhibitor of anchorage-
dependent and anchorage-independent cell growth. Expression of
HIN-1 in MDA-MB-435 cells causes reversion of their invasive
morphology when these cells are grown in a three-dimensional culture
system. As further evidence that HIN-1 can influence invasive behavior,
expression of HIN-1 markedly inhibited the invasion and migration of
breast cancer cell lines in Boyden chamber assays. Expression of
HIN-1 in synchronized cells inhibits cell cycle re-entry and the
phosphorylation of the retinoblastoma protein (Rb), while in
exponentially growing cells HIN-1 induces apoptosis without apparent
cell cycle arrest or an effect on Rb phosphorylation. To begin to dissect
the mechanism by which HIN-1 suppresses growth, we analyzed the
activation status of various signal transduction pathways involved in cell
proliferation and survival using activation state specific antibodies. This
investigation revealed that mitogen-induced phosphorylation of Akt
(Ser 473) is inhibited in HIN-1-expressing cells. Expression of HIN-1
also inhibits Akt-mediated retention of p27 in the cytoplasm. Further
supporting the role of Akt in HIN-1-mediated growth inhibition,
expression of constitutively activated Akt abrogates HIN-1-mediated
growth arrest.
Conclusion Taken together, these studies provide further evidence
that HIN-1 possesses tumor suppressor functions and suggest that
these activities may be mediated through the Akt signaling pathway.
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Background The signal transducer and activator of transcription 1
(STAT1) in human primary mammary carcinoma was found to be a
predictor of good prognosis for the outcome of disease [1]. This is in
accordance with its documented role in growth arrest and in pro-
apoptotic signaling.
Methods In order to define signaling pathways employed by STAT1 to
exert its effect on the tumor and to define the role of interferon gamma
(IFN-γ) in its activation, we have investigated the expression of known
STAT1 target genes and of IFN-γ in the primary tumor by quantitative
RT-PCR. The study was performed with a total of 111 different primary
tumor samples.
Results The expression of the two tumor suppressor genes IRF-1 and
suppressor of cytokine signaling 1 (SOCS1) were found to be
correlated with the activation status of STAT1, as determined by
measuring tyrosine phosphorylation of STAT1 by western blotting,
DNA binding by electromobility shift assays and nuclear localization by
immunohistochemistry. IFN-γ expression was correlated to the
expression of some, but not all, STAT1 target genes. However, it did
not correlate with constitutive STAT1 activation. Survival analysis
revealed that, in contrast to STAT1 activation, IFN-γ expression was
not a predictor of a longer overall or relapse-free survival.
Conclusions Our results indicate that, in the majority of primary
mammary carcinomas investigated, the constitutive activation of STAT1
does not depend on increased IFN-γ secretion (e.g. as a result of an
inflammatory reaction in the tumor). This suggests a prominent role for
IFN-γ-independent mechanisms leading to the constitutive activation of
STAT1 in primary mammary carcinomas. The frequent induction of the
tumor suppressor genes SOCS1 and IRF-1 in carcinoma tissue with
activated STAT1 implies a potential role of these genes in mediating
the good prognostic effects of STAT1 activation.
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Background Tumor protein D52 (TPD52), a tumor-associated antigen,
is overexpressed in the majority of breast, prostate and ovarian
cancers, where it is also amplified in a proportion of cases. Comparing
TPD52 (or D52) protein expression with clinical parameters indicates
that increased D52 expression is an early event in the development of
prostate cancer and possibly other cancers. The D52 protein is a
member of a family that includes the related proteins D53 and D54.
Studies to date indicate that while D52-like proteins share common
molecular functions as putative adaptor proteins, D52-like genes are
not equally overexpressed or targeted by gene amplification in cancer.
As a first step in allowing the specific targeting of D52 overexpression
in cancer, it is therefore imperative to determine the effects of
increasing or reducing the expression of D52 and related proteins in
mammalian cells.
Methods Expression vectors encoding human D52, two human
isoforms of both D53 and D54, and mouse D52 have been
constructed in the pCDNA3.1 vector. Similarly, expression constructs
have been derived that encode pEGFP-tagged forms of human D52,
and two human D53 isoforms. Transient and stable DNA transfections
were carried out using Lipofectamine 2000 reagent into the MDA-MB-
231 human breast carcinoma cell line, and the Balb/c 3T3 fibroblastic
cell line. In addition, an Ambion pSilencer system is being developed to
reduce D52 expression in MCF-7 breast carcinoma cells. Protein
expression in transfected cell populations is assessed using western
blotting and indirect immunofluorescence. Cell proliferation rates are
assessed using MTT assays, and anchorage-independent growth is
assessed by quantitating colony formation in soft agar after a 2-week
assay period.
Results We have previously studied the effects of expressing D52 or
D53 in MDA-MB-231 breast carcinoma cells, which express relatively
low levels of both proteins. While stably transfected MDA-MB-231 cell
lines could be derived when D52 or D53 were expressed from the β-
actin promoter, these could not be obtained when pEGFP-tagged D52
and D53 or untagged D53 were expressed from the CMV promoter.
Transient transfections revealed that expression of these proteins
commonly produced high proportions of multinucleated cells (40–44%
by 24 hours post transfection), compared with vector controls.
Expressing mouse D52 under the control of the CMV promoter
increased the cellular proliferation rate in pooled stable 3T3
transfectants, relative to the vector alone, as measured using MTT
assays. We are currently carrying out similar transfections with
additional D52-like expression constructs in 3T3 cells, and knocking
down D52 expression in MCF7 breast carcinoma cells, which express
high levels of D52 and D53 proteins.
Conclusions These studies indicate that the exogenous expression of
D52-like proteins produces different phenotypes in different cell types.
Expressing multiple D52-like proteins in MDA-MB-231 cells adversely
affects their ability to complete mitosis, whereas increased proliferation
rates in mouse D52-expressing 3T3 cells support previous results
implicating D52 as a regulator of cell proliferation in human leukemic
and chick neuroretinal cells. Further studies are now required to
determine whether reducing D52 expression negatively impacts upon
the growth of breast cancer cells.
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Amplifications of large chromosomal regions have been detected by
microarray-based comparative genomic hybridization in breast tumors
and breast cancer cell lines. Many of the genes within these amplicons
also show increased expression on microarrays, indicating that these
genes are probably of importance in breast cancer development. A
significant number of the genes showing both amplifications and
increased expression are located in amplified regions of human
chromosome 8q. Copy number abnormalities on chromosome 8q are
further correlated with poor survival outcome and the presence of
TP53 mutations. In our research we used cell-line-based functional
assays to identify and characterize genes on human chromosome 8q to
identify those that directly contribute to the evolution of breast tumors.
Hierarchical clustering of tumor gene expression profiles has identified
distinct subtypes of breast tumors. We have chosen specific breast
cancer cell lines in our studies as models for two of these subtypes:
basal-like and luminal breast tumors. In order to knock down gene
expression in these cell lines, we constructed a self-inactivating murine
stem cell virus (MSCV)-based shRNA expression vector. The vector,
pSiRPG, contains a highly efficient selection marker (Puromycin) and
an Enhanced Green Fluorescent Protein marker for the detection of
cells harboring the constructs. We have demonstrated efficient
expression of siRNAs in cell lines that are difficult to transfect using
standard methods. We also constructed a Gateway-compatible
expression vector, pRetroTRexD30, on the MSCV back bone. Full-
length cDNAs from more than 30 chromosome 8q genes selected in
our project have so far been transferred into this vector.
The siRNA constructs are currently being used to knock down gene
expression in cell lines showing high endogenous expression of these
8q genes. In parallel experiments, the genes are overexpressed in cell
lines showing low or undetectable endogenous expression. In these
experiments, cell lines harboring overexpression or siRNA constructs
are assayed for cancer-relevant phenotypes such as growth rate
changes, the ability to grow in low serum concentrations and/or
hypoxic conditions, sensitivity to chemotherapeutic drugs, apoptosis
induction, and the ability to form colonies in agar.
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Background Chromosome 3 is abnormal in a variety of human
cancers. An assay, based on a non-random elimination of human
chromosome segments in mouse–human microcell hybrids during
tumor growth in SCID mice, has been developed. It is called the
Elimination test (Et), and is designed for the identification of
chromosomal regions containing putative TSGs. A commonly lost
segment, termed chromosome 3 common eliminated region 1
(C3CER1) (also referred to as CER1), was identified using the Et. This
region spans ~2.4 Mb at 3p21.3 and contains 33 active genes,
including the putative TSGs: LF, LIMD1 and RIS1. It was recently
reported that the LIMD1 gene product functions in connection with
pRB to suppress cell proliferation. Here, we addressed the question of
whether the C3CER1 region at 3p21.3 is preferentially lost in actual
human breast tumors, and whether the fragile nature of FRA3B induces
terminal deletions leading to 3p14.2-pter losses or whether the
eventual 3p21.3 losses are interstitial. We also analysed whether the
LIMD1 gene was mutated in human breast tumors.
Methods To evaluate the loss of C3CER1 in human tumor tissues we
performed loss of heterozygosity (LOH) analysis of 159 breast tumors. We
compared the deletion frequency of the C3CER1 area with two other
regions on 3p; that is, the FHIT/FRA3B region at 3p14.2 and VHL at
3p25.3. The tumor material was screened for mutations with the SSCP
method, and samples with abnormal mobility in SSCP gels were
sequenced in an ABI 3100 genetic analyser. We are conducting multipoint
FISH analysis to confirm microdeletions in the breast tumor specimens.
Results LOH was detected in the C3CER1 region in 84% of
informative tumors. Thirty-nine percent of LOH-positive tumors showed
LOH at all informative C3CER1 markers. The other 61% had a
discontinuous LOH pattern suggesting interstitial deletions or
breakpoints. In the VHL and FHIT regions, deletions were observed in
69% and 30% of tumors, respectively. We found polymorphism in the
first three exons of LIMD1, but sequencing revealed no mutations
leading to changes in the protein product.
Conclusion Of the three 3p regions analysed, the highest deletion
frequency was observed at the C3CER1 region. We demonstrate that the
interstitial deletions including C3CER1 prevail over 3p14.2-pter losses.
The LIMD1 gene is not frequently mutated in breast cancer biopsies.
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Deregulation of cell cycle control is a hallmark of cancer. The primary
cyclins (A, B1, D1, D3 and E) are crucial for cell cycle progression [1].
Secondary cyclins (C and H) have putative indirect effects on cell cycle
propulsion and have not been previously evaluated in breast cancer. We
have examined protein expression and gene amplification of cyclins in
breast carcinomas and correlated the findings with clinical follow-up data.
We have previously demonstrated that overexpression of cyclin A is
associated with poor prognosis in breast cancer patients [2]. In this
study we wanted to evaluate the impact of other cyclins, both at the
gene level and at the protein level. We wanted to evaluate whether the
overexpression of cyclins is a result of gene amplification, as well as to
evaluate the prognostic value of gene amplification of different cyclins
for breast cancer patients. The impact of TP53 gene mutations on
gene amplification of cyclins was also evaluated.
Real-time quantitative PCR was used to detect gene amplification of
cyclin A, cyclin B1, cyclin C, cyclin D1, cyclin D3, cyclin E and cyclin H
in tumour tissue from 80 patients operated for invasive breast
carcinomas, while immunohistochemistry was applied to detect protein
expression of the same cyclins.
Among the 80 breast cancer tumour samples examined, 26.7% was
defined to have ccnA2 gene amplification, 37.2% had ccnB1 gene
amplification, 82.6% of the samples harboured amplification of ccnC,
74.4% had ccnD1 gene amplification, 41.9% had ccnD3 gene
amplification, 29.1% of the patients had ccnE gene amplification and
9.3% of the samples showed amplification of the ccnH gene.
When correlation between gene amplification and protein expression
was evaluated, we observed a statistical significant correlation
between gene amplification and protein expression of cyclin A
(correlation coefficient = 0.287, P = 0.009) and cyclin D3 (correlation
coefficient = 0.906, P = 4.9 × 10–33). Protein expression as well as
gene amplification of cyclin A was also correlated with gene
amplification of other cyclins. When the impact of gene amplification of
different cyclins on the patient survival was analysed, only gene
amplification of cyclin A was associated with patient survival.
We found a significant interaction between amplification of cyclin A
and cyclin E (Cox regression, P = 0.02). These two cyclins are
sequentially time related in the cell cycle. The effect of amplification of
cyclin A was therefore tested in a stratified analysis both when the
cyclin E gene was not amplified and when the cyclin E gene was
amplified. When the cyclin E gene was not amplified, the statistical
strength of the cyclin A amplification increased with a HR of 5.5 (95%
confidence interval: 2.2–14.3, P < 0.0001). When cyclin E was
amplified, amplification of cyclin A had no significant impact on survival
(P = 0.45).
In summary, we have analysed gene amplification and protein
expression of both primary and secondary cyclins in invasive breast
carcinomas. Overexpression and gene amplification of cyclin A is
correlated with gene amplification of other cyclins. Only gene
amplification and overexpression of cyclin A was associated with poor
prognosis, and amplification of cyclin A is the strongest prognostic
factor in patients that have a normal amplicon of cyclin E.
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Background Estrogen receptor (ER) status is an important parameter
in breast cancer management as ER-positive breast cancers have a
better prognosis than ER-negative tumors. This difference comes
essentially from the lower aggressiveness and invasiveness of ER-
positive tumors.
Results Here, we demonstrate that IL-8 is clearly overexpressed in
most ER-negative breast cell lines and breast tumor samples tested.
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We have also performed a large clinical study on breast tumor samples
to determine whether IL-8 expression could be correlated with other
clinical parameters. In addition, in vitro studies show that the invasion
potential of ER-negative breast cancer cells is associated at least in
part with expression of IL-8, but not with IL-8 receptor levels. Moreover,
IL-8 increases the invasiveness of ER-positive breast cancer cells, thus
confirming the invasion-promoting role of IL-8. Overexpression of IL-8
in ER-negative breast cancer cells involves a high transcriptional
activity of the IL-8 promoter. By analysing the IL-8 promoter, we have
identified the elements responsible for IL-8 overexpression in ER-
negative breast cancer cells.
Conclusion Taken together, these results provide the basis for the
control of IL-8 expression in breast cancer and define IL-8 as a novel
marker of breast cancers.
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Background IGFBP5 plays a role in mediating the effects of IGFs,
which are important in mammary gland development [1] and
carcinogenesis [2]. IGF-independent effects of IGFBP5 have also been
described and it has been postulated that these are at least partially
mediated via IGFBP5 localized in the nucleus [3,4].
Methods The cellular localization of IGFBP5 was analyzed by confocal
microscopy after either applying exogenous fluorescent-labeled
recombinant protein or applying immunostaining of cells ectopically
expressing IGFBP5. HC11, MCF10A mammary epithelial and T47D
mammary carcinoma cell lines were used in this study.
Results Nuclear localization of IGFBP5 was observed under two
conditions: fluorescent-labeled IGFBP5 added to cells with selectively
permeabilized plasma but not nuclear membrane; and cells transfected
with IGFBP5 expression vectors lacking the coding region for the
signal peptide. By contrast, non-permeabilized cells could be
stimulated to take up IGFBP5 only into intracellular vesicles outside the
nucleus and this was enhanced by adding a conjugate of polylysine
and transferrin, indicating an endocytotic uptake route. In addition, cells
transfected with IGFBP5 containing the signal peptide secreted
IGFBP5 into the medium but did not show any detectable nuclear
staining.
Conclusions Nuclear localization of IGFBP5 in mammary epithelial
cells required the crossing of the plasma membrane, which does not
appear to occur under normal cell culture conditions. Exit of IGFBP5
from endosomal vesicles into the cytosol followed by nuclear uptake
was never observed. Our results indicate a minor role or no role of
nuclear IGFBP5 in mediating its IGF-independent effect in the
mammary epithelium and in breast cancer.
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Several lines of evidence suggest that chromosome 8 is likely to harbor
tumor suppressor gene(s) involved in breast cancer. We have shown
previously that microcell-mediated transfer of human chromosome 8
into the breast cancer cell line MDA-MB-231 results in reversion of
tumorigenicity of these cells and is accompanied by expression
changes of a clinically relevant set of genes.
In the present study we demonstrate that the transfer of human
chromosome 8 into another breast cancer cell line, CAL51, results in
hybrids characterized by suppression of tumorigenicity in vitro and in
vivo as compared with the parental cells. Loss of the transferred
chromosome 8 results in reappearance of the CAL51 phenotype.
Oligonucleotide microarray analysis identified 78 probe sets
differentially expressed in the hybrids as compared with CAL51 and
the rerevertant cells. The majority of these genes is involved in signal
transduction, developmental processes, angiogenesis, cadherin
signaling, Wnt signaling or inflammation.
It is of particular interest that the 78-gene signature is also reflected in
a panel of breast tumors, lymph node and distant metastases, and is
correlated with several prognostic markers including tumor size,
grading, metastatic behavior and estrogen receptor status.
As opposed to the corresponding non-tumorigenic phenotypes
demonstrated for the MDA-MB-231-derived and CAL51-derived
microcell hybrids, the respective differentially expressed genes strongly
differ from each other. However, it was of special interest that the
majority of genes of both gene sets could be integrated into a similar
spectrum of biological processes and pathways.
Our findings provide an experimental system to identify and evaluate
genes but, more importantly, signatures of biological processes and
pathways involved in the development and/or progression of breast
cancer.
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Background Several cytogenetic studies demonstrated frequent allelic
losses at defined regions on chromosome 6 in breast tumors,
suggesting the presence of tumor suppressor gene(s) (TSG)
contributing to breast cancer (BC) tumorigenesis. Different techniques
identified several candidate TSGs on chromosome 6 in BC, but no
functional evidence for a TSG function for these genes could so far be
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supplied. In order to identify key genes and elucidate the regulatory
pathways that are involved in the development and progression of BC,
we combined array-based expression profiling with a powerful
functional approach, the microcell-mediated chromosome transfer.
Methods and results An intact copy of chromosome 6 was transferred
into the 6q deleted and highly invasive BC cell line MDA-MB-231 using
the microcell-mediated chromosome transfer. It was demonstrated by
microsatellite allelotyping, CGH and FISH that the hybrid clones
contain two fragments of chromosome 6, spanning 6p22-q14 and
6q15-6q27. The transfer of parts of chromosome 6 into the MDA-MB-
231 cells resulted in reduced anchorage-dependent growth, reduced
in vitro invasion and a strongly reduced tumorigenic potential.
In order to identify genes responsible for the observed reversion of the
tumorigenic phenotype in MDA-MB-231 cells, differential gene
expression between the parental cell line and the hybrid clones was
analysed using oligonucleotide micro-arrays (HG-U133; Affymetrix,
Santa Clara, CA, USA). The identified set of differentially expressed
genes will be presented.
Conclusions Our results provide functional evidence that the
suppression of the tumorigenic phenotype of the BC cell line MDA-MB-
231 is mediated by a specific set of genes regulated by one or more
genes on chromosome 6.
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Background Transforming growth factor beta (TGF-β) is a potent
tumor suppressor but it can also enhance tumor metastasis by
inducing epithelial to mesenchymal transition, cell migration, and
changes in tumor microenvironment. The mechanisms underlying the
metastatic switch in TGF-β function are not well understood. We have
recently reported that TGF-β regulates tropomyosin-based actin
microfilament fibers [1], which are essential for cell proliferation,
morphology and motility [2]. Smads and p38 MAPK mediate induction
of tropomyosin and formation of stable actin microfilament fibers
(stress fibers), thereby reducing cell motility. Tropomyosin (TM) is a
dimeric coil-coiled protein that binds along actin microfilaments forming
a head-to-tail polymer. TM stabilizes microfilaments and protects them
from the depolymerizing action of gelsolin and cofilin. Importantly,
TGF-β induction of stress fibers inversely correlated with metastatic
behavior of tumor cells. The metastastic breast cancer MDA-MB-231
cell line with active TGF-β signaling did not express TM isoforms
encoded by the TPM1 gene. DNA demethylating agent increased
TPM1 expression. We hypothesized that DNA methylation may
suppress TPM1 and tropomyosin-based actin fibers, thereby reducing
TGF-β control of tumor cell invasion and metastasis. The goals are to
define the mechanisms underlying loss of tropomyosin expression and
changes in TGF-β tumor suppressor function.
Methods RT-PCR and immunoblotting analysis of expression
tropomyosin isoforms encoded by TPM1 and TPM2 genes in a panel of
normal epithelial (MCF10A, NMuMG) and carcinoma (MCF7, MDA-
MB-231, MDA-MB-435, A549, SW620, SW480) cell lines. DNA
methylation of the TPM1 promoter was analyzed by bisulfite
sequencing in normal and cancer breast cell lines. Cell
migration/invasion was studied using transwell and wound-healing
assays. Actin filaments and focal adhesions were studied by
immunofluorescence. The role of TPM1 was studied using inducible
Tet-Off MDA-MB-231 cell lines.
Results Both TPM1 and TPM2 genes were expressed in normal and
non-metastatic tumor cell lines. In metastatic breast and colon tumor
cell lines, however, TPM1 expression was significantly reduced or
absent, whereas TPM2 was expressed at low levels. Treatment of
metastatic cell lines (MDA-MB-231, MDA-MB-435, SW620) with
demethylating agent 5-aza-2′-deoxycytidine (5-aza-dC) increased
TPM1 expression with little effect on TPM2. Importantly, 5-aza-dC
treatment of MDA-MB-231 cells restored TGF-β induction of TPM1
and formation of stress fibers. Forced expression of TPM1 using the
Tet-Off system increased stress fibers in MDA-MB-231 cells and
reduced cell migration. A potential CpG island spanning the TPM1
proximal promoter, exon 1, and the beginning of intron 1 was identified.
Bisulfite sequencing showed significant cytosine methylation in
metastatic cell lines that correlated with a reduced expression of
TPM1.
Conclusion Tropomyosin-based stress fibers are essential for TGF-β
control of cell motility and invasion. Epigenetic suppression of TPM1
may alter tumor suppressor function of TGF-β and contribute to the
acquisition of metastatic phenotype.
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Background Promoter hypermethylation is a common inactivation
mechanism in the development and progression of neoplastic
transformation. For mammary carcinoma numerous genes have been
described to be silenced due to aberrant methylation, some of them
already in intraductal carcinomas. Much less is known about the
association of hypermethylation events with the different histological
subtypes of breast cancer.
Methods Genomic DNA was isolated from fresh-frozen and formalin-
fixed paraffin-embedded biopsies and was treated with bisulfite for
subsequent methylation analysis. Altogether 40 lobular breast cancer,
89 ductal breast cancer, and 20 normal breast tissue samples were
analyzed. For this purpose, real-time PCR-based quantitative
methylation assays were developed for the following genes: p16INK4a,
cyclin D2, RASSF1A, GSTp1, RIZ-1, HIN-1, APC, DAP kinase, Twist,
and SOCS-1.
Results A stringent threshold for scoring a sample as ‘methylated’
(mean of the methylation level in the control group plus twice the
standard deviation) was established for every gene analyzed.
Differences in DNA methylation between ductal and lobular breast
cancer concerning frequency, intensity, age dependence and
concurrence of hypermethylation were uncovered. The most frequently
hypermethylated genes in the whole series of 129 breast cancer
specimens were cyclin D2 (75.2%), RASSF1A (71.3%), and HIN-1
(66.7%). The p16INK4a and the RIZ-1 genes were only rarely
methylated. A quantitative analysis of the methylation levels using the
Mann–Whitney test revealed a statistical significant association of the
methylation of the genes DAP kinase and cyclin D2 with the lobular
subtype. By contrast, a mere qualitative scoring of methylation data did
not reveal any significant differences.
Conclusions The results presented in this study demonstrate that
subtype-specific patterns of aberrant gene methylation exist in breast
cancer, which will help to elucidate the underlying biological
differences. These subtype-specific patterns could only be revealed by
using stringent real-time PCR-based quantitative methylation assays.
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Background Aberrant methylation of normally unmethylated CpG
islands has been associated with transcriptional inactivation of defined
tumor suppressor genes (TSG) in human cancer. Abnormal methylation
therefore serves as an alternative to the genetic loss of a tumor
suppressor gene function by deletion or mutation.
Methods Methylation profiling was performed by methyl-sensitive PCR
with genes involved in cancerogenesis: RB1, p14, p15, p16, CDH1,
MGMT, HIC1, N33, LAMC3 and TGFBR1. Methylation profiles of
these genes were obtained for 105 breast cancer (BC) specimens.
Five specimens (section material) of the normal mammary gland tissue
and peripheral blood lymphocytes of 30 healthy subjects were also
investigated.
Results By methylation-sensitive PCR with specific primers we
detected no methylation of any investigated genes in control peripheral
blood lymphocytes and in five normal breast tissues. High frequencies
of promoter methylation were observed for the major TSG involved in
controlling the cell cycle through the Cdk-Rb-E2F signaling pathway:
RB1, 17%; p16, 56%. Methylation of both genes was revealed in 12%
of tumors. p15 was methylated in 2% only. No methylation was
observed for the CpG island of p14. The methylation frequency was
rather high in the case of the CDH1 promoter (37%), maximal in the
case of the HIC1 promoter (79%), and relatively low in the case of
MGMT (8%) and N33 (9%). Methylation was shown to be 32.5% for
LAMC3. Laminins contain motifs providing cell growth and
differentiation via selective activation of signaling pathways dependent
on protein kinase C and, probably, involved in metastases spreading.
We have detected abnormal methylation of the TGFBR1 CpG island in
35% samples. TGFBR1 takes part in transforming growth factor beta
signaling, mainly resulting in inhibition of cell proliferation. None of
tumors showed methylation of all genes. No gene was methylated in
11% of tumors, and at least one gene in 89% of tumors.
Conclusion We have shown that CpG methylation in the promoter
regions of TSG is common to sporadic BC. Genes with a higher
methylation frequency may be included in the BC methylotype.
Identification of the genes with a high methylation frequency is a
necessary step in characterizing a particular tumor. Along with other
molecular genetic markers, the methylation profile may be employed in
early diagnostics and prognostication.
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Background Wnt signaling, initially identified in early embryogenesis of
Drosophila, is involved in a large set of cellular processes, including
proliferation, differentiation, migration, and apoptosis. Canonical Wnt
signaling is involved in cell fate choices, stem cell renewal and
differentiation, whereas non-canonical signaling deals with
morphological changes and tissue organization. Since the discovery of
Wnt-1 as a virally-induced oncogene in mouse mammary tumors, Wnt
signaling has become a center of interest in human breast
carcinogenesis. Surprisingly, genetic aberrations of Wnt signaling have
been revealed in different malignancies including colon cancer, liver
cancer and hematological cancer, but not in breast cancer. Thus,
epigenetic changes in Wnt signaling, rather than mutations, may be
more relevant to breast cancers in humans. However, this aspect of
Wnt signaling in breast cancer is not fully understood. We aimed to
study the expression of key components of Wnt signaling in breast
cancer. Here, we report the preliminary results obtained from our
expression profiling studies for all known Wnt ligand, frizzled receptor,
co-receptor and Lef/TCF transcription factor genes, using a set of cell
lines and primary tumors.
Methods We studied the expression profile of 34 Wnt pathway genes
by the RT-PCR technique. RNAs were extracted from a telomerase-
immortalized human mammalian epithelial cell line (HMEC), six breast
cancer cell lines and 15 breast tumors. Tumor samples were selected
following pathological analysis of fresh-frozen tissue slices.
Corresponding cDNAs were synthesized and subjected to PCR
amplification using specific pairs of primers. Equal loading of total cDNAs
was checked by PCR analysis of the housekeeping gene GAPDH.
Results HMEC cells, used as a normal control, expressed many Wnt
signaling genes, including 9/19 (48%) Wnt ligands, 7/9 (78%) frizzled
receptors, LRP-5, LRP-6, as well as four LEF/TCF transcription factors.
Expression patterns of frizzled receptors, LRP-5, LRP-6, and LEF/TCF
transcription factors did not show major changes in breast cancer cell
lines. The major change in Wnt signaling genes was observed at the
level of ligand expression. The expression of Wnt-3a, Wnt-4, Wnt-6,
Wnt-8b and Wnt-9a were upregulated in 50% or more breast cancer
cell lines. Conversely, the expression of Wnt-5a, Wnt-9b and Wnt-16
was downregulated. Our ongoing studies with breast tumors indicate
that Frizzled-1, Frizzled-2 and Frizzled-6 expression is also maintained
in breast tumors. Moreover, upregulation of Wnt-4 and Wnt-9a, as well
as downregulation of Wnt-5a expression, were observed in 79–100%
of tumors.
Conclusion These observations provide evidence for redundant
expression of major genes involved in Wnt signaling in both normal and
malignant breast cells. The expression of at least nine Wnt genes in
HMEC strongly suggests that some Wnt ligands may provide autocrine
or paracrine signaling to normal breast epithelial cells. Six Wnt genes
were commonly expressed in both HMEC and breast cancer cell lines,
suggesting that some Wnt ligands may not be significantly involved in
malignant transformation of mammary epithelial cells. On the other
hand, malignant cells have upregulated the expression of Wnt-3a,
Wnt-4, Wnt-6, Wnt-8b and Wnt-9a genes that may play a positive role
in malignancy. Wnt-3a and Wnt-4 are known to display transforming
activity in mammary epithelial cells. The function of Wnt-8b in
mammalian cells is not well known, but its Xenopus homolog displays
strong axis-duplication activity, suggesting that it may also be a
transforming Wnt. On the other hand, the expression of Wnt-5a,
Wnt-9b and Wnt-16 was switched-off in malignant breast cells. Although
the functions of Wnt-9b and Wnt-16 are not well known, Wnt-5a has
been identified as a tumor suppressor in hematological malignancies,
and acts as an antagonist of canonical Wnt signaling. Taken together,
these results indicate that there is a switch in Wnt ligand expression
pattern in breast cancer cells, and that this may provoke a functional
switch in Wnt signaling from non-canonical to canonical pathways.
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Background BRCA1 possesses a number of features common to
transcriptional regulatory proteins, suggesting that it may regulate the
expression of one or more downstream genes. It is important to
determine which genes are transcriptionally influenced by BRCA1 in
vivo to explain its role in tumor suppression and in cancer development.
In our previous study, a BRCA1 overexpression system enabled us to
define the genes whose expression levels were induced in MCF-7
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breast cancer cells by using the PCR-dependent suppression
subtractive hybridization technique [1].
Herein, we report the preliminary results obtained from our real-time
expression profiling of normal-matched primary breast tumors for six
genes, three of which were previously reported [1]. The association
between the gene expression profiles and histopathological states of
these tumors will contribute to the definition of possible diagnostic
markers.
Methods Breast tumors were selected following pathological analysis
of fresh-frozen tissue sections. RNAs were extracted from 31 normal-
matched breast tumor tissues. Synthesized cDNA samples were
subjected to real-time PCR using the QuantiTect SYBR green PCR
Master Mix with gene-specific primers. GAPDH is used as a
housekeeping gene for normalization. The gene expression levels were
quantified using the delta–delta Ct method after normalizing each
tumor with its normal counterpart.
Results The real-time expression level of BRCA1 was highly correlated
with ERBIN and SMG1 (Pearson correlation, Minitab; n = 31;
r = 0.765 and r = 0.673, respectively; P < 0.0001). The pairwise
correlations of BRCA1 expression with those of RENT2 and OVCA1,
but not with OVCA2, were at moderate levels (r = 0.41 and r = 0.46,
respectively; P < 0.05). Furthermore, primary breast tumors were
hierarchically clustered into two major groups based on their real-time
gene expression profiles using the CLUSTER program and were
visualized by TRIVIEW [2]. Cluster I tumors were characterized by a
high-level expression in BRCA1 target genes (n = 20; 1.52 ± 0.6, log2)
and were low grade on average (37.5% I, 50% II, 12.5% III; n = 16).
On the other hand, Cluster II included higher grade tumors (45% II,
55% III; n = 11) expressing BRCA1 target genes at a lower level
(n = 11; –0.79 ±0.7, log2). Based on the Mann–Whitney U test,
Cluster I and Cluster II were significantly different in terms of their
tumor grades (W = 206; P = 0.0059).
Conclusion This study demonstrated that real-time RT-PCR studies
provide highly accurate quantitative profiling for marker gene
association with tumor subtypes. The mRNA expression of ERBIN,
ERBB2/HER2 binding protein, was found to be tightly correlated with
that of BRCA1 in primary breast tumors, as found in MCF7 cells
ectopically expressing BRCA1 [1]. The OVCA1 tumor suppressor
gene (17p13.3) that displays frequent LOH in both ovarian cancer and
breast cancer also showed correlation with BRCA1 in primary breast
tumors used in our study. A certain degree of expression variability, part
of which could be attributable to the variation in tumor grade, exists for
the genes used in this study, including BRCA1. Our findings support
the view that association of the patients’ clinical and pathological
parameters with the gene expression profiles of breast tumor samples
carries great importance in the classification of tumor subtypes.
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Background During the past decade, microarray-based gene
expression analysis gave rise to a large number of candidate genes for
the diagnostics and therapy of cancer. Bioinformatic approaches
delivered gene sets, the expression patterns of which were predictive
for certain cancer phenotypes. A synergy between these advances and
the development of screening tools for a rapid and reliable screening of
marker gene expression represents an important step towards an
improved treatment of cancer.
Methods For the semiquantitative expression screening of 11
candidate genes for drug resistance in melanoma, we combined
multiplex RT-PCR (mRT-PCR) with subsequent microfluidic fragment
analysis.
Results The functionality of this approach was demonstrated by low
interexperimental variations of amplicon quantities after endpoint
analysis. Applied to RNA samples derived from drug-sensitive and
drug-resistant melanoma cell lines, mRT-PCR delivered results
qualitatively concordant with data obtained from northern blot analyses
and array analyses. A preliminary screen of four additional melanoma
cell lines points to IL1B, APOD, and CYR61 as interesting candidates
for drug-resistance associated genes. First tests using an automated
on-chip electrophoresis platform indicate the applicability of this
approach for high-throughput measurements.
Conclusion mRT-PCR combined with on-chip electrophoresis reveals
a rapid and easy-to-handle method for candidate gene set evaluation
from limited amounts of mRNA. Using gene sets indicative for different
tumor phenotypes, this procedure may represent an alternative for
future cancer diagnostics.
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Background Among breast cancer patients receiving ionizing radiation
(IR) treatment, a subgroup shows adverse long-term effects in the
normal tissue. Radiation-induced fibrosis (RIF) is one of the most
serious complications, and risk of RIF is a dose-limiting factor in the
treatment of breast cancer patients with IR. The mechanisms whereby
IR induces RIF are not fully understood. However, several observations
indicate that the variation in normal tissue sensitivity and the consequent
risk of developing late morbidity may be genetically determined. The aim
of this study was to obtain a comprehensive overview of the changes in
gene expression after IR and to identify genes that can be used to
predict risk of RIF, using microarray analyses.
Materials and methods Normal fibroblasts were achieved from 41
patients treated with postmastectomy radiotherapy in Aarhus,
Denmark, from 1978 to 1982 and subsequently evaluated in detail with
regard to development of RIF. The fibroblasts were grown to early
confluency before they received radiation. Total RNA was isolated both
before and after radiation, labelled and hybridized to cDNA microarrays
consisting of 15,000 cDNAs and ESTs [1]. Expression profiles were
identified using hierarchical cluster analyses [2]. Statistically significant
changes in gene expression were identified using significance analysis
of microarrays (SAM), and predictive genes were identified using
prediction analysis for microarrays (PAM) [3].
Results and conclusion Microarray data were first analyzed in order to
identify radiation-responsive genes. While several genes were involved
in known IR response pathways such as cell cycling, proliferation and
stress, a substantial fraction of the genes were involved in processes
not previously associated with IR response. Of particular interest are
genes involved in extracellular matrix composition. SAM analyses were
also applied to identify genes in which the expression level correlated
with the level of fibrosis. PAM analyses identified a limited set of
predictive genes that may provide a basis for a diagnostic tool in the
identification of patients with adverse responses to radiation, and to
improve and optimize radiotherapy at the individual level.
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Background Repair of damaged DNA is a highly regulated process in
normal tissue. Several human genetic diseases are known to be or
suspected to be due to defects in DNA repair or cell cycle control.
Some of these patients are radiation sensitive and/or predisposed for
cancer as a cause of mutations in genes involved in these cellular
pathways. A well-known group of radiation-sensitive patients is the
ataxia-telangiectasia (A-T) patients. This disease is caused by
mutations in the ATM (A-T mutated) gene, whose gene product is
involved in detecting double-strand breaks. In this study we are trying
to reveal the cause of radiation sensitivity in a group of radiation-
sensitive patients having an A-T phenotype without mutations in ATM.
Methods Gene expression studies were conducted using 15k cDNA
(NRH) microarrays on lymphoblastoid cell lines obtained from four
control individuals (‘normal’), four A-T patients and 10 radiation-
sensitive patients, before and after radiation. Cells were harvested prior
to radiation (0 hours) and at 2 hours, 8 hours and 24 hours,
respectively, after exposure to ionizing radiation. The cell lines were
irradiated with a dose of 2.0 Gy. To be able to study possible
similarities and differences in the expression patterns between the
three groups of cell lines, we used cluster analyses.
Preliminary results The preliminary results suggest that the radiation-
sensitive patients constitute a heterogeneous group, and that the
cause of their radiation sensitivity may be diverse. Conversely, several
samples showed consistency in their gene expression patterns, which
might reveal relevant genes and unknown pathways. To understand the
biological context we need a broader base of comparison. Ongoing
experiments include more samples in this study and will hopefully
enable us to reveal the cause of the radiation sensitivity in these
patients and bring us a step closer to the understanding of early
malignancy development.
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Background Women who received mantle-field irradiation following
Hodgkin’s lymphoma (HL) have an age-dependent increased risk of
developing breast cancer. It has been estimated that approximately
90% of the breast carcinomas in these patients is a result of their
radiation treatment, which makes this series extremely appropriate to
determine a potentially radiation-induced genomic profile.
Methods In this study we have used array-comparative genomic
hybridization (array-CGH) and gene expression profiling (GEP)
technology to assess the genomic and gene expression changes in
radiation-induced breast tumors. For genomic profiling we used DNA
isolated from paraffin-embedded primary breast tumors of breast
following HL (BfHL) patients (n = 29). These DNAs were hybridized to
a small custom-designed BAC array containing 180 clones specifically
selected on their function in the DNA-damage repair pathway or breast
cancer susceptibility. For gene expression profiling, RNA was isolated
from fresh-frozen tissue samples of 13 BfHL patients and hybridized on
35K human oligo-array as well as from sporadic breast tumors that
were included as controls, matched for age at diagnosis and no
exposure to radiation.
Results Hierarchical clustering of all the array-CGH data divided the
samples into two groups. One cluster consisted of the tumors that had
developed in the unprotected area of the breast that received high-
dose radiation (20–40 Gy) during treatment. These tumors showed a
significantly higher frequency of amplifications and deletions than those
that had developed in the low-dose radiation (1–10 Gy) breast area
and the control breast tumors. We performed supervised classification
on the two groups in order to construct a predictor for identification of
tumors that occurred in high-dose irradiation or low-dose irradiation
fields. A classifier employing 15 BAC clones achieved the best cross-
validation performance, and had an associated validation performance
of 91.7%.
Hierarchical clustering of the GEP data was performed using 6111
significantly differently expressed oligomers, which resulted in a
clustering of the so-called radiation-induced tumors separate from the
sporadic tumors (software program Genesis). A supervised
classification strategy of these two groups revealed 50 significant
genes that could differentiate low-dose and high-dose radiation BfHL
versus sporadic tumors. Importantly, the ‘radiation profile’ found with
the array-CGH could be confirmed by the GEP data; for example,
deleted genomic regions showed downregulation of expression.
Conclusion Our preliminary results indicate that low-dose radiation as
well as the high-dose radiation-induced tumors can be distinguished
from sporadic tumors on the basis of their genomic and expression
profile.
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Background Breast cancer is a complex, heterogeneous disease at
the molecular level. Recent advances proposed a new molecular
taxonomy of breast cancer that defines molecular subtypes such as
luminal or basal-like cancers. Hopefully this may modify breast cancer
management. A great part of our knowledge on breast carcinomas is
based on studies of breast cancer cell lines (BCC). Although many
data are available on BCC lines, less is actually known on their
molecular characterization. We have determined the molecular subtype
of 31 BCC using DNA microarrays and confirmed their phenotype by
immunohistochemistry (IHC) on ‘cell microarrays’ (CMA).
Methods DNA array results were obtained on an Affymetrix station.
CMA was constructed in a paraffin block from an agarose core of cell
line pellets. Proteins studied in IHC were: estrogen and progesterone
receptors, transcription factors GATA 3 and GATA 4, tyrosine kinase
receptors (EGFR, ERBB2, MET), sialomucin MUC1, luminal cyto-
keratins CK8/18 and CK19, basal cytokeratins CK5/6 and CK14,
CALLA receptor (CD10), caveolae receptors CAV1 and CAV2,
mesenchymal vimentin and alpha smooth actin.
Results Hierarchical clustering sharply discriminated two groups of
BCC. To determine whether a BCC was of ‘luminal’ or ‘basal-like’
subtype, hierarchical clustering was done with the subset of genes
selected by Sørlie and colleagues to discriminate molecular subtypes
of tumors: eight BCC were luminal-like, 12 were basal-like, and 11
were not clearly affected to one subtype. Supervised analysis selected
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the most discriminant genes between basal and luminal subtypes, and
corresponding antibodies were tested on CMA when available. The
immunohistochemical profile was in accordance with the transcriptional
profile.
Conclusion According to the molecular classification of breast tumors,
we have determined two different subtypes of cell lines, luminal and
basal-like, and isolated a subset of genes that discriminates both
subtypes. The DNA array data were confirmed at the protein level. This
characterization of breast cell lines provides a powerful tool to study
specifically each molecular subtype of breast cancers. The master
genes isolated from each group may be new targets for breast cancer
management.
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Background Differentiation markers characteristic of multiple cell
types in the mammary gland have emerged as a dominant feature in
gene expression profiles that segregate primary human breast cancers.
Immunohistochemical and mRNA expression profiling studies of large
breast cancer cohorts have reproducibly identified a subset of tumors
(~15%) that express markers characteristic of the basal layer of the
mammary gland. This is in contrast to the many human breast cancers
that uniformly express luminal markers such as the simple cytokeratins
(K8/K18) and appear to originate from transformed luminal epithelial
cells. A logical next step is to determine the dominant signaling
pathways and genetic defects that drive tumor initiation and
progression, and to understand how they are related to cell lineage in
each breast cancer subtype. A large number of breast cancer cell lines
have been isolated and individually characterized over the past few
decades. We and others have begun to comprehensively align these
cell lines with primary tumors based on gene expression profiles and
other parameters in order to improve the relevance of data obtained
from these experimental models for understanding human disease.
Methods We have characterized a panel of 51 breast cell lines for a
large number of properties including in vitro and in vivo growth rates,
morphology on plastic and in three-dimensional matrices, and
sensitivity to estrogens/anti-estrogens. Baseline microarray profiles
were generated using Agilent 60-mer oligonucleotide arrays for each
cell line. In addition, we have generated ‘signature profiles’ for selected
cell lines in response to exogenous stimulation such as estrogen and
TGF-β. A constraint-based analysis of microarray profiles generated
from primary tumors and breast cancer cell lines in combination with
response signatures was used to identify candidate genes and
pathways that may play dominant roles in the breast cancer subgroups.
Results The 51 breast cell line panel was segregated into two roughly
equal sized groups comprised of those with dominant luminal features
and those with progenitor or non-luminal properties. The top ~600
genes that distinguish luminal versus non-luminal cell lines were
identified. All of the luminal cell lines express ESR1, HER-2 (ERBB2) or
both. The non-luminal cell lines express many components of the wnt
signaling pathway, including ligands, frizzled receptors and secreted
inhibitory proteins. Interestingly, the majority of the non-luminal cell lines
express significantly higher levels of the ROR1 receptor tyrosine kinase
relative to luminal cells. The non-luminal cell lines further segregate into
those with predominantly basal features versus those with
mesenchymal features. A dominant feature of the mesenchymal cell
lines is evidence of elevated, autocrine TGF-β signaling.
Conclusion Based on our characterizations and array data for a large
panel of breast cancer cell lines, primary tumors and response
signatures, we propose an integrated model for the molecular
classification of breast cancer. This model connects dominant signal
transduction pathways with cell-type origin, and further resolves the
biological and clinical significance of the well-established markers ER
and HER-2. The proposed stratification is likely to help explain the well-
known diversity in response of breast cancers to standard therapeutic
regimens and, more importantly, may identify appropriate breast cancer
subtypes amenable to targeted therapeutics.
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Background Gene expression profiling has been used to identify
specific subgroups of breast carcinomas. Perou and Sørlie [1-3]
described five subtypes (basal, luminal A and luminal B, ErbB2 and
normal-breast like). Here we have categorized the 295 tumors that
were previously assessed with the 70-gene prognosis profile
according to these five subtypes.
Methods In 295 stage I and stage II breast carcinomas treated at the
Netherlands Cancer Institute, we have obtained gene expression data
of 25,000 genes using micro-array analysis. We have used the
previously described Intrinsic Gene Set [3] to define basal type, luminal
A and luminal B, ErbB2 and normal epithelium-like type tumors (431 of
487 unique genes matched). We have used two different methods to
classify the tumors: two-dimensional hierarchical cluster analysis and
nearest centroid classification. We have compared the reproducibility
by both methods and we have analyzed clinical outcome (distant
metastasis-free probability and overall survival) of these 295 patients
based for the different classes. The median follow-up is 6.7 years for all
patients and 7.8 years for patients alive.
Results Based on hierarchical clustering, the basal subgroup can be
easily recognized; the ErbB2 group is reasonably well defined and the
luminal A and luminal B groups form a large cluster, with subclusters
that have more luminal A or luminal B patients. For the nearest centroid
classification we used a correlation threshold of 0.1 to classify patients.
One hundred and nine (37%) patients did not have a correlation of
more than 0.1 to one of the five centroids (‘unclassifiable’). Forty-five
(15.25%) patients were assigned to the basal group, 39 (13.2%)
ErbB2, 47 (16%) luminal A, 45 (15.25%) luminal B and 10 (3.3%)
normal-breast like. The relatively large group of patients that could not
be assigned to one of the classes was further analyzed. These tumors
appear to represent a relatively homogeneous group that differs from
those that can be classified. The ER receptor is positive in 106/109
(120/188 classifiable patients: two-sided Fisher’s exact P < 1 × 10–9)
and 80% of the tumors are histological grade I or grade II (47% for
classifiable patients; P < 1 × 10–6). Not surprisingly, the 10-year overall
survival is higher in these patients as well (80% vs 64%; log-rank:
0.0005). Using predicting analysis of micro-arrays [4], the
unclassifiable ‘class’ could be predicted using 200 genes with an
accuracy of 90% (cross-validation results).
The 10-year metastasis-free probability and overall survival for the
subgroups are: basal, 54% and 46%; erbB2, 55% and 56%; luminal A,
70% and 83%; luminal B, 56% and 63%; and normal-breast like, 67%
and 90% (overall P value: metastasis-free probability, 0.15 and overall
survival, 0.001).
Conclusion In this series of consecutively treated breast cancer
patients, the molecular portraits identify patients that differ with respect
to prognosis. The relatively high proportion of unclassifiable patients
can possibly be explained by both the cross-platform matching, the
difference in clinical stage (locally advanced in the original series
versus early stage in our patients), and the fact that the original
classification was derived from a relatively small series of tumors. The
Breast Cancer Research    Vol 7 Suppl 2 Third International Symposium on the Molecular Biology of Breast Cancer
S45
subgroup that could not be classified using the intrinsic genes contains
mainly ER-positive and grade I or grade II tumors.
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Background Gene expression profiling has been used to define
molecular phenotypes of complex diseases such as breast cancer. The
Luminal A and Basal subtypes have been repeatedly identified and
validated as the two main subtypes out of the total of five of breast
tumors originally identified by Perou and colleagues [1]. These two
subtypes of breast tumors have also been associated with a significant
difference in clinical outcome: the Luminal A subtype patients have
been correlated with a significantly longer overall survival or they lived
considerably longer before experiencing relapse or metastatic disease,
whereas patients with Basal subtype tumors showed the shortest
overall survival time or experienced much shorter disease-free time
intervals [2,3]. To further substantiate the prognostic value of such
expression-based phenotypes in diagnosis/prognosis of breast cancer,
we report here an extended study on identification and molecular
characterization of clinically relevant subtypes in early stage breast
carcinomas.
Methods In this study, we profiled 20 biopsy tissues from early stage
breast carcinomas using the Applied Biosystems Human Genome
Survey Microarrays, which is a relatively new array platform containing
31,700 60-mer oligonucleotide probes representing a set of 27,868
individual human genes, with single-color chemiluminescence
detection. To identify the subtypes in these tumors, we first carried out
a centroid correlation analysis coupled with an unsupervised
hierarchical clustering analysis. We utilized the ‘intrinsic’ gene list
consisting of 534 genes that have been used to define the five
subtypes of breast tumors and their core expression centroids in 122
previously published breast tumors samples [3]. Using the mapped
526 intrinsic genes, we computed the Pearson’s correlation coefficient
of each sample from this study to each of the five centroids and
assigned each sample to the subtype to which it showed the highest
correlation. As a second approach, we applied a supervised analysis
using the ‘Nearest Shrunken Centroid classifier’ and the PAM software
[4]. We took the previously published 122 Norway/Stanford tumor
samples and the mapped 526 intrinsic genes as the training set to
identify the predictor genes for the five subtypes. We then used this
classifier to predict the subtypes of each of the 20 early stage
carcinomas analyzed in this study. The same analyses were applied on
parallel datasets generated from Stanford cDNA Arrays and Agilent
Human Whole Genome Arrays. Welch–ANOVA analysis coupled with
Benjamini and Hochberg False Discovery Rate multiple testing
corrections were performed to identify the ‘signature’ genes that are
most differentially expressed between the subtypes. PANTHER™
protein classification analysis (Applied Biosystems, Foster City, CA,
USA) [5,6] and PathArt™ (Jubilant Biosys Ltd) pathway analysis were
carried out to identify molecular mechanisms underlying these
‘signature genes’. A minimal set of genes that best discriminated the
two identified subtypes were determined using PAM analysis on the
combined datasets generated on the three different array platforms.
Results Both unsupervised and supervised analysis identified the two
main clinically relevant subtypes of breast cancer, Luminal A
(correlated with a relatively good outcome) and Basal-like (correlated
with the poorest outcome). The identification of the Luminal A and
Basal subtypes in these early stage breast carcinomas was further
validated by parallel data generated from Stanford cDNA Arrays and
Agilent Human Whole Genome Arrays. Statistical analysis identified
1210 genes as signature genes characterizing the two subtypes of
breast cancer. Protein function and biological pathway analysis on
these signature genes revealed different molecular mechanisms
descriptive of the two expression-based subtypes: signature genes of
the Luminal A subtype were over-represented by genes involved in fatty
acid metabolism and steroid hormone-mediated signaling pathways, in
particular estrogen receptor-signaling, while signature genes of the
Basal-like subtype were over-represented by genes involved in cell
proliferation and differentiation, the p21-mediated pathway, and the
G1–S checkpoint of cell cycle signaling pathways. Finally, we identified
a minimal set of 59 predictor genes to best discriminate and
characterize the Luminal A and Basal subtypes using PAM analysis on
the combined data from the three array platforms. These predictor
genes were further verified by TaqMan® expression assays.
Conclusions We have identified and validated the two previously
defined clinically relevant subtypes, Luminal A and Basal, in early stage
breast carcinomas. This finding further substantiates the prognostic
value of such expression-defined phenotypes in breast cancer at an
earlier stage. Signature genes characterizing these two subtypes also
revealed that distinct molecular mechanisms have been
preprogrammed at an early stage in the different subtypes of the
disease. Our results provide further evidence that these breast tumor
subtypes represent biologically distinct disease entities and may
require different therapeutic strategies. Finally, validated by multiple
gene expression platforms, the set of 59 predictor genes identified in
this study define potential prognostic molecular markers for breast
cancer.
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Background The axillary lymph node status is the most powerful
prognostic factor for breast cancer patients to date. The molecular
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mechanisms that control lymph node metastasis, however, remain
poorly understood. The aim of our study was to define patterns of
genes or gene regulatory pathways that drive breast cancer lymph
node metastasis.
Methods We compared the gene expression profiles of 15 primary
breast carcinomas and their matching lymph node metastases using
microarrays. Furthermore, we analyzed the expression profiles of two
primary breast tumors and a metastasis obtained from the same
patient.
Results The gene expression profile of a primary breast carcinoma is
more similar to its affiliated metastasis than the second primary tumor
of the same patient. In general, primary breast carcinomas and lymph
node metastases do not differ at the transcriptional level by a common
subset of genes. However, subtle differences in the expression of
genes involved in extracellular matrix organization and growth factor
signaling are detected in individual pairs of matching primary and
metastatic tumors. Surprisingly, however, different sets of these genes
are either upregulated or downregulated in lymph node metastases.
Conclusions The overall gene expression profiles of primary breast
carcinomas are maintained in their lymph node metastases. This
similarity in gene expression can be attributed to tumor-intrinsic factors
rather than to patient-specific factors. No common denominator for
breast cancer lymph node metastasis could be identified, suggesting
that breast carcinomas do not use a shared gene set to accomplish
lymph node metastasis.
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We are analyzing human breast tumors and metastases with Affymetrix
U133 Plus 2.0 GeneChips, following isolation of uniform tumor cell
populations by laser-capture microdissection and linear amplification of
RNA. Genome-wide expression profiles of currently 68 breast
carcinomas, eight lymph node metastases, and eight normal breast
samples were determined, and were correlated with detailed clinical
outcome data to identify new and improved diagnostic marker genes of
breast cancer. These marker genes were validated by real-time PCR as
well as by IHC and/or FISH on tissue arrays. We identified a set of
genes by which these patients could be classified into those with a
short overall survival and those with a good prognosis with high
accuracy (P < 0.0006). The prognostic markers thus identified
included the estrogen receptor (ESR1), a known key prognostic marker
gene of breast cancer. Defined sets of <60 genes each were identified
that discriminated significantly (P < 0.01) between control patients and
patients who develop lymph node, bone, or lung metastases, or other
distant metastases. In contrast, >1000 genes were differentially
expressed in primary tumors progressing to liver metastases, thus
identifying a novel breast cancer subclass comprising ~15% of our
cases. Downregulation of p14A and p14B, two homologous proteins
of unknown function, was found to be associated with lung metastases.
Tumors expressing high levels of p14A and p14B do not metastasize
to the lung, tend to have a low tumor grade, are predominantly
hormone receptor-positive, and are associated with a longer overall
survival. This metastasis suppressor activity of p14A and p14B
appears to be lung-specific, as no effect on liver metastasis and only a
slight delay on bone metastasis formation were observed in tumors
expressing high levels of p14A or p14B. We also identified ~75 genes
coregulated with HER2, an RTK oncogene highly relevant to breast
cancer therapy. Sixteen out of the 20 genes most closely co-expressed
(P < 10–5) are located in the same chromosomal region as HER2,
suggesting that this entire region is co-amplified in ~20–30% of breast
carcinomas. Furthermore, a potential key role in breast cancer
progression of the PI3K/mTOR and the WNT signaling pathways was
strongly suggested by our expression profiles. We found that
stimulation of protein synthesis and cell growth via PI3K, mTOR, and
eIF4E is the primary function of IGF signaling, and that activation of the
WNT pathway in breast tumors significantly correlated with metastases
and poor prognosis.
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Background Some clinical features of hereditary breast cancer, which
develops in the presence of germline mutations in BRCA genes, are
different from those of sporadic cases. Within recent years, better
understanding of cancer biology and successful classification of
tumors into distinct, clinically relevant subgroups were made possible
by the methods of global gene expression analysis. Thus, we decided
to compare gene expression profiles of hereditary versus sporadic
breast cancer and possibly find the molecular basis underlying clinical
observations.
Methods Microarray analysis was performed with HG U133 Plus 2.0
(Affymetrix, Santa Clara, CA, USA) oligonucleotide microarrays,
allowing detection of 47,500 transcripts. We have so far performed
gene expression profiling in 25 tumor samples obtained from 24
patients: 14 patients with hereditary breast cancer (with and without
proven BRCA1 mutation) and 10 patients with sporadic breast
carcinoma. We also analyzed, as the reference, six normal breast
tissues collected from patients with breast cancer.
Results We compared the expression profile in hereditary breast
cancer and the normal breast tissue and found 2983 differentially
expressed genes (Welch t test, Benjamini–Hochberg False Discovery
Rate below 0.01). By identical criteria we found 648 genes that are
significantly changed between sporadic breast cancer and normal
tissue. The merged list contained 3138 genes showing changed
expression between cancer and normal breast tissue, with 493 genes
that were common in both comparisons. We further verified which of
the 3138 genes exhibit differences between hereditary and sporadic
tumors. We found that 42 probe sets show statistically significant
differences between these groups (non-parametric Mann–Whitney
test, False Discovery Rate < 0.05). However, only one of these genes
(PARK7) remained significantly changed (both by parametric and non-
parametric approach) between hereditary and sporadic cases, when
taking into account all probe sets present on the array. This gene has
been shown to be associated with poor prognosis in ER-negative
breast cancer by Nagahata and colleagues [1]. Next, we analyzed
hereditary and sporadic cancer tissues in subgroups of ER-positive
and ER-negative tumors. Interestingly, in the ER-negative group, top
genes differentiating between hereditary and sporadic cancers were
still functionally related to the estrogen metabolism and signaling.
Finally, we verified the signature of hereditary breast cancer published
by Hedenfalk and colleagues [2,3] – two lists of genes, characteristic
for BRCA1/BRCA2-linked breast cancer and for BRCAx-linked
hereditary breast cancer, that in total correspond to 204 probe sets on
the U133 2.0 Plus array (ESTs not included). In our dataset the most
significant of these genes (TOB1, transducer of ERBB2) exhibited a
False Discovery Rate equal to 0.13, thus not passing the criteria of
statistical significance.
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Conclusions We have specified a signature of 42 genes that
differentiate between normal breast tissue and breast cancer and
simultaneously allow classification of hereditary and sporadic tumors.
However, the range of difference between these classes is rather mild
and is strongly influenced by the ER status. Taking this into account,
together with the fact that in our study group the signature proposed
by Hedenfalk and colleagues does not allow for differentiation between
sporadic and hereditary cancers, it is clear that further studies on the
larger group of cases are necessary.
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Background Until now, microarray studies exploited the differences
between cancer and corresponding normal tissues or the molecular
differences between tumor histotypes originating from one tissue.
However, a sound understanding of neoplastic transformation and
progression will benefit from comparison of tumors originating from
diverse tissues, especially if they share some biological or clinical
properties. Such analysis may aid to seek novel therapeutic targets,
which are tumor-specific rather than tissue-specific.
The aim of our study was to compare the expression profile in breast
cancer (BC) and ovarian cancer (OC), two female adenocarcinomas
with similar genetic background and comparable chemosensitivity and
radiosensitivity.
Methods We compared expression profiles of 21 breast carcinomas
and 17 serous ovarian carcinomas. We used the GeneChip U133 2.0
Plus microarray and a standard amplification procedure. We applied
two methods of data preprocessing, RMA and MAS5 algorithm, and
compared the results (only RMA data are shown).
Results Both preprocessing approaches resulted in a huge difference
between BC and OC (4427 genes, False Discovery Rate lower than
0.1%). To base the comparison on well-described transcripts, we used
the signature of neoplastic transformation proposed by Rhodes and
colleagues [1] in a large meta-analysis of 40 cancer datasets. From
168 probe sets found on the U133 2.0 array that were corresponding
to Rhodes genes, 30 were differentially expressed between BC and
OC (the strongest differences were within KDELR2, PLK1, PPP2R5C,
ACLY, G3BP, MMP9, TRA1, HSPD1) and the remaining 138 probe
sets did not show differences in expression. The results confirm the
Rhodes signature in BC and OC; however, these genes were not able
to ensure the full subdivision of tumors into breast and ovarian
(hierarchical clustering). Furthermore, we analyzed the tissue-specific
expression of genes that were either uniformly or differentially
expressed in BC versus OC, by comparison with normal tissues (data
from GeneAtlas 2.0 [2]).
In the next step, we performed the unsupervised analysis of BC and
OC expression profiles. By Singular Value Decomposition we revealed
that the samples were divided into three large clusters, which
corresponded to two groups of breast carcinomas (BC1 and BC2) and
a separate group of ovarian cancers (OC). These groups were properly
separated by expression of estrogen receptor probe set ESR1, which
was low in BC1, showed variable and moderate expression in OC and
showed very high expression in BC2. The expression of ESR1 was
similar to the ER result in routine clinical test, with the exception of two
BC cases with high ESR1 and negative ER by immunohistochemistry.
Conclusions There is large similarity in expression of neoplastic
transformation signature genes between breast and ovarian
carcinomas. Thirty genes from this set are differentially expressed
between these cancers. The most prominent difference in the gene
expression profile of these tumors could be explained by ESR1 gene
expression and may be related to the tissue hormonal profile.
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Background A recently developed expression profiling technique,
termed comparative expressed sequence hybridisation (CESH), was
applied for the study of lymph-node negative breast cancer. CESH
allows global detection of chromosomal regions with differential gene
expression in a way similar to that of comparative genomic hybridisation
[1]. Using CESH, we compared gene expression patterns between
three different breast cancer subtypes: invasive lobular carcinoma
(ILC), poorly differentiated invasive ductal carcinoma ERBB2-positive
(ERBB2-positive IDC) and poorly differentiated invasive ductal
carcinoma ERBB2-negative (ERBB2-negative IDC).
Aims We intended to investigate whether different morphological
breast cancer subtypes are characterised by distinct gene expression
patterns. Furthermore, we aimed to identify chromosomal regions that
harbour genes with potential significance in the underlying biological
behaviour of these subtypes.
Methods Total RNA was extracted from 24 frozen tissue blocks
representing eight ILC cases, eight ERBB2-positive IDC cases and
eight ERBB2-negative IDC cases. Reverse-transcribed RNA (cDNA)
from four cases of the same subtype was pooled, resulting in the
formation of two cDNA pools per subtype. First, both cDNA pools of
the same subtype were paired with each other. Second, cDNA pools of
different subtypes were compared.
Results Comparing cDNA pools of the same subtype showed no
significant differences in gene expression profiling. Most strikingly,
CESH was able to discriminate ILC from poorly differentiated IDC by
three differentially expressed regions, including relative overexpression
at 8p21-p22 and relative underexpression at 8q13-q23 and at 16q22.
Collation of all CESH data led to the identification of an ERBB2
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signature, comprising relative overexpression at 3q24-q26.3, 17q12-
q21 and 20q12-q13.1 and relative underexpression at 8q24.3.
Interpretation and conclusion CESH has proved useful for the study
of lymph-node-negative breast cancer. It highlights regions of
differential gene expression that are selectively associated with breast
cancer subtypes and supports the hypothesis that ERBB2-positive IDC
is a distinct disease entity. Moreover, CESH was able to identify an
ERBB2 signature, comprising four chromosomal regions harbouring
genes with potential significance in the aggressive behaviour of
ERBB2-positive disease.
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Background The histological grade (HG) in breast cancer provides
important prognostic information. However, its interobserver variability
and poor reproducibility, especially for tumours of intermediate grade,
have limited its clinical potential. We hypothesized that molecular
characterization of the grade may allow for full exploitation of the
association between the grade and relapse beyond the ability of
traditional grading procedures.
Methods Six datasets totalling about 700 primary breast cancers,
mostly publicly available data, were used in the analysis. Gene
expression profiles (GEP) from Affymetrix U133A GeneChips were
contrasted between HG 1 (low grade) and HG 3 (high grade) tumours
on a training set of 64 estrogen-receptor-positive breast cancer
samples. A set of genes positively and negatively correlated with grade
was identified on this training set and chosen as grade reporting
genes. A scoring system called the ‘gene-expression grade index’
(GGI), which essentially summarizes the grade reporting genes by their
average expression level, was introduced. The GGI was applied to
patients not used in the gene selection to test its prognostic value.
Results Using 33 HG 1 and 31 HG 3 ER-positive breast carcinomas,
112 Affymetrix probe sets were significantly upregulated in grade 3
and 16 in grade 1, at a stringent and objective cut-off P value of 0.05
for a false discovery count >0. These 128 probe sets represent 97
different reporter genes. Quantifying the level of expression of these
reporter genes with the GGI, many tumors in the HG 2 (intermediate
grade) populations assume values typical for the HG 1 and HG 3
groups in the same study. The HG 2 tumors can therefore be naturally
split into a ‘HG 1 like’ group and a ‘HG 3 like’ group, to which we
attribute a gene expression grade (GG) of 1 and 3, respectively. Their
survival curves follow the GGI and are similar to those of the HG 1 and
HG 3 groups, respectively, splitting HG 2 into a good prognosis group
and a poor prognosis group (Fig. 1).
Similar observations were made in the different datasets analysed, in
untreated as well as in systemically treated patients, and on the three
different main types of microarray platforms, with substantial variability
in the number of reporter genes available. Almost all known
clinicopathological variables were significantly associated with clinical
outcome in univariate analysis, while in a multivariate model only the
GG, tumour size and nodal status were significant factors. Replacing
the HG with the GG significantly improved the prognostic two-group
classification obtained with the Nottingham Prognostic Index.
Conclusion Gene-expression-based grading has the potential to
significantly improve current grading systems by rendering them more
objectively measurable and improving their prognostic value. The
superior performance of the two-grade GG system challenges the
purpose of classifying tumors as of intermediate grade. Reproduction
of these findings in four independent datasets, and across different
platforms and with a simple computational system, gives hope that the
approach will prove robust and reliable.
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The human genome contains a large amount of cis-regulatory DNA
responsible for directing both spatial and temporal gene-expression
patterns. Previous studies have shown that, based on their mRNA
expression patterns, breast tumors could be divided into five
subgroups (Luminal A, Luminal B, Normal-like, ErbB2+-like, and Basal-
like), each with a distinct molecular portrait [1]. Whole genome gene-
expression analyses of independent sets of breast tumors have
revealed repeatedly the robustness of this classification [2]. These
patterns have clinical implications in terms of disease-free survival time
and are always determined by the same set of genes in all datasets [3].
A list of 552 genes, whose expression in terms of mRNA varied
considerably among the different tumors but little between two
samples of the same tumor, has been nominated to be sufficient to
separate these tumor subgroups. Why exactly these genes? What is
the mechanism of their abnormal regulation? Genes are regulated by
multiple transcription binding sites that interact with a specific
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combination of transcription factors. Here we report the promoter
composition of the genes that strongly predict the patient subgroups.
Using a random expectation value (re-value) to generate a background
model, we analyzed a total of 277 cis-elements (Genomatix software).
The gene classes showed a clear separation when based solely on
their promoter composition. This finding suggests that studying those
transcription factors associated with the observed expression pattern
in breast cancers could identify novel and important biological
pathways, including the NF-κB and Ets transcription factor families.
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Background Tumors of the mammary gland belong to the most
common tumors in the female dog. Ovarian hormones and signaling
cascades involving them play an important role in mammary tumor
formation and progression in the female dog, as early ovariectomy may
reduce the incidence of mammary carcinoma from 30% to less than
2%. The phenotypic expression of canine mammary tumors may vary,
even within one affected animal. In the past, growth factor-independent
canine mammary cell lines have been isolated [1]. Molecular
characterization of these cell lines and correlation of their molecular
signatures to biological behavior may lead to better understanding of
signaling pathways involved in mammary cancer and classification of
spontaneous mammary tumors.
Methods Three canine mammary tumor cell lines (CMT) originating
from primary mammary spindle cell tumor (CMTU309), primary
mammary osteosarcoma (CMTU335) and primary mammary anaplastic
carcinoma (P114) were compared directly with each other in this
study. Cell lines were tested for in vitro invasion using a Transwell
assay. Total RNA was isolated from cells grown to near confluence. In
vitro transcription followed by labeling and hybridization to a cDNA
microarray was carried out according to published protocols [2]. In a
loop design of hybridization, labeled cRNA from cell lines were
hybridized against each other on a dog-specific cDNA microarray
containing 20,160 independent genes, which was developed and
spotted in our laboratory. Statistical analysis of microarray data was
carried out using significance analysis of microarrays [3]. Further
analysis of microarray data was done using GeneSpring.
Results The Transwell invasion assay revealed a clear difference in in
vitro invasiveness between canine mammary tumor cell lines. P114
showed a highly invasive phenotype whereas CMTU309 was the least
invasive cell line. The cell lines under investigation showed a significant
difference in doubling time but no difference in growth factor
dependence. Microarray data analysis yielded a total of 451
differentially expressed genes. Among them, about 111 genes were
differentially expressed in P114 compared with CMTU335, 110 genes
were differentially expressed in P114 against CMTU309 and 230
genes were significantly regulated in CMTU309 against CMTU335.
GeneSpring analysis of the microarray data revealed genes unique to
each cell line, which were differentially expressed (twofold) in one cell
line against the other two cell lines. Unique gene lists containing 19
genes for CMTU309, 62 genes for CMTU335 and 33 genes for P114
were obtained.
Conclusion Our study yielded a novel set of genes unique for each
canine mammary cell line in this study. Next, the contributions of these
genes, among which some 50% are not annotated towards phenotypic
differences between these cell lines, are under investigation.
Acknowledgement This project is funded by the Morris Animal
Foundation, Englewood, Colorado, USA.
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Background We have recently shown that BRCA1 breast tumors can
be identified on the basis of their somatic genetic aberrations detected
by comparative genomic hybridization (CGH) profiles with high
performance (sensitivity: 96%) [1]. Also, BRCA2 show some specific
alterations, but are more similar to sporadic breast tumors [2]. These
results illustrate that breast tumors from different genetic backgrounds
(BRCA1 and BRCA2) develop different genomic instabilities, and
therefore genomic profiles. We hypothesize that this may also be true for
BRCAx (BRCA3, BRCA 4, etc.) tumors. We therefore applied CGH to
familial breast cancer cases from families without BRCA1/2 mutations.
Aims To produce high-resolution profiles for various types of familial
breast cancer, including BRCA1, BRCA2 and BRCAx. To build
classifiers based on aCGH profiles. We further aim to optimize class
discovery by parallel data analysis of continuous and discrete data as
obtained by ‘amplicon-finding’ algorithms [3]. We also compare
BRCA1/2 murine breast tumors with human tumors in an attempt to
extract maximal biological meaning from the ploody changes observed
in both species [4].
Methods Array-CGH was performed on genomic DNA isolated
exclusively from formalin-fixed paraffin-embedded archival breast
cancer specimens. Prior to hybridization, multiplex PCR was performed
to assess DNA quality. Then, genomic DNA samples were hybridized
to a 3500 BAC array [4] representing one clone for each 1 Mb across
the human genome.
Results We produced array-CGH profiles for 24 BRCA1 tumors, 16
BRCA2 tumors, 19 control (unselected) tumors and 50 tumors from
high-risk families (BRCAx, no BRCA1/2 mutations identified) and
show, first, that they reproduce metaphase-CGH profiles. Pronounced
alterations included 1p-loss (including the DNA damage response
protein FRAP1) in 40% of tumors of all classes. An extensive region on
1q (including MUC1) shows gain in many tumors but most frequently
so (up to 70%) in BRCA1 tumors. In a region on 3p (including the
tumor suppressor RASSF1), loss was observed in >40% of BRCA1
tumors. 3q (including Evi1) was amplified in all tumors classes but
most frequently in BRCA1/2 (70%) compared with controls (20–25%).
4p loss is significantly more frequent in BRCA1 (45%) than in either
BRCA2 or controls (10–20%) and contains a BRCA1 interacting
gene, CtBP1. The centromeric region of chromosome 5 shows loss in
10% of BRCA2, 25% of CONTR and 45–50% of BRCA1 tumors
studied. Preliminary analysis of the array-CGH results for the familial
breast tumor series, designated BRCAx, show that this is not a
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homogeneous group. Generally, BRCAx profiles present with fewer
gains and losses compared with BRCA1, BRCA2 and sporadic breast
tumors. This is a finding that needs further quantification and
confirmation.
Conclusions Array-CGH can be successfully applied on archival
formalin-fixed tumor samples. Array-CGH profiles prove useful in the
classification of hereditary (BRCA1) breast tumors. Further data
analysis should reveal whether BRCAx can be classified is this manner.
We propose the use of array-CGH profiles in clinical genetic
counseling and are currently working towards this goal.
Acknowledgement EvB and SJ are funded by the Dutch Cancer
Society, NKB.
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Since its invention by Kallioniemi and colleagues in 1992 [1],
comparative genomic hybridization (CGH) has revolutionized the
detection and mapping of chromosomal imbalances in neoplasias.
However, conventional CGH is handicapped by its low resolution.
Array-based CGH brings the resolution towards a molecular level. With
a capillary printer we produce arrays on CodeLink slides with 3158
BAC clones, which randomly represent the whole genome. With our
homemade arrays, we can detect and map numerical aberrations in a
single experiment with about 1 Mb resolution. Furthermore, we have
optimized printing, labeling, hybridization, scanning and analysis tools.
Reverse-labeling (exchanging the tumor and reference DNA labeling
dyes) gives us reliable results even in samples with a substantial
admixture of normal cells.
In the Danish Centre for Translational Breast Cancer Research, a 5-
year project involving 500 high-risk patients is underway. Both
prospective and retrospective studies are planned with a systems
biological approach involving a multitude of analyses, including array-
CGH. Twenty breast cancer samples have been analyzed in a
preliminary study. Chromosome 1q (15/20), chromosome 8 (14/20),
chromosome 11 (5/20), chromosome 17q (9/20) and chromosome
20q (6/20) gains (duplications and amplifications), and chromosome
22 (7/20) deletions are the most frequent aberrations, which is
consistent with the previously published conventional CGH results [2].
Our findings will continuously be integrated with all the other results
from the same tumors.
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Predicting the metastatic potential of primary malignant tissues has
direct bearing on the choice of therapy. Several microarray studies
yielded gene sets whose expression profiles successfully predicted
survival. Nevertheless, the overlap between these gene sets is almost
zero. One of the main open questions in this context is whether the
disparity can be attributed only to trivial reasons such as different
technologies, different patients and different types of analysis. To
answer this question we concentrated on one single breast cancer
dataset, and analyzed it by one single method, that used by van ‘t Veer
and colleagues [1], to produce an outcome predictive signature set of
70 genes. We show that in fact the resulting set of genes is not
unique; it is strongly influenced by the subset of patients used for gene
selection. Many equally predictive lists could have been produced from
the same analysis. Three main properties of the data explain this
sensitivity: many genes are correlated with survival; the differences
between these correlations are small; and the correlations fluctuate
strongly when measured over different subsets of patients. A possible
correlation of this finding and the complexity of gene expression in
cancer is discussed.
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Background Copy number alterations (CNAs) are believed to
constitute key genetic alterations in the cellular transformation of many
tumors [1]. Microarray-based comparative genomic hybridization (array-
CGH) allows the construction of high-resolution genome-wide maps of
copy number alterations, and statistical software packages are
available for exploring and analysing array-CGH data (see, for example,
[2,3]), facilitating the delineation of the boundaries of CNAs in
individual tumors and thereby localizing and identifying potential
oncogenes and tumor suppressor genes. Although CNAs vary widely
with respect to size and location, some genomic regions are known to
have much higher prevalence of alteration than others. Mapping the
location of these CNA hotspots facilitates location of genes of potential
importance to tumor development as well as identification of alterations
forming key steps in tumor development. There is, however, a need for
consistent ways of combining array-CGH results for different arrays.
Here, we present a statistical modelling-based approach for this.
Methods Suppose we have available for each gene (clone) on an array
a binary (0/1) variable indicating whether the gene is amplified or not.
Such data may be constructed from array-CGH data using one of the
aforementioned software packages. Each tumor may then be
represented by an m-dimensional binary vector, where m is the number
of genes on the array. For an experiment involving n tumors we thus
have a set of m-dimensional vectors z1, …, zn and we consider the
latter to be realizations from a multivariate distribution P(z). We
consider three models for P(z) of increasing sophistication. The first
assumes complete independence between genes, the second
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assumes a Markov-chain dependence structure and the third assumes
a Markov Random Field dependence structure [4]. We demonstrate how
P(z) can be estimated in each case and show that, by suitable
constrained maximization of P(z), we may determine genomic intervals
corresponding to probable occurring intervals of copy number alteration.
Results The method is demonstrated (for all three models) on
simulated binary copy number status data for varying number of genes
and tumors. We also demonstrate the use on real array-CGH data that
have been processed by CGH-Explorer [2] in order to obtain a binary
copy number status vectors for each tumor.
Conclusion We have proposed a novel statistical method for the
derivation of probable intervals of CNA, based on copy number status
data from a sample of tumors. The method is based on a probabilistic
model for the copy number status in a tumor, and we have discussed
three models of increasing sophistication. The most basic of the three
models corresponds to simply reporting all genes that are amplified in
at least k% of the tumors. The other two models take into consideration
the important fact that neighboring genes are not, in general, altered
independently of each other. Utilizing this property of copy number data
allows derivation of probable intervals of CNA that are less prone to
noise degradation than alternative methods. In addition, results are
derived in the context of a well-defined probabilistic framework and are
therefore more easily interpretable.
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Array-based comparative genomic hybridization (aCGH) measures
copy number variations at multiple loci simultaneously, providing an
important tool for studying genomic alterations associated with cancer,
developmental disorders, and germline copy number polymorphisms.
The broadest utility of aCGH is obtained by enabling flexible and high-
resolution probing of regions of interest while preserving the greatest
possible complexity of targets derived from whole genome samples.
We therefore developed probe design criteria, assay conditions, and
analysis methods that enable 60-mer oligonucleotide arrays to be used
for CGH measurements using total genomic DNA [1]. We designed a
60-mer oligonucleotide array with 40K probes specifically designed for
CGH representing sequences throughout the human genome with a
bias for known and predicted gene loci. We tested the performance of
this array for reproducibly measuring and mapping losses, and
amplification events of varying levels and sizes using both unamplified
and phi29 (Qiagen, Valenica, CA, USA) amplified total genomic DNA
from a series of model systems. The mean slope of experimental versus
theoretical log-ratios for chromosome X probes on this genome-wide
human CGH array in XY versus XX hybridizations typically exceeds 0.9,
with probe by probe error rates of less than 10% in the separation of
their log-ratio distributions. Additionally, we used this platform to
examine well-characterized cell lines, including diploid cells with partial
deletions in chromosome 18q, and diploid and aneuploid tumor cell
lines with known amplification and deletion events. We show that the
highly processive DNA polymerase phi29 can be used to prepare
aCGH templates from as little as 10 ng starting material that yield high-
quality aCGH measurements throughout the genome. While phi29
provides a simplified isothermal method for amplifying limiting material,
non-specific DNA fragments of high MW are generated in the absence
of sufficient input template. Although these products do not hybridize
to the array, the presence of these amplification products obscures the
accurate quantification of DNA template specific to the input genomic
DNA prior to the labeling reaction. To ensure reproducible and robust
aCGH assay quality, we developed methods and protocols using the
Agilent BioAnalyzer (Agilent Technologies, Palo Alto, CA, USA) to
enable accurate quality control for key prehybridization steps,
including: phi29 amplification of genomic samples, restriction digestion
of templates and target labeling. We have also developed visualization
tools and statistically robust computational tools that take into account
the estimated errors on the measured log ratios in mapping aberration
boundaries, and for identifying common aberrations across multiple
samples. We tested the reproducibility of our platform using tumor cell
line samples including the colon adenocarcinoma cell line HT29 in
hybridizations performed in different laboratories (Agilent Labs,
National Human Genome Research Institute, Translational Genomics
Institute). We present results, using these methods, demonstrating that
in situ synthesized 60-mer oligonucleotide arrays can reproducibly
detect genomic lesions including single copy and homozygous
deletions, and variable amplicons throughout the genome using full
complexity genomic DNA samples.
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Discovering DNA copy number alterations is a major goal in studying
susceptibility and the cause of diseases such as cancer. Agilent
Technologies’ whole genome comparative genomic hybridization array
(aCGH) together with highly optimized reagents and protocols are
used to generate genome-wide profiles of cancers to help in the
identification of causative, diagnostic and prognostic changes. The
comparison of the aCGH profile from the breast cancer tumor primary
cell line with the aCGH profile of EBV-transformed peripheral blood
from the same breast cancer patient showed several regions of DNA
loss and gain. These regions were confirmed to correlate with the
disease on a panel of flash-frozen breast cancer tumor samples. Using
Agilent Technologies’ CGHAnalytics software, candidate genes and
ESTs have been identified for these regions of interest. Further studies
on large breast cancer patient cohorts are required to see whether
these candidate genes and ESTs are causative and would have
profound prognostic implications.
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Comparative genomic hybridization (CGH) is an effective tool for the
detection of genomic copy number aberrations. Many conditions such
as cancer and developmental disorders occur when modifications,
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such as amplifications or deletions, to the genome lead to changes in
gene copy number. The use of oligonucleotide-array CGH (aCGH)
provides a much more sensitive assay for the detection of genomic
variance than traditional CGH methods.
The Agilent 2100 bioanalyzer and associated RNA assays are now
established industry standards for checking the integrity of RNA
samples. Furthermore, the on-chip electrophoresis capabilities for DNA
analysis play an important role in the quality-control assessment of
DNA used in the context of aCGH. One important function of the
bioanalyzer is to provide an assessment of the intactness of the input
(genomic) DNA. For instance, current DNA amplification methods with
φ29 require an intact template but genomic DNA extracted from
formalin-fixed paraffin embedded tissues exhibit a wide range of
fragmentation patterns. It is extremely useful to know the quality of the
DNA before using it in expensive and time-consuming reactions such
as labeling and amplification. Here we look at the use of the bioanalyzer
in the context of aCGH quality control, monitoring critical steps in the
workflow including DNA amplification, digestion of template and
labeling.
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Background There is considerable interest in linking microarray-based
gene expression profiles to clinical endpoint variables such as survival.
Standard statistical methodologies typically fail when the number of
covariates (genes) far exceeds the number of samples (patients). For
example, the standard Cox proportional hazards model cannot be
directly applied to data of this form. Several methods have been
proposed for dealing with this problem in Cox regression, including
partial least squares regression (PLS) [1]. Nguyen and Rocke [2]
proposed first applying PLS in order to derive a small set of covariates,
and then performing proportional hazards regression on the reduced
set of covariates. In their approach, however, PLS is applied to survival
times without taking into consideration the fact that the latter may be
censored. A further problem with their approach is that the PLS step of
their procedure is based on the assumption of a Gaussian (normal)
likelihood.
Methods Here, we propose a novel method for combining Cox
proportional hazards regression and PLS. This method is a direct
generalization of PLS to arbitrary likelihoods, whereas the original PLS
method (including that used by Nguyen and Rocke) is designed for
Gaussian likelihoods only. Furthermore, in our method PLS is directly
integrated with the optimization of the Cox partial likelihood.
Specifically, we propose to utilize the equivalence between PLS and a
modification of the well-known numerical optimization method called
the conjugate gradients (CG) algorithm: applying the modified CG
algorithm to a Gaussian likelihood yields PLS. We propose instead to
apply the modified CG algorithm to the Cox partial likelihood, hence
directly generalizing the PLS algorithm to the Cox likelihood. Our
method will take into account the censoring of the outputs, as only the
original data will be used during the estimation. Our method also easily
generalizes to other likelihoods than the Cox proportional hazards
likelihood.
Results We present results from the use of these methods for a
dataset containing gene expression data and survival outcome from
patients with breast cancer published by Sørlie and colleagues [3].
Conclusion We have presented a method for generalizing PLS that
utilizes the equivalence between PLS and the well-known conjugate
gradients method. We have applied this method to a Cox partial
likelihood to predict survival outcome for patients based on gene
expression data. The generalized PLS method presented could easily
be applied to other likelihoods as well.
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Background Gene expression profiling of breast carcinomas has
increased our understanding of the heterogeneous biology of this
disease, and promises to impact clinical care. The aim of this study was
to evaluate the prognostic value of gene expression-based
classification as well as established prognostic markers, including
mutation status of the TP53 gene, in a group of breast cancer patients
with long-term (>10 years) follow-up.
Methods The clinical and histopathological parameters of 215 breast
cancer patients were studied for their effects on clinical outcome using
the Kaplan–Meier estimator, the log-rank test and univariate/
multivariate Cox regression. The prognostic impact of mutations in the
TP53 gene, identified using TTGE followed by sequencing, was also
evaluated. Eighty of the samples were analyzed for gene expression
using 42K spot cDNA microarrays.
Results Both univariate and multivariate analysis showed that the TP53
mutation status was the strongest predictor of breast cancer survival
for these 215 patients, superior to tumor size and nodal status.
Hierarchical clustering of gene expression identified four groups of
patients with statistically significant survival differences (P = 0.0008);
‘luminal A’ and ‘normal-like’ subgroups with good prognosis, a ‘basal-
like/ERBB2’ group having a very poor outcome within the first 2 years,
and a ‘luminal non-A’ group showing an even poorer prognosis at 10-
year follow-up. The basal-like/ERBB2 subgroup had a significantly
higher frequency of mutations in the TP53 gene than the other
subgroups (P < 0.001). Adding the gene expression-based
classification as a separate parameter in multivariate analysis showed
that this classification was an even stronger predictor of outcome than
any of the other markers, with TP53 mutations status being
approximately equally significant.
Conclusion Our results suggest that gene expression profiles provide
additional prognostic information supplementing currently established
clinical markers. The results also highlight the role of TP53 as a
determinant of the expression profile and as an important prognostic
marker of breast cancer.
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Background The HER2/ERBB2 receptor tyrosine kinase plays a critical
role in the pathogenesis of breast cancer. Amplification and/or
overexpression of HER2 occurs in 20–30% of Caucasian breast cancers
and correlates with poor prognosis. However, within the group of
patients overexpressing HER2, there are obvious differences regarding
the course of the disease. This study identifies different molecular
subtypes among 47 HER2-positive tumors based on genome-wide
expression profiling. A subset of these tumors was analyzed for TP53
mutations, a gene commonly mutated among breast carcinomas.
Materials and methods RNA isolated from 35 infiltrating ductal breast
carcinomas (IDC) with associated HER2 immunohistochemistry (IHC)
data were analyzed using 42,000 clone cDNA microarrays. Seventeen
of these samples that showed 2+ or 3+ protein expression were
evaluated by fluorescence in situ hybridization (FISH). Using microarray
data from this cohort, we determined an RNA expression threshold
associated with IHC/FISH positivity. Twenty-nine IDCs from Norway
with TP53 mutation data and whose RNA expression of HER2
exceeded this threshold were added to the subsequent analysis, giving
a total of 47 samples defined as HER2-positive. ANOVA correction was
used to address differences in methodology and the data were analyzed
with hierarchical clustering and disease-specific genomic analysis.
Results At least three molecular subtypes of HER2-positive breast
carcinomas were identified by hierarchical clustering of the 18 HER2-
positive samples based on the 42K array data. One subgroup contained
tumors that overexpressed estrogen receptor (ER)-associated genes,
another subgroup expressed cell-to-cell and cell-to-stroma signaling
genes as well as varying amounts of the ER-associated genes, whereas a
third subgroup showed no expression of the ER-associated gene cluster.
These subgroups were confirmed when analyzing the 47 samples.
TP53 mutation data were available for 32 of the 47 samples and 21 of
these had a somatic TP53 mutation. We found less mutations in the
ER group, with five mutations and seven wild type, than in the other two
groups (four wild type and 16 mutated). This difference was significant
(P = 0.034).
Discussion The TP53 mutations seem to be differentially distributed
among the molecular subtypes of HER2-positive tumors. Further
studies are required to shed light on the implications of this finding.
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The p53 gene is subject to frequent mutations in tumors, often leading
to accumulation of excess mutant p53 protein, which can exhibit
biological gain of function. In particular, mutant p53 exerts anti-
apoptotic effects. Likewise, NF-κB is a potent inhibitor of apoptosis,
whose extended activation can promote cancer. We discovered that
mutant p53 is in complex with the p65 NF-κB subunit in tumor cells
treated with TNF, a potent inducer of NF-κB. In addition, we
demonstrated that mutant p53 enhances the transcriptional activity of
NF-κB and its anti-apoptotic efficacy. Moreover, we were able to show
that mutant p53 and NF-κB are recruited together with the p300
acetyltransferase to anti-apoptotic target gene promoters. Interestingly,
mutant p53 ablation attenuates the activity of NF-κB and renders
cancer cells susceptible to killing by TNF. Finally, we observed a close
correlation between the high frequency of p53 mutations and the
elevated expression of NF-κB target genes in breast tumors. Therefore,
our findings support an important role of NF-κB in mediating the
oncogenic activities of mutant p53 in tumor cells.
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Background The tumor suppressor gene TP53 encodes a
transcription factor controlling numerous cellular growth and signaling
pathways, and thus it has been entitled the safeguard of genome
integrity. The TP53 activity is regulated through several mechanisms
including transcription and translation control, protein stability and
interaction, and subcellular localization. TP53 reacts to a variety of
cellular stress responses. The gene is frequently mutated in human
cancers, and cells with inactivated TP53 protein are able to resist cell
cycle arrest, DNA repair or apoptosis.
Methods We assessed TP53 mRNA expression in 88 tumor samples
from breast cancer patients with locally advanced disease using the
real-time quantitative RT-PCR technique. Real-time PCR was carried
out on the ABI Prism 7000 sequence detection system (TaqMan;
Applied Biosystems, Foster City, CA, USA). All relative quantity values
of TP53 mRNA were normalized to the average mRNA levels of two
independent endogenous control references.
Results and conclusions The TP53 mRNA intensities in human breast
tumors exhibit a specific mutational pattern. In tumors with missense or
in-frame mutations mRNA expression levels are significantly elevated
compared with wild-type TP53, and in tumors with non-sense, frame-
shift or splice mutations mRNA expression levels are significantly
reduced compared with the wild-type TP53 mRNA expression.
Consequently, distinctive groups based on the mRNA expression levels
and mutation type can be created as wild type, group I (missense and
in-frame mutations) or group II (nonsense, frame-shift and splice
mutations). These three groups show significant differences in relation
to patient progesterone receptor status, C-ERBB2/HER status, tumor
grade, distribution of the different breast cancer subtypes and survival
rates.
Interestingly, the TP53 wild type shows a wide range of mRNA
expression. The lowest or highest quartiles of wild-type TP53 mRNA
expression are significantly correlated to the patient estrogen receptor
status, tumor grade and distribution of the different breast cancer
subtypes.
Since TP53 interacts with various other tumor suppressor genes and
oncogenes, mRNA transcript levels of HDM2, CDC37, C-MYC, and
others have been determined, and their relation to the TP53 mRNA
expression pattern are under further investigation.
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Background The prognostic significance of TP53 mutations in breast
cancer has been investigated in several studies, but the independency
of TP53 towards other prognostic factors and the nature of the
mutations that may carry a worse prognosis are still unclear.
Methods Retrospective series of breast cancer cases from 10
hospitals in seven different European countries were combined to
assemble a large dataset of clinical and molecular data on 1794
European women with primary breast cancer who were followed-up for
10 years, and whose tumor had been screened for TP53 mutation by
gene sequencing. The association between TP53 gene mutation and
breast-specific cancer death was examined in univariate and
multivariate models including classical prognostic factors of survival.
Results TP53 gene mutations were more frequent in tumors of ductal
and medullar types, aggressive phenotype (high grade, large size,
node-positive cases and low hormone receptor contents) and in
women under 60 years old. An elevated risk of breast-specific cancer
death within 10 years of follow-up was found in patients with a TP53
mutation within exons 5–8 in their tumor compared with patients with
no such mutation (relative risk, 2.27; P < 0.0001). This association
remained valid after adjustment for tumor size, nodes status and
hormone receptor contents. An interaction between TP53 gene
mutation and PR content was found, patients with TP53 mutation and
negative PR status having a very bad prognosis independently of tumor
size, node status and ER status. More importantly, in patients with PR-
positive status, TP53 mutation was associated with a strong reduction
in survival over 10 years. Among specific types of TP53 mutations,
non-missense mutations and missense mutations in the DNA-binding
surface (L2/L3 and LSH motifs) had a worse prognosis than mutations
outside the DNA-binding surface. Among missense mutations, those at
codon 179 and the R248W mutant were associated with the highest
mortality rates.
Conclusion These results clearly show that TP53 gene mutation is an
independent factor of prognosis in breast cancer, and advocate its use
in clinical practice to improve cancer management.
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Background Recent data suggest that the Arg72Pro polymorphism of
the TP53 gene is correlated to TP53 mutations and prognosis in
breast cancer [1,2]. In addition, LOH with retention of the Arg allele
has been associated with reduced disease-free survival and overall
survival [3].
Patients and methods In the period January 1990–1994 a
consecutive cohort of 204 Danish women were diagnosed with primary
breast cancer. TP53 mutations were assessed by denaturing gradient
gel electrophoresis analysis and DNA sequencing. The Arg72Pro
polymorphism was measured in DNA extracted from blood
lymphocytes and LOH was measured in DNA extracted from invasive
breast carcinomas by a method including PCR, primer extension
reactions and denaturing high-performance liquid chromatography
analyses [4].
Results Mutations in the TP53 gene in tumour DNA were associated
with a significantly higher probability of distant metastases
(P < 0.0001). The Arg72Pro polymorphism was neither significantly
associated with TP53 mutations (P > 0.2) nor with probability of
distant metastases (P > 0.2). Among patients heterozygous at TP53
codon 72, LOH in tumour tissue was significantly associated with
TP53 mutations – with 10 out of 40 patients with LOH carrying a TP53
mutation but only one out of 28 patients with no LOH (P = 0.04).
However, patients with LOH at TP53 codon 72 did not have a
significantly higher probability of distant metastases as compared with
patients with no LOH (P > 0.2). But within the group of patients with
LOH, a significantly higher probability of distant metastases was found
for patients with retention of the Pro allele (11/24) as compared with
patients with retention of the Arg allele (2/16) (P = 0.04). Among
patients with retention of Pro, five patients out of 24 patients (21%)
had TP53 mutations as compared with five patients out of 16 patients
(31%) with retention of Arg.
Conclusion Our findings suggest that the Arg72Pro polymorphism is
neither associated with TP53 mutations nor with breast cancer
prognosis. However, LOH at codon 72 among heterozygous patients
might be associated with TP53 mutations, and patients with retention
of the Pro allele might experience a poorer prognosis as compared with
patients with retention of the Arg allele.
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Over the years we have screened for TP53 mutations in different
patient materials using temporal temperature gel electrophoresis
(TTGE) [1], followed by direct sequencing of samples with aberrant
migrating bands to determine the nature of the sequence alteration.
Mutations in the TP53 gene are associated with several different
cancer types and have been shown to have both prognostic and
predictive implications. In this project we are evaluating whether a
commercial available array platform for sequencing the TP53 gene
using a primer extension assay (APEX) is as sensitive, rapid and cost-
effective as TTGE/sequencing.
The array is designed by Asper Biotech [2]. Genomic DNA is amplified
by PCR, and dUTP is incorporated. The amplification products are then
concentrated and purified with spincolumns. Amplification products are
fragmented by Uracil N-glycosylase, and unincorporated dNTPs are
inactivated by shrimp alkaline phosphatase. The fragmented PCR
products are mixed with thermosequenase and four fluorescence-
labelled ddNTPs. The sample mixture is transferred to a chip that
contains sequence-specific oligonucleotides. So far, exons 2–9 are
included on the array. Genorama™ QuattroImager is used for scanning.
The Genorama imaging system and genotyping software are used for
imaging and semiautomatic sequence analysis.
DNA samples from 48 primary breast carcinomas, 11 ovarian
carcinomas and 34 cell lines were used for evaluation. Results from a
titration experiment with different ratios of the Arg/Arg and Pro/Pro
alleles on codon 72 in the TP53 gene showed that mutations could be
detected even if the mutated cells were present in less than 5%. We
have experienced that homozygous and hemizygous mutations
occasionally are missed by the TTGE technique, but that they all were
easily detected by APEX [3]. Detection of deletions and insertions,
however, is not yet optimal using the APEX technology and they are
frequently missed. For the tumour samples the resequencing efficiency
using APEX was 92% for both DNA strands and 99.5% for sense
and/or antisense strands.
The strength of using the APEX technology is that both strands are
simultaneously analyzed, and that no further sequencing is needed. It is
rapid and sensitive. Cost-effectiveness is still under evaluation.
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We set out to determine the feasibility of using microarray-based
resequencing for cancer gene mutation screening by designing
GeneChip CustomSeq Resequencing arrays (Affymetrix, Santa Clara,
CA, USA) for interrogation of ARAF, BRAF, CDK4, CDK6, CDKN2A,
KLF6, HRAS, KRAS, MET, NRAS, PTEN, RAF1, RB1, RET and TP53
(164 exons in total). Arrays also included four intronic bases on either
side of the exons to cover splice sites, thus the arrays covered a total of
23,966 bases. Overall performance was very good, with accuracy
>99.99% and coverage ~97.5%. Twenty NSCLC samples were
analyzed using the arrays, and several well-characterized somatic
mutations and germline variants were found. The most significant novel
finding was the detection of a transforming MET mutation (T1010I) in a
NSCLC patient.
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Background Approximately 30% of patients with localized breast
cancer eventually develop distant metastases despite optimal surgery
and adjuvant therapies. This fact has been attributed to early tumor
seeding via the bloodstream. Therefore, identification of breast cancer
cells in blood could enable early detection of micrometastases and
could potentially be of prognostic significance. The aim of our study
was to evaluate the correlation between circulating breast cancer cells
and classical prognostic factors.
Methods From February 1999 until April 2004 blood samples from 81
patients, aged 36–72, stages I and II, with or without metastases to
regional lymph nodes, were collected every 3–6 months. All patients
underwent therapeutic surgery and subsequent adjuvant therapies.
Blood samples were screened for mRNA encoding hMAM, EGFR,
CK-19 and β-hCG by nested RT-PCR. The result of the test was
treated as positive when the expression of one or more mRNA markers
was observed in at least two samples taken from the same patient.
Clinical data, such as histological grade, pT-grade and pN-grade,
menopausal status, estrogen receptor and progesterone receptor
status, malignancy grade and others were available for analysis.
Results We found that breast cancer cells were present in peripheral
blood of patients even in very early stages of the disease. Any of the
two-marker tests used in our experiments, hMAM/β-hCG, hMAM/
EGFR or EGFR/β-hCG, allowed comparable detection of breast
cancer cells: in 68–74% of lymph node-positive (N1) and 49–59% of
lymph node-negative (N0) patients. Addition of a third marker did not
significantly increase detection sensitivity. While analyzing the
presence of cancer cells in blood samples collected before
mastectomy, we found cancer cells in the blood of only 13% of N0
patients, but in 46% of N1 patients. Thirteen of the 81 patients (16%)
experienced recurrence of the disease within a 4-year follow-up period.
We did not find any correlation between the presence of cancer cells
and recurrence or any other clinical prognostic factors except one:
patients with premenopausal status had cancer cells in the blood in
37% of cases, in comparison with those with postmenopausal status
who had cancer cells in 63% of cases.
Conclusion We have shown that a two-marker RT-PCR assay for
hMAM/β-hCG, hMAM/EGFR or EGFR/β-hCG may be used for
detection of occult breast cancer cells in peripheral blood. Except for
menopausal status, we did not find any correlation between the
presence of cancer cells in the blood and classical prognostic factors.
Our data may suggest a different mechanism of disease dissemination
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We investigated the prognostic significance of circulating breast
cancer cells in peripheral blood detected by quantitative RT–PCR of
marker genes in patients with advanced breast cancer. Blood samples
from 94 breast cancer patients with metastatic disease (M1) were
examined for circulating tumour cells by studying the mRNA expression
of CK19, p1B, PS2, EGP2, mammaglobin and SBEM by real-time
PCR. Using a score function, developed for predicting circulating
tumour cells by quadratic discriminant analysis (QDA), four expression
levels were combined into a single discriminant value. Tumour cells
were present in 24 out of 94 (31%) of the patients, as compared with
0 out of 104 controls. The patients with a positive QDA value did have
a progression-free survival at 1 year of 3% and overall survival at
2 years of 17%, against 22% and 36% for patients with a negative
QDA value (P = 0.015 and P = 0.0053, respectively).
Breast cancer patients with metastatic disease have a significantly
worse progression-free survival and overall survival when circulating
tumour cells can be detected in their peripheral blood [1]. This method
was used but was not sensitive enough to predict survival on the basis
of a positive score in peripheral stem cell preparations (PBSC) of
patients treated in a high-dose chemotherapy trial. The number of
tumour cells in these preparations is too low.
We therefore sought a method that would specifically select breast
tumour cells. We now show that a combination of magnetic beads cell
separations and one-step cDNA synthesis of mRNA increases the
sensitivity by at least 10-fold. Ten MCF7 cells mixed into 10 ml
peripheral blood of a healthy control can be easily identified.
To validate this new method we will analyze blood samples of 200
stage I or stage II breast cancer patients and 50 PBSC of breast
cancer patients (and 20 PBSC of patients with lymphoid malignancy as
controls). So far, 30 stage I or stage II patients have been evaluated
with the marker panel of six genes. A combination of four markers
employed in the discriminant score revealed a sensitivity of 10% in
detecting epithelial marker genes in peripheral blood.
The cell separation technique allows at least a 10-fold increase in
sensitivity to detect tumour cell specific mRNA in mixed cell
suspensions. Further analysis of the 50 PBSC patients and the
prospective 200-patient stage I and stage II diagnostic study will reveal
specificity and sensitivity. Interim results indicate an increase in
sensitivity of at least 10%.
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Background A significant number of early breast cancer (EBC)
patients considered as high risk using standard prognostic factors
develop metastasis despite standard adjuvant therapy. A better
prediction of clinical outcome is needed to optimize and individualize
therapeutic decisions.
Methods To identify a protein signature correlating with metastatic
relapse, we performed surface-enhanced laser desorption/ionization-
time of flight mass spectrometry profiling of early postoperative serum
from 81 high-risk EBC patients. Denatured serum samples were
fractionated and the resulting fractions were incubated with
ProteinChip arrays (Ciphergen Biosystems, Fremont, CA, USA).
Results Several protein peaks were differentially expressed according
to clinical outcome (long-term metastasis-free survival versus
metastatic relapse). By combining partial least squares and logistic
regression methods, we built a multiprotein model that correctly
predicted outcome in 83% of patients. Consistency and robustness of
the model were verified using leave-one-out cross-validation. Five-year
metastasis-free survival in ‘good prognosis’ and ‘poor prognosis’
patients as defined using the multiprotein index were strikingly different
(83% vs 22%, P < 0.0001, log-rank test). In a multivariate Cox
regression including conventional pathological factors and multiprotein
index, only the latter retained independent prognosis significance for
metastatic relapse. Major components of the multiprotein index were
identified and included haptoglobin, C3a complement fraction,
transferrin, apolipoprotein C1 and apolipoprotein A1.
Conclusions Postoperative serum protein pattern may have an
important prognostic value in high-risk EBC. In addition, it may reveal
new insights on the metastatic process while providing new targets for
future therapeutics.
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Background The present study aimed to investigate the clinical
relevance of minimal residual cancer in breast cancer patients before
and after high-dose adjuvant chemotherapy with or without progenitor
stem cell support.
Methods One hundred and eighteen high-risk stage II breast cancer
patients entering the Scandinavian Study Group multicentre trial [1]
were randomised to nine cycles of dose-escalated FEC (5-flurouracil,
epirubicin, cyclophosphamide) or three cycles of standard FEC followed
by high-dose chemotherapy. Bone marrow (BM) samples at diagnosis
and 6 months after completion of chemotherapy were assessed for the
presence of cytokeratin-positive (CK+) cells. CK+ cells in BM were
evaluated as a prognostic and predictive marker and were compared
with other defined prognostic factors of the primary tumour.
Results Monitoring BM changes at time of diagnosis and at 6 months
post-treatment is an independent predictive factor for breast cancer-
specific survival (P = 0.001, univariate analysis). Those who have
consistent CK-negative BM findings constitute a group of patients with
good prognosis.
Conclusion Monitoring of CK+ cells in BM before and after high-dose
chemotherapy with or without stem cell support can be used clinically
as a surrogate maker to predict outcome in breast cancer patients.
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Background All solid tumors, including breast cancer, contain areas of
low oxygen tension (hypoxia). Hypoxic cells are highly aggressive and
metastatic, although the underlying processes remain unclear. We
have found lysyl oxidase (LOX) expression to be increased by hypoxia
in a variety of human cancer cell types. Lysyl oxidase (LOX) plays an
essential role in the formation and maintenance of the extracellular
matrix, and has previously been linked to increased in vitro invasion of
breast cancer cells [1].
Methods Human breast and cervical cancer cells were deprived of
oxygen for 18 hours and the expression levels of LOX were examined
by RT-PCR (including quantitative), northern blotting and western
blotting. LOX activity was inhibited by antisense or siRNA treatment or
by addition of a chemical inhibitor, and the effect on in vitro invasion
was examined using Boyden chambers. The in vivo metastatic potential
of these cells was also examined in air and hypoxia via tail-vein injection
of mice subsequently housed for 4 weeks under 20% or 10% oxygen
and assessment of lung micro metastases. Previously published micro-
array datasets were examined for correlation between LOX expression
and metastasis in human breast cancer patients [2,3].
Results Incubation of human breast and cervical cancer cells in
oxygen-deprived conditions resulted in elevated levels of LOX due to a
hypoxia inducible factor 1-dependent increase in mRNA levels.
Oxygen-deprived cells demonstrated enhanced in vitro invasion that
could be blocked by transfection with LOX antisense oligonucleotides
or LOX-specific siRNA, or by treatment with an inhibitor of LOX activity.
Cells stably expressing LOX siRNA grew slightly faster in air but
demonstrated non-invasive and non-metastatic phenotypes in three-
dimensional culture, and formed dramatically fewer lung micro
metastases in vivo when injected into mouse tail veins, particularly
those housed in hypoxic conditions. Analysis of expression data from
breast cancer patients revealed a good correlation between LOX and
lymph node status (Pearson correlation value of 0.78).
Conclusion Our data reveal that hypoxia-induced LOX plays a key role
in invasion and metastasis in human breast (and cervical) cancer, and
that inhibition of LOX blocks these processes and may enhance
effectiveness of therapy. These novel findings suggest that LOX may
represent a novel marker of patient prognosis, particularly as an
indicator of lymph node status in breast cancer.
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Recent evidence has demonstrated the importance of bone marrow-
derived endothelial precursor cells (EPC) in the contribution to
postnatal physiological and pathological neovascularization, and in
tumor growth and angiogenesis. These cells are recruited
undifferentiated; in response to systemic or chemoattractive signals,
such as vascular endothelial growth factor (VEGF), they lodge in the
growing or lesioned tissue and differentiate into endothelial cells in
response to local stimuli and cell–cell interactions. The extent and the
significance of the EPC contribution for the growing of most tumors,
including breast carcinomas, are still not defined. We analysed the
peripheral blood mononuclear cells (PBMNC) of 48 breast cancer
patients and found that 16.7% of them have circulating EPC. These
cells were detected by RT-PCR expression of AC133 and kinase
domain receptor (KDR). Furthermore, using an ELISA assay, we also
found an association between circulating AC133+KDR+cells and
VEGF plasma levels in these patients. We also found AC133 and KDR
positivity in breast carcinoma tissues. To our knowledge, this is the first
report addressing the recruitment of EPC to breast tumors. Strategies
to impair the mobilization and incorporation of EPC into tumors may
interfere with the growth of these tumors.
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It is established that stroma surrounding breast carcinoma can be
altered in comparison with its normal counterpart, and histological
observations recognize lesions with loose stroma rich in hyaluronic acid
(HA) and recognize lesions with dense stroma rich in fibulin-1,
collagens, laminins, fibronectin and fibrillins. Previous studies have
shown that adhesion of tumor cells to different extracellular matrix
(ECM) components interferes with drug responses. Thus, to address
the functional and biological behavior of the breast cancer-related ECM
proteins in response to cytotoxic treatments, the breast carcinoma cell
line MDAMB361 was injected into athymic mice in the presence of a
matrix containing high levels of fibulin-1, laminin-1 and collagens. The
grown tumors displayed significantly (P = 0.01) reduced sensitivity to
DXR compared with the same cells injected without the matrix, strongly
indicating that the ECM milieu of tumor impacts the responsiveness of
tumor cells to drugs. The analysis of changes in the ECM components
in response to DXR treatment revealed that the human breast
carcinoma cell lines SKBR-3, MCF-7, MDAMB157 and MDAMB361
upmodulated fibulin-1 transcript [1] and protein levels, particularly in a
form exhibiting a molecular weight (about 50 kDa) lower than expected
(about 74 kDa), thus suggesting that tumor cells may actively
reorganize their matrix environment. In parallel with the increase of
fibulin-1 the same stress conditions determined decreased expression
of hyaluronan synthetases, the enzymes involved in the synthesis of HA.
These preliminary findings provide support for a role of ECM in
response to drugs and suggest that reorganization of the ECM
following chemotherapy is the basis of drug-induced resistance.
Available online http://breast-cancer-research.com/supplements/7/S2
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Background A different view of the tumour as a functional tissue
interconnected with the microenvironment has recently been described
[1]. Numerous reports in the past years indicate that the growth and
progression of breast cancer cells, as well as other tumour cells,
depend not only on their malignant potential, but also on stroma
components present in the surrounding microenvironment [2]. Recent
gene expression profiling studies on breast cancer showed that
molecular classification of tumours based on the gene expression
patterns can identify clinically different subtypes of cancer with
different prognosis or disease outcome [3,4]. However, since tumours
are functional tissues dynamically interconnected with the micro-
environment, this approach could give even more information if the
tumor phenotype profile is related to the tumor-surrounding stroma
characteristics.
Materials and methods Immunohistochemical staining was carried out
for several extracellular matrix (ECM) molecules such as fibronectin,
fibulin 1, and laminin in a cohort of 29 formalin-fixed, paraffin-embedded
primary breast tumours. Furthermore, evaluation of haematoxylin and
eosin sections was performed to classify the surrounding stroma in
categories of loose, dense or mixed, respectively.
Gene expression analysis was performed using 22K 60-mer Human 1A
Oligonucleotide (G4110A) provided by Agilent. A specific extracellular
matrix ECM gene list of 282 unique ECM-related genes was created by
a basic search in the Human 1A(V2) platform on the Agilent website
[5] and was used to interrogate the 29 breast cancer transcriptional
profiles. To validate and test the robustness of the obtained results, a
new dataset of 123 primary breast carcinomas was queried with the
ECM gene list.
Results We defined a set of 282 ECM-related genes whose
expression separated the tumours in three main groups. We compared
the ECM groups, defined by gene expression profile, with the IHC
staining results and with stroma categories. Significant correlation
between stroma categories and the ECM gene expression profile was
retrieved. In contrast, the IHC results were not significantly correlated
to the results from with the other methodologies we applied.
Samples were also classified based on breast cancer subtypes
published by Sørlie and colleagues [6] using a selected list of 534
genes, known to discriminate tumours in subclasses with clinical
implication. In our study, basal-like tumours showed a strong
steadiness in clustering in a specific group (ECM1), while the other
subtypes were clustering across the three ECM groups.
To validate our data and to correlate the ECM groups to clinical
outcome, we utilized the ECM gene list in a new dataset of 123
samples, where long-term follow-up information was available. The new
analysis allowed us to identify the same three clusters, indicating the
robustness of the ECM classification. Survival analyses showed
significantly different outcomes for the patients belonging to the three
ECM groups. The ECM1 group was associated with poor overall
survival and this was not only related to the high frequency of basal
tumors in this group, which are known to display a poor prognosis,
since luminal-like tumors were also classified in this group.
Conclusion Gene expression profiling of breast carcinomas allows the
identification of three subgroups of tumors according to ECM-
associated gene expression. This classification provides new
information on breast carcinoma biology and new parameters that may
impact both prognosis and prediction of response to therapy.
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Background The Brn-3b transcription factor is elevated in many breast
cancers compared with levels found in normal breast epithelial cells.
High levels of Brn-3b increase growth and proliferation of cancer cells,
both in vitro and in vivo, but also alter migration and confer resistance
to growth inhibitory stimulus [1]. Conversely, low levels of Brn-3b slow
the growth of these cells. As a transcription factor, Brn3b changes the
growth and behaviour of breast cancer cells by modifying the
expression of target genes, either directly or indirectly upon association
with the proliferation-associated estrogen receptor (ER) [2]. A number
of Brn-3b target genes have been identified that alter the growth and
behaviour of these cancer cells. For instance, Brn-3b transactivates the
promoter of the cyclin-dependent kinase, CDK4 [3], that is required for
cell cycle progression and hence proliferation. Brn-3b also represses
the promoter of the tumour suppressor gene, BRCA1, and inversely
correlates with BRCA1 protein in tumour biopsies. We have recently
demonstrated that the small heat shock protein, HSP27, is also
regulated by Brn-3b [4]. High expression of HSP27 in breast cancers
is associated with increased anchorage-independent growth,
increased invasiveness and resistance to chemotherapeutic drugs and
poor prognosis. Thus, in cancers expressing high levels of Brn-3b the
downstream target genes regulated by this transcription factor can
alter the growth and behaviour of these cells.
Methods Western blot analysis of tumour samples was used to
correlate Brn-3b and HSP27 proteins. Transient co-transfection and
reporter assays were used to look at the effects of Brn-3b and/or ER
on the HSP27 promoter. Short hairpin RNA interference was used to
target Brn-3b protein and to test its requirement for transactivation of
the HSP27 promoter. EMSA was used to demonstrate direct binding
of Brn-3b to a specific site in the HSP27 promoter. Chromatin
immunoprecipitation (ChIP) was performed to show that Brn-3b was
associated with the HSP27 promoter in intact cells.
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Results Brn-3b protein levels correlated strongly with HSP27 levels in
a significant number of breast cancer biopsies (R = 0.87) as well as in
the breast cancer cell line, MCF7. Overexpression of Brn-3b in MCF7
cells resulted in increased HSP27 protein levels while reducing Brn-3b
proteins using antisense correlated with decreased HSP27 compared
with controls. Co-transfection analysis using a HSP27 reporter
construct showed that Brn-3b could directly transactivate HSP27
promoter but cooperated with the ER for maximal expression.
Decreasing Brn-3b using targeted RNA interference prevented
activation of the HSP27 promoter by Brn-3b alone but also attenuated
the response by ER. The Brn-3b site in the HSP27 promoter is flanked
by two sequences that constitute half estrogen receptor elements.
Site-directed mutagenesis demonstrated that this DNA sequence was
required for maximal transactivation while the ChIP assay showed that
Brn-3b protein binds to the HSP27 promoter in vivo.
Conclusion The ability of Brn-3b to increase expression of proteins
such as HSP27 in cancer cells may help to understand the altered
growth and migration of tumour cells with elevated Brn-3b proteins.
Therefore factors such as Brn-3b, which increase the expression of
HSP27 in breast cancers, are likely to affect the progression of
diseases, prognosis and outcome of treatment.
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Genomic studies have identified at least five distinct subtypes of breast
tumors [1]. These subtypes are believed to develop from different
epithelial cell types and show different overall survival outcomes. Of
particular interest is the estrogen receptor (ER)-negative Basal-like
subtype, which accounts for 10–15% of all breast tumors and shows
poor outcomes. In the breast cancer clinic, there are currently two
biologically directed therapies that target either the ER or HER2
proteins. The Basal-like tumors lack both of these proteins [2], and
hence the only treatment options for these patients are cytotoxic
chemotherapies. A goal of ours was therefore to use primary breast
tumor gene expression data and cell line models to identify and validate
candidate biologically-based therapies for Basal-like tumors.
To identify potential targets, the gene expression data for approximately
1500 drug targets were examined across a breast tumor data set of
150 samples. Squalene epoxidase (SQLE) was expressed in most
Basal-like tumors, as well as in the Basal-like tumor-derived cell lines
SUM102 and SUM149. SQLE is an attractive target because it is
highly expressed, it is a rate-limiting step in the cholesterol biosynthetic
pathway, and there is an available inhibitor (NB598) [3]. Recent
studies using inhibitors of HMGCoA reductase (the first rate-limiting
step) in epithelial cell lines suggest that inhibition of this pathway may
be a potential target for therapeutic intervention [4].
Using the SUM102 and SUM149 cell lines and two more widely used
luminal/ER+ lines (MCF-7 and ZR-75-1), we treated cells with NB598
and separately with lovastatin (an HMGCoA reductase inhibitor) and
determined their sensitivity by identifying their 72-hour IC50 dose.
Sensitivity was similar across three of the four cell lines for NB598,
with the exception of SUM102, which was approximately 300 times
more sensitive. Conversely, sensitivity to lovastatin was similar across
three of the four cell lines except MCF-7, which was approximately five
times more resistant. Since many drugs are rarely used as single
agents, we also looked at the interactions between these two inhibitors
and commonly used chemotherapeutics. Drug-combination sensitivities
again varied across the four cell lines; however, it appears that
combinations of NB598 and 5-fluorouracil were typically synergistic,
while combinations with carboplatin or paclitaxel were typically
antagonistic. Similar analyses are being performed for lovastatin/
chemotherapy combinations. Gene expression responses of these cell
lines were also assayed using DNA microarrays. The effect on the
cholesterol pathway showed that, for MCF-7 and SUM102, adding
either inhibitor greatly induced most genes in the cholesterol
biosynthetic pathway, while SUM149 treated with lovastatin showed
induction of the pathway but treatment with NB598 did not. ZR-75-1
treated with either drug showed a slight reduction in expression of the
pathway. These in vitro data suggest that inhibition of SQLE activity
can reduce cell line proliferation rates and, in some instances, was
synergistic with chemotherapy. These data also suggest that inhibition
of the cholesterol pathway by addition of HMGCoA reductase
inhibitors is different from inhibition of the pathway with SQLE
inhibitors.
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Cancer is the second leading cause of death in the United States.
Traditional treatments for cancer, such as radiation and chemotherapy,
are frequently ineffective and are often associated with painful side
effects that diminish the quality of life for patients. New strategies for
the treatment of cancer are greatly needed. Oncolytic viruses represent




Genetically modified adenoviruses — specifically, adenovirus serotype
5 (Ad5) — are commonly used to generate oncolytic viruses. These
adenoviruses are replication-selective, meaning that they have been
engineered to replicate only in cancer cells bearing certain mutations.
For example, ONYX-015 is a mutant adenovirus designed to exploit the
loss of functional p53, a loss common to many cancer cells, in order to
selectively destroy malignant cells [1]. Although the use of oncolytic
viruses holds great promise for cancer therapy, the success of this
strategy depends on the ability of adenovirus to infect cancer cells. We
are using a panel of 50 breast cancer cell lines to study Ad5 infectivity.
Affymetrix array data and CGH data have been collected for all of these
cell lines. We have found that the ability of Ad5 to infect these cell lines
is highly variable. CAR and αv integrins are known to be required for
Ad5 entry. However, the infectivity of the breast cancer cell lines does
not correlate with CAR levels or αv integrin levels. For example, BT474
cells appear to have ample CAR expressed on the surface but are
infected at very low rates. Alternatively, both HCC 2185 cells and MDA
MB 435 cells express very little CAR on the surface but are highly
infectible. We are currently investigating the possibility that other
cellular factors are influencing the ability of Ad5 to infect breast cancer
cells.
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Background The treatment plan for a breast cancer patient is based
on tumor size and grade, lymph node involvement and steroid hormone
receptors. Lymph node status is the strongest prognostic factor for
breast cancer patients. About 25% of node-negative patients
experience recurrence or metastasis [1]. Additional methods might be
important for better treatment strategies. Malignant cells have an
altered metabolism, and metabolic mapping might become a tool in
cancer diagnostics. High-resolution magic angle spinning (HR-MAS)
magnetic resonance (MR) spectroscopy of tissue biopsies provides
detailed information on their metabolic composition [2]. The aim of this
study was to compare MR spectroscopic findings from breast cancer
tissue with histological grading of tumor and patient lymph node status.
Methods Breast cancer and non-involved adjacent tissue were excised
from patients with palpable breast cancer diagnosed as invasive ductal
carcinoma (IDC). Tissue specimens were analyzed in D2O-PBS in a
50 µl MAS rotor (4 mm o.d.). HR-MAS MR spectra were recorded on a
BRUKER AVANCE DRX600 spectrometer at 4°C. The samples were
spun at 5 kHz. Proton MR spin echo spectra were acquired with a total
echo time of 285 ms and presaturation of the water peak. A pathologist
scored the relative areas of normal and neoplastic elements visually
after MR analysis. Samples with less than 5% tumor content were
excluded. This resulted in a final database consisting of 115 samples:
48 non-involved tissue and 69 IDCs (grade I [n = 4], grade II [n = 33]
and grade III [n = 32]). Of the 69 tumor samples, 37 were from
patients with no spread and 32 samples were from patients with
lymphatic spread of cancer cells. The spectral region 2.9–4.8 ppm was
selected for principal component analysis (PCA). Two sample sets
were used as PCA input: all samples (n = 115) and tumor samples
(n = 69). Classification of IDC groups (grade I, grade II and grade III)
and lymphatic spread was performed by a probabilistic neural network
(PNN) strategy [3]. The 25 first principal component (PC) scores from
PCA of tumor samples were used as the input in PNN. Both PCA and
PNN were performed with full cross-validation.
Results The 2D score plot of PC2 and PC3 from the PCA of all
samples is shown in Fig. 1. All samples from non-involved tissue are
clearly separated from tumor samples. Tumor samples intersperse with
no possibility to differentiate among the three types of grading. The
PNN of spectra from tumor samples resulted in true classification of 56
of the 69 samples with respect to grading, whereas two samples were
not classified. The specificity and sensitivity of classification exceeded
80% for all groups.
A PCA score plot of PC2 and PC3 for tumor samples is shown in Fig.
2. A trend of clustering with respect to lymph node status can be seen.
Classification results of node-positive and node-negative samples
using PNN is presented in Table 1. Samples from patients with spread
of cancer cells to lymph nodes can be predicted with a specificity of
97% and a sensitivity of 92%.
Conclusion PCA led to a complete separation of the non-involved and
cancerous samples. The metabolism of cancerous tissue is clearly
different from non-involved tissue. Samples from lymph node-positive
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Figure 1
Principal component analysis score plot of all samples (n = 115).
Labeling of samples from patient diagnosis.
Figure 2
Principal component analysis score plot of tumor samples (n = 69).
Labeling of samples from patient lymph node status.
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and lymph node-negative patients could not be separated by PCA,
while PNN led to classification of the two groups with misclassification
of only four samples. Metabolic patterns in breast tumors from patients
with lymphatic spread differ from those without lymphatic spread.
These findings show that HR-MAS of breast cancer biopsies has the
potential of becoming a diagnostic tool.
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Altered growth factor responses in phospho-protein-driven signaling
networks are crucial to cancer cell survival and pathology. Profiles of
cancer cell signaling networks might therefore identify mechanisms by
which such cells interpret environmental cues for continued growth.
Using multiparameter flow cytometry, we monitored phospho-protein
responses to environmental cues in acute myeloid leukemia at the
single cell level. By exposing cancer cell signaling networks to
potentiating inputs, rather than relying upon the basal levels of protein
phosphorylation alone, we could discern unique cancer network
profiles that correlated with genetics and disease outcome. Strikingly,
individual cancers manifested multiple cell subsets with unique network
profiles, reflecting heterogeneity at the level of signaling response. The
results revealed a dramatic remodeling of signaling networks in cancer
cells. Thus, single cell measurements of phospho-protein responses
reveal shifts in signaling potential of a phospho-protein network,
allowing for categorizing of cell network phenotypes by
multidimensional molecular profiles of signaling.
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Many genes/proteins have been involved in cellular transformation.
However, a systems-level understanding of this pathological process is
still absent. To address this question we developed a strategy to
generate preliminary models of the networks around known cancer
gene products. By examining functional genomic information as gene
expression profiles, disease-associated genetic networks and systems-
level integrated networks, we defined a ‘breast cancer gene module’
with predicted novel functional relationships to known breast cancer
tumor suppressors. Genes within this module encoded for novel
functional relationships with BRCA1 and BRCA2. Among the novel
components identified we functionally characterized the hyaluronan-
mediated motility receptor (HMMR, human Rhamm), which defines a
BRCA1/BRCA2 protein network involved in the control of centrosome
number and chromosome segregation. Biochemical data reveal that
BRCA1/BRCA2 and HMMR form complexes, that HMMR is
ubiquitinated by BRCA1/BARD1, and that BRCA1 and HMMR
together regulate centrosome duplication in tissue culture cell lines
derived from breast tissue. Our results indicate that similar strategies
could help to build and complete other cancer-related cellular
networks, and thus to understand how they are affected and/or
contribute to cellular transformation.
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Alternative splicing of transcripts may lead to different mRNA species
and therefore to potentially different proteins. Any failure or error in the
splicing control mechanism can be involved in a number of pathological
processes, such as cancer. Splice isoforms that are disease specific
could therefore serve as excellent diagnostic markers, which are easily
identifiable by PCR.
Computational prediction of alternative splice variants has been highly
facilitating the identification of novel splice isoforms. Our prediction
strategy is based on the genomic mapping (SpliceNest) of EST
consensus sequences and library annotation provided in the GeneNest
database. This revealed 427 genes with at least one tissue-specific
transcript as well as 1120 genes showing tumor-specific isoforms. Out
of these genes, a subset of predicted isoforms was experimentally
verified by an RT-PCR screening approach. We have set up an
experimental strategy that allows us to screen expression of genes in
up to 112 different human tissues of multiple developmental stages
and cell lines. Within this project, the electrophoretic separation of RT-
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Table 1
Classification results of lymph node status from the probabilistic neural
network
Classification Actual negative Actual positive Total
Negative 34 1 35
Positive 3 31 34
Total 37 32 69
Sensitivity: 97%, specificity: 92%.
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PCR products turned out to be the bottleneck impeding the switch
from a medium-throughput to a high-throughput strategy. To
circumvent the limitations of DNA slab gel analysis, a laboratory
prototype of an automated on-chip electrophoresis system that allows
high-throughput analysis of DNA fragments was implemented in the
workflow. In our experimental set-up, we analyzed RT-PCR samples on
4 × 96-well plates within a defined sequence of consecutive one-on-
one measurements. The high-throughput experimental verification of
computationally predicted tissue specific isoforms revealed a high
success rate in confirming their expression in the respective tissue.
However, low expression levels of the respective transcript and the
limited sensitivity of the experimental method can explain failed
detection of the restricted expression pattern.
The combination of computational prediction of alternative splicing
events with high-throughput experimental verification facilitates the
efficient detection of tissue-specific and tumor-specific transcripts.
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Good RNA quality assessment is considered one of the most critical
elements to obtain meaningful gene expression data via microarray or
real-time PCR experiments. Advances in microfluidic technology have
improved RNA quality measurements by allowing a more detailed look at
patterns of RNA degradation via the use of electrophoretic traces.
However, the interpretation of such electropherograms still requires a
certain level of experience and can vary from one researcher to the next.
The ‘RNA integrity number’ (RIN) algorithm is introduced to assign a
user-independent integrity number to each RNA sample. The RIN has
been developed using neural networks by ‘teaching’ this algorithm with
a large number of RNA integrity data. The RIN score, based on a
quality numbering system from 1 to 10 (in ascending quality), facilitates
the classification of RNA samples to be used in the context of the gene
expression workflow. It was found that the RIN is more reliable than the
ribosomal ratio when assessing the integrity of RNA samples. The RIN
is shown to be largely independent of RNA concentration, independent
of instrument (Agilent 2100 bioanalyzer), and most importantly
independent of the origin of the RNA sample. Using the RIN,
researchers can work towards standardization of RNA integrity
measurement, ensuring reproducibility and reliability of gene expression
experiments.
